PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
2794752-7	1989	Additionally, qinghaosu resulted in a dose-dependent increase in red cell lysis and methemoglobin generation while decreasing reduced glutathione concentration.	artemisinin	14-23	hemoglobin subunit gamma 2	Homo sapiens	84-97
33894419-0	2021	Artemisinin derivatives inhibit adipogenic differentiation of 3T3-L1 preadipocytes through upregulation of CHOP.	artemisinin	0-11	DNA-damage inducible transcript 3	Mus musculus	107-111
33976269-5	2021	Artemisinin-resistance was assessed through in-vivo parasite clearance half-life (PC1/2), ex-vivo ring-stage survivability (RSA), and genome analysis of kelch13 and other candidate gene (pfcrt, pfmdr1, pfatpase 6, pfdhfr and pfdhps).	artemisinin	0-11	proprotein convertase subtilisin/kexin type 1	Homo sapiens	82-87
33757384-0	2021	Prolongation of allograft survival by artemisinin treatment is associated with blockade of OX40-OX40L.	artemisinin	38-49	tumor necrosis factor receptor superfamily, member 4	Mus musculus	91-95
33757384-0	2021	Prolongation of allograft survival by artemisinin treatment is associated with blockade of OX40-OX40L.	artemisinin	38-49	tumor necrosis factor (ligand) superfamily, member 4	Mus musculus	96-101
33977847-0	2021	Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptor-binding domain (RBD).	artemisinin	62-73	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	126-131
33556535-0	2021	Artemisinin protects endothelial function and vasodilation from oxidative damage via activation of PI3K/Akt/eNOS pathway.	artemisinin	0-11	AKT serine/threonine kinase 1	Homo sapiens	104-107
33556535-0	2021	Artemisinin protects endothelial function and vasodilation from oxidative damage via activation of PI3K/Akt/eNOS pathway.	artemisinin	0-11	nitric oxide synthase 3	Homo sapiens	108-112
33453127-7	2021	Artemisinin bound MD2 showed much less collapse during the molecular dynamic simulations, which supports the increased stability of MD2 upon artemisinin binding.	artemisinin	0-11	lymphocyte antigen 96	Mus musculus	132-135
33453127-7	2021	Artemisinin bound MD2 showed much less collapse during the molecular dynamic simulations, which supports the increased stability of MD2 upon artemisinin binding.	artemisinin	141-152	lymphocyte antigen 96	Mus musculus	18-21
33453127-7	2021	Artemisinin bound MD2 showed much less collapse during the molecular dynamic simulations, which supports the increased stability of MD2 upon artemisinin binding.	artemisinin	141-152	lymphocyte antigen 96	Mus musculus	132-135
33453127-8	2021	Flow cytometry analysis showed artemisinin inhibited LPS-induced TLR4 dimerization and endocytosis in microglial BV-2 cells.	artemisinin	31-42	toll-like receptor 4	Mus musculus	65-69
33453127-9	2021	Therefore, artemisinin was found to inhibit the TLR4-JNK signaling axis and block LPS-induced pro-inflammatory factors nitric oxide, IL-1beta and TNF-alpha in BV-2 cells.	artemisinin	11-22	toll-like receptor 4	Mus musculus	48-52
33453127-0	2021	Artemisinin inhibits TLR4 signaling by targeting co-receptor MD2 in microglial BV-2 cells and prevents lipopolysaccharideinduced blood brain barrier leakage in mice.	artemisinin	0-11	toll-like receptor 4	Mus musculus	21-25
33453127-9	2021	Therefore, artemisinin was found to inhibit the TLR4-JNK signaling axis and block LPS-induced pro-inflammatory factors nitric oxide, IL-1beta and TNF-alpha in BV-2 cells.	artemisinin	11-22	mitogen-activated protein kinase 8	Mus musculus	53-56
33453127-0	2021	Artemisinin inhibits TLR4 signaling by targeting co-receptor MD2 in microglial BV-2 cells and prevents lipopolysaccharideinduced blood brain barrier leakage in mice.	artemisinin	0-11	lymphocyte antigen 96	Mus musculus	61-64
33453127-5	2021	In vitro protein intrinsic fluorescence titrations and saturation transfer difference (STD)-NMR showed the direct binding of artemisinin to TLR4 co-receptor MD2.	artemisinin	125-136	toll-like receptor 4	Mus musculus	140-144
33453127-9	2021	Therefore, artemisinin was found to inhibit the TLR4-JNK signaling axis and block LPS-induced pro-inflammatory factors nitric oxide, IL-1beta and TNF-alpha in BV-2 cells.	artemisinin	11-22	interleukin 1 alpha	Mus musculus	133-141
33453127-5	2021	In vitro protein intrinsic fluorescence titrations and saturation transfer difference (STD)-NMR showed the direct binding of artemisinin to TLR4 co-receptor MD2.	artemisinin	125-136	lymphocyte antigen 96	Mus musculus	157-160
33453127-6	2021	Cellular thermal shift assay (CETSA) showed that artemisinin binding increased MD2 stability, which implies that artemisinin directly binds to MD2 in the cellular context.	artemisinin	49-60	lymphocyte antigen 96	Mus musculus	79-82
33453127-6	2021	Cellular thermal shift assay (CETSA) showed that artemisinin binding increased MD2 stability, which implies that artemisinin directly binds to MD2 in the cellular context.	artemisinin	49-60	lymphocyte antigen 96	Mus musculus	143-146
33453127-9	2021	Therefore, artemisinin was found to inhibit the TLR4-JNK signaling axis and block LPS-induced pro-inflammatory factors nitric oxide, IL-1beta and TNF-alpha in BV-2 cells.	artemisinin	11-22	tumor necrosis factor	Mus musculus	146-155
33453127-6	2021	Cellular thermal shift assay (CETSA) showed that artemisinin binding increased MD2 stability, which implies that artemisinin directly binds to MD2 in the cellular context.	artemisinin	113-124	lymphocyte antigen 96	Mus musculus	79-82
33453127-6	2021	Cellular thermal shift assay (CETSA) showed that artemisinin binding increased MD2 stability, which implies that artemisinin directly binds to MD2 in the cellular context.	artemisinin	113-124	lymphocyte antigen 96	Mus musculus	143-146
33453127-10	2021	Furthermore, artemisinin restored LPS-induced decrease of junction proteins ZO-1, Occludin and Claudin-5 in primary brain microvessel endothelial cells, and attenuated LPS-induced blood brain barrier disruption in mice as assessed by Evans blue.	artemisinin	13-24	tight junction protein 1	Mus musculus	76-80
33453127-7	2021	Artemisinin bound MD2 showed much less collapse during the molecular dynamic simulations, which supports the increased stability of MD2 upon artemisinin binding.	artemisinin	0-11	lymphocyte antigen 96	Mus musculus	18-21
33453127-10	2021	Furthermore, artemisinin restored LPS-induced decrease of junction proteins ZO-1, Occludin and Claudin-5 in primary brain microvessel endothelial cells, and attenuated LPS-induced blood brain barrier disruption in mice as assessed by Evans blue.	artemisinin	13-24	occludin	Mus musculus	82-90
33453127-10	2021	Furthermore, artemisinin restored LPS-induced decrease of junction proteins ZO-1, Occludin and Claudin-5 in primary brain microvessel endothelial cells, and attenuated LPS-induced blood brain barrier disruption in mice as assessed by Evans blue.	artemisinin	13-24	claudin 5	Mus musculus	95-104
33453127-11	2021	In all, this study unambiguously adds MD2 as a direct binding target of artemisinin in its anti-neuroinflammatory function.	artemisinin	72-83	lymphocyte antigen 96	Mus musculus	38-41
33933588-7	2021	Immunofluorescence microscopy demonstrated the rescue of gephyrin and gamma2-GABAA-receptor protein levels in the brain of treated mice with both, artemisinin and artesunate, most efficiently with a low dose of artesunate.	artemisinin	147-158	gephyrin	Mus musculus	57-65
33875422-10	2021	Between one in three and one in six individuals harbored reduced activity alleles of CYP2A6, CYP2B6, CYP2D6 and CYP2C8 with important implications for artemisinin, chloroquine and amodiaquine therapy.	artemisinin	151-162	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	85-91
33903109-2	2021	Single nucleotide polymorphisms (SNPs) in other molecular markers, such as ap2mu and ubp1, were associated with artemisinin resistance in rodent malaria and clinical failure in African malaria patients.	artemisinin	112-123	upstream binding protein 1	Homo sapiens	85-89
33878252-0	2022	Artemisinin-treatment in pre-symptomatic APP-PS1 mice increases gephyrin phosphorylation at Ser270: a modification regulating postsynaptic GABAAR density.	artemisinin	0-11	presenilin 1	Mus musculus	45-48
33878252-0	2022	Artemisinin-treatment in pre-symptomatic APP-PS1 mice increases gephyrin phosphorylation at Ser270: a modification regulating postsynaptic GABAAR density.	artemisinin	0-11	gephyrin	Mus musculus	64-72
33878252-5	2022	Here, we studied the effects of artemisinin on gephyrin in the brain of young APP-PS1 mice.	artemisinin	32-43	gephyrin	Mus musculus	47-55
33878252-10	2022	Thus, our results reveal that artemisinin modulates expression as well as phosphorylation of gephyrin at sites that might have important impact on GABAergic synapses in AD.	artemisinin	30-41	gephyrin	Mus musculus	93-101
33875422-10	2021	Between one in three and one in six individuals harbored reduced activity alleles of CYP2A6, CYP2B6, CYP2D6 and CYP2C8 with important implications for artemisinin, chloroquine and amodiaquine therapy.	artemisinin	151-162	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	93-99
33875422-10	2021	Between one in three and one in six individuals harbored reduced activity alleles of CYP2A6, CYP2B6, CYP2D6 and CYP2C8 with important implications for artemisinin, chloroquine and amodiaquine therapy.	artemisinin	151-162	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	101-107
33875422-10	2021	Between one in three and one in six individuals harbored reduced activity alleles of CYP2A6, CYP2B6, CYP2D6 and CYP2C8 with important implications for artemisinin, chloroquine and amodiaquine therapy.	artemisinin	151-162	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	112-118
32747720-0	2021	The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-kappaB/NLRP3 signaling.	artemisinin	4-15	toll-like receptor 4	Rattus norvegicus	87-91
33827592-0	2021	Molecular surveillance of drug resistance: Plasmodium falciparum artemisinin resistance single nucleotide polymorphisms in Kelch protein propeller (K13) domain from Southern Pakistan.	artemisinin	65-76	kelch like family member 2	Homo sapiens	123-128
33827592-0	2021	Molecular surveillance of drug resistance: Plasmodium falciparum artemisinin resistance single nucleotide polymorphisms in Kelch protein propeller (K13) domain from Southern Pakistan.	artemisinin	65-76	keratin 13	Homo sapiens	148-151
33827592-1	2021	BACKGROUND: K13 propeller (k13) polymorphism are useful molecular markers for tracking the emergence and spread of artemisinin resistance in Plasmodium falciparum.	artemisinin	115-126	keratin 13	Homo sapiens	12-15
33827592-1	2021	BACKGROUND: K13 propeller (k13) polymorphism are useful molecular markers for tracking the emergence and spread of artemisinin resistance in Plasmodium falciparum.	artemisinin	115-126	keratin 13	Homo sapiens	27-30
33827592-3	2021	The study describes single nucleotide polymorphisms in Kelch protein propeller domain of P. falciparum associated with artemisinin resistance from Southern Pakistan.	artemisinin	119-130	kelch like family member 2	Homo sapiens	55-60
32747720-0	2021	The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-kappaB/NLRP3 signaling.	artemisinin	4-15	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	92-101
32747720-0	2021	The artemisinin analog SM934 alleviates dry eye disease in rodent models by regulating TLR4/NF-kappaB/NLRP3 signaling.	artemisinin	4-15	NLR family, pyrin domain containing 3	Rattus norvegicus	102-107
33460658-0	2021	Interaction of artemisinin protects the activity of antioxidant enzyme catalase: A biophysical study.	artemisinin	15-26	catalase	Bos taurus	71-79
33758353-7	2021	In BV2 microglial cells treated with LPS (100 ng/mL), pre-application of artemisinin (40 muMu) significantly reduced the production of proinflammatory cytokines (i.e., TNF-alpha, IL-6) and suppressed microglial migration.	artemisinin	73-84	tumor necrosis factor	Mus musculus	168-177
33758353-7	2021	In BV2 microglial cells treated with LPS (100 ng/mL), pre-application of artemisinin (40 muMu) significantly reduced the production of proinflammatory cytokines (i.e., TNF-alpha, IL-6) and suppressed microglial migration.	artemisinin	73-84	interleukin 6	Mus musculus	179-183
33758353-8	2021	Furthermore, we revealed that artemisinin significantly suppressed the nuclear translocation of NF-kappaB and the expression of proinflammatory cytokines by activating the AMPKalpha1 pathway; knockdown of AMPKalpha1 markedly abolished the anti-inflammatory effects of artemisinin in BV2 microglial cells.	artemisinin	30-41	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	96-105
33758353-8	2021	Furthermore, we revealed that artemisinin significantly suppressed the nuclear translocation of NF-kappaB and the expression of proinflammatory cytokines by activating the AMPKalpha1 pathway; knockdown of AMPKalpha1 markedly abolished the anti-inflammatory effects of artemisinin in BV2 microglial cells.	artemisinin	30-41	protein kinase, AMP-activated, alpha 1 catalytic subunit	Mus musculus	172-182
33758353-8	2021	Furthermore, we revealed that artemisinin significantly suppressed the nuclear translocation of NF-kappaB and the expression of proinflammatory cytokines by activating the AMPKalpha1 pathway; knockdown of AMPKalpha1 markedly abolished the anti-inflammatory effects of artemisinin in BV2 microglial cells.	artemisinin	30-41	protein kinase, AMP-activated, alpha 1 catalytic subunit	Mus musculus	205-215
33758353-8	2021	Furthermore, we revealed that artemisinin significantly suppressed the nuclear translocation of NF-kappaB and the expression of proinflammatory cytokines by activating the AMPKalpha1 pathway; knockdown of AMPKalpha1 markedly abolished the anti-inflammatory effects of artemisinin in BV2 microglial cells.	artemisinin	268-279	protein kinase, AMP-activated, alpha 1 catalytic subunit	Mus musculus	205-215
33508479-4	2021	In this review, antimalarial activity of the most active artemisinin derivatives modified at C-10/C-11/C-16/C-6 positions and synthetic peroxides (endoperoxides, 1,2,4-trioxolanes, 1,2,4-trioxanes, and 1,2,4,5-tetraoxanes) are systematically summarized.	artemisinin	57-68	homeobox C10	Homo sapiens	93-97
33508479-4	2021	In this review, antimalarial activity of the most active artemisinin derivatives modified at C-10/C-11/C-16/C-6 positions and synthetic peroxides (endoperoxides, 1,2,4-trioxolanes, 1,2,4-trioxanes, and 1,2,4,5-tetraoxanes) are systematically summarized.	artemisinin	57-68	RNA polymerase III subunit K	Homo sapiens	98-102
33632304-0	2021	Artemisinin attenuated oxidative stress and apoptosis by inhibiting autophagy in MPP+-treated SH-SY5Y cells.	artemisinin	0-11	M-phase phosphoprotein 6	Homo sapiens	81-84
33359205-0	2021	Polymorphisms in Plasmodium falciparum chloroquine resistance transporter (Pfcrt) and multidrug-resistant gene 1 (Pfmdr-1) in Nigerian children 10 years post-adoption of artemisinin-based combination treatments.	artemisinin	170-181	plasmodium falciparum chloroquine resistance transporter (pfcrt) and multidrug-resistant gene 1	None	17-112
33599403-2	2021	Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone.	artemisinin	43-54	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
33632304-4	2021	The purpose of this study is to explore the neuroprotective effect of ART on 1-methyl-4-phenyliodine iodide (MPP +)-treated SH-SY5Y cells and underlying mechanism.	artemisinin	70-73	M-phase phosphoprotein 6	Homo sapiens	109-112
33632304-12	2021	ART could significantly increase the viability of SH-SY5Y cells treated with MPP+ and reduce oxidative stress damage and apoptosis.	artemisinin	0-3	M-phase phosphoprotein 6	Homo sapiens	77-80
33620584-2	2021	Recently, artemisinin (ART) and its derivatives have been investigated as potential anticancer agents for the treatment of highly aggressive cancers via the induction of ferroptosis by iron-mediated cleavage of the endoperoxide bridge.	artemisinin	10-21	artemin	Homo sapiens	23-26
33483501-0	2021	Artemisinin-resistant K13 mutations rewire Plasmodium falciparum"s intra-erythrocytic metabolic program to enhance survival.	artemisinin	0-11	keratin 13	Homo sapiens	22-25
33596950-5	2021	RESULTS: Among all the compounds screened, 1-aryltetrahydro-beta-carbolines 2 and 3 displayed significant anti-plasmodial activity against both the artemisinin-sensitive and artemisinin-resistant strain of Plasmodium falciparum.	artemisinin	148-159	carbolines 2 and 3	None	65-83
33596950-5	2021	RESULTS: Among all the compounds screened, 1-aryltetrahydro-beta-carbolines 2 and 3 displayed significant anti-plasmodial activity against both the artemisinin-sensitive and artemisinin-resistant strain of Plasmodium falciparum.	artemisinin	174-185	carbolines 2 and 3	None	65-83
33560385-3	2021	Screening of a targeted antineoplastic drug library revealed that B-cell lymphoma 2 (BCL2) inhibitors synergize with artemisinins, and validation assays confirmed that the selective BCL2 inhibitor, venetoclax (VEN), synergized with artemisinin analogs to inhibit growth and induce apoptotic cell death of multiple acute leukemia cell lines in vitro.	artemisinin	117-128	BCL2 apoptosis regulator	Homo sapiens	66-83
33560385-3	2021	Screening of a targeted antineoplastic drug library revealed that B-cell lymphoma 2 (BCL2) inhibitors synergize with artemisinins, and validation assays confirmed that the selective BCL2 inhibitor, venetoclax (VEN), synergized with artemisinin analogs to inhibit growth and induce apoptotic cell death of multiple acute leukemia cell lines in vitro.	artemisinin	117-128	BCL2 apoptosis regulator	Homo sapiens	85-89
33483501-1	2021	The emergence and spread of artemisinin resistance, driven by mutations in Plasmodium falciparum K13, has compromised antimalarial efficacy and threatens the global malaria elimination campaign.	artemisinin	28-39	keratin 13	Homo sapiens	97-100
33483501-4	2021	K13-mediated artemisinin resistance in the Cambodian Cam3.II line was reversed by atovaquone, a mitochondrial electron transport chain inhibitor.	artemisinin	13-24	keratin 13	Homo sapiens	0-3
33483501-5	2021	These results suggest that mitochondrial processes including damage sensing and anti-oxidant properties might augment the ability of mutant K13 to protect P. falciparum against artemisinin action by helping these parasites undergo temporary quiescence and accelerated growth recovery post drug elimination.	artemisinin	177-188	keratin 13	Homo sapiens	140-143
31965935-7	2021	RESULTS: Artemisinin derivatives, artemisinin-derived dimers, hybrids and artemisinin-transferrin conjugates, could significantly improve anticancer activity, and their IC50 values are lower than those of reference molecules such as doxorubicin and paclitaxel.	artemisinin	74-85	transferrin	Homo sapiens	86-97
33481164-0	2021	Artemisinin analogue SM934 protects against lupus-associated antiphospholipid syndrome via activation of Nrf2 and its targets.	artemisinin	0-11	nuclear factor, erythroid derived 2, like 2	Mus musculus	105-109
33441725-4	2021	Furthermore, we show that upon artemisinin exposure, genome-wide binding sites for PfGCN5 are increased and it is directly associated with the genes implicated in artemisinin resistance generation like BiP and TRiC chaperone.	artemisinin	31-42	heat shock protein family A (Hsp70) member 5	Homo sapiens	202-205
33441725-4	2021	Furthermore, we show that upon artemisinin exposure, genome-wide binding sites for PfGCN5 are increased and it is directly associated with the genes implicated in artemisinin resistance generation like BiP and TRiC chaperone.	artemisinin	31-42	MARVEL domain containing 2	Homo sapiens	210-214
33441725-4	2021	Furthermore, we show that upon artemisinin exposure, genome-wide binding sites for PfGCN5 are increased and it is directly associated with the genes implicated in artemisinin resistance generation like BiP and TRiC chaperone.	artemisinin	163-174	heat shock protein family A (Hsp70) member 5	Homo sapiens	202-205
33441725-4	2021	Furthermore, we show that upon artemisinin exposure, genome-wide binding sites for PfGCN5 are increased and it is directly associated with the genes implicated in artemisinin resistance generation like BiP and TRiC chaperone.	artemisinin	163-174	MARVEL domain containing 2	Homo sapiens	210-214
32939611-0	2020	Antinociception induced by artemisinin nanocapsule in a model of postoperative pain via spinal TLR4 inhibition.	artemisinin	27-38	toll-like receptor 4	Mus musculus	95-99
32386317-10	2020	Finally, Artemisinin treatment in PC3 cells repressed E2F5 along with MMP-2/MMP-9 while triggering TFPI2 expression which alleviated PC3 aggressiveness possibly through inhibition of MMP activities.	artemisinin	9-20	microseminoprotein, prostate associated S homeolog	Xenopus laevis	34-37
32386317-10	2020	Finally, Artemisinin treatment in PC3 cells repressed E2F5 along with MMP-2/MMP-9 while triggering TFPI2 expression which alleviated PC3 aggressiveness possibly through inhibition of MMP activities.	artemisinin	9-20	E2F transcription factor 5	Homo sapiens	54-58
32386317-10	2020	Finally, Artemisinin treatment in PC3 cells repressed E2F5 along with MMP-2/MMP-9 while triggering TFPI2 expression which alleviated PC3 aggressiveness possibly through inhibition of MMP activities.	artemisinin	9-20	matrix metallopeptidase 2	Homo sapiens	70-75
32386317-10	2020	Finally, Artemisinin treatment in PC3 cells repressed E2F5 along with MMP-2/MMP-9 while triggering TFPI2 expression which alleviated PC3 aggressiveness possibly through inhibition of MMP activities.	artemisinin	9-20	matrix metallopeptidase 9	Homo sapiens	76-81
32386317-10	2020	Finally, Artemisinin treatment in PC3 cells repressed E2F5 along with MMP-2/MMP-9 while triggering TFPI2 expression which alleviated PC3 aggressiveness possibly through inhibition of MMP activities.	artemisinin	9-20	tissue factor pathway inhibitor 2	Homo sapiens	99-104
32386317-10	2020	Finally, Artemisinin treatment in PC3 cells repressed E2F5 along with MMP-2/MMP-9 while triggering TFPI2 expression which alleviated PC3 aggressiveness possibly through inhibition of MMP activities.	artemisinin	9-20	microseminoprotein, prostate associated S homeolog	Xenopus laevis	133-136
32386317-12	2020	This study also indicates a therapeutic potential of artemisinin, a natural compound which acts by correcting dysfunctional E2F5/TFPI2/MMP axis in PCa.	artemisinin	53-64	E2F transcription factor 5	Homo sapiens	124-128
32386317-12	2020	This study also indicates a therapeutic potential of artemisinin, a natural compound which acts by correcting dysfunctional E2F5/TFPI2/MMP axis in PCa.	artemisinin	53-64	tissue factor pathway inhibitor 2	Homo sapiens	129-134
33078701-11	2020	Purported artemisinin and lumefantrine drug resistance SNPs in atp6, 3D7_1451200, and mdr1 were detected but did not correlate with parasite recurrence, nor did day 7 lumefantrine concentrations.	artemisinin	10-21	mitochondrially encoded ATP synthase 6	Homo sapiens	63-67
33078701-11	2020	Purported artemisinin and lumefantrine drug resistance SNPs in atp6, 3D7_1451200, and mdr1 were detected but did not correlate with parasite recurrence, nor did day 7 lumefantrine concentrations.	artemisinin	10-21	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
32861782-1	2020	The present study aims to evaluate the inhibitory effects of artesunate (a semi-synthetic derivative of artemisinin) on HSP70 and Bcl-2 expression in two breast cancer cell lines, 4T1 and MCF-7.	artemisinin	104-115	heat shock protein family A (Hsp70) member 4	Homo sapiens	120-125
32729005-8	2020	The artemisinin-treated myocardial I/R rats demonstrated less severe myocardial I/R injury (smaller infarct size and lower CK-MB, LDH), significant inhibition of cardiac autophagy (decreased LC3II/I and increased p62), improved mitochondrial electron transport chain activity, concomitant with decreased activation of NLRP3 inflammasome (decreased NLRP3, ASC, cleaved caspase-1, IL-1beta).	artemisinin	4-15	microtubule-associated protein 1 light chain 3 alpha	Rattus norvegicus	191-198
32861782-1	2020	The present study aims to evaluate the inhibitory effects of artesunate (a semi-synthetic derivative of artemisinin) on HSP70 and Bcl-2 expression in two breast cancer cell lines, 4T1 and MCF-7.	artemisinin	104-115	BCL2 apoptosis regulator	Homo sapiens	130-135
33381036-5	2020	Artemisinin treatments not only attenuate insulin resistance and restore islet ss-cell function in T2DM but also have potential therapeutic effects on diabetic complications, including diabetic kidney disease, cognitive impairment, diabetic retinopathy, and diabetic cardiovascular disease.	artemisinin	0-11	insulin	Homo sapiens	42-49
33173001-5	2020	Mutant P. berghei K13 parasites also displayed delayed clearance in vivo upon treatment with artesunate and achieved faster recrudescence upon treatment with artemisinin.	artemisinin	158-169	keratin 13	Homo sapiens	18-21
33173001-7	2020	Furthermore, a Plasmodium-selective proteasome inhibitor strongly synergized dihydroartemisinin action in these P. berghei K13 mutant lines, providing further evidence that the proteasome can be targeted to overcome artemisinin resistance.	artemisinin	84-95	keratin 13	Homo sapiens	123-126
33173001-8	2020	Taken together, our findings provide clear experimental evidence for the involvement of K13 polymorphisms in mediating susceptibility to artemisinins in vitro and, most importantly, under in vivo conditions.IMPORTANCE Recent successes in malaria control have been seriously threatened by the emergence of Plasmodium falciparum parasite resistance to the frontline artemisinin drugs in Southeast Asia.	artemisinin	137-148	keratin 13	Homo sapiens	88-91
33173001-9	2020	P. falciparum artemisinin resistance is associated with mutations in the parasite K13 protein, which associates with a delay in the time required to clear the parasites upon drug treatment.	artemisinin	14-25	keratin 13	Homo sapiens	82-85
33173001-10	2020	Gene editing technologies have been used to validate the role of several candidate K13 mutations in mediating P. falciparum artemisinin resistance in vitro under laboratory conditions.	artemisinin	124-135	keratin 13	Homo sapiens	83-86
33173001-12	2020	Here, we have used CRISPR/Cas9 gene editing to introduce K13 mutations associated with artemisinin resistance into the related rodent-infecting parasite, Plasmodium berghei Phenotyping of these P. berghei K13 mutant parasites provides evidence of their role in mediating artemisinin resistance in vivo, which supports in vitro artemisinin resistance observations.	artemisinin	87-98	keratin 13	Homo sapiens	57-60
32868072-7	2020	We demonstrate that TGF-beta mediated Smad2 linker region phosphorylation and GAG chain elongation was attenuated by artemisinin; however, we observed no effect on VSMC proliferation.	artemisinin	117-128	transforming growth factor alpha	Homo sapiens	20-28
32868072-7	2020	We demonstrate that TGF-beta mediated Smad2 linker region phosphorylation and GAG chain elongation was attenuated by artemisinin; however, we observed no effect on VSMC proliferation.	artemisinin	117-128	SMAD family member 2	Homo sapiens	38-43
33142414-8	2020	All the results proved the effectiveness of the hybridization approach to develop novel artemisinin-sulfonamide compounds targeting CA IX for cancer treatment.	artemisinin	88-99	carbonic anhydrase 9	Homo sapiens	132-137
33239368-0	2020	Elucidation of DNA Repair Function of PfBlm and Potentiation of Artemisinin Action by a Small-Molecule Inhibitor of RecQ Helicase.	artemisinin	64-75	recq helicase	None	116-129
33150340-2	2020	Dihydroartemisinin (DHA), a main active metabolite of anti-malarial drug artemisinin (ART), inhibits cancer cell invasion and migration by decreasing the translationally controlled tumor protein (TCTP), as reported in a few literature studies.	artemisinin	7-18	tumor protein, translationally-controlled 1	Homo sapiens	154-194
33150340-2	2020	Dihydroartemisinin (DHA), a main active metabolite of anti-malarial drug artemisinin (ART), inhibits cancer cell invasion and migration by decreasing the translationally controlled tumor protein (TCTP), as reported in a few literature studies.	artemisinin	7-18	tumor protein, translationally-controlled 1	Homo sapiens	196-200
33150340-2	2020	Dihydroartemisinin (DHA), a main active metabolite of anti-malarial drug artemisinin (ART), inhibits cancer cell invasion and migration by decreasing the translationally controlled tumor protein (TCTP), as reported in a few literature studies.	artemisinin	86-89	tumor protein, translationally-controlled 1	Homo sapiens	154-194
33150340-2	2020	Dihydroartemisinin (DHA), a main active metabolite of anti-malarial drug artemisinin (ART), inhibits cancer cell invasion and migration by decreasing the translationally controlled tumor protein (TCTP), as reported in a few literature studies.	artemisinin	86-89	tumor protein, translationally-controlled 1	Homo sapiens	196-200
33173001-0	2020	Plasmodium berghei K13 Mutations Mediate In Vivo Artemisinin Resistance That Is Reversed by Proteasome Inhibition.	artemisinin	49-60	keratin 13	Homo sapiens	19-22
33173001-2	2020	Artemisinin resistance is primarily driven by mutations in the P. falciparum K13 protein, which enhance survival of early ring-stage parasites treated with the artemisinin active metabolite dihydroartemisinin in vitro and associate with delayed parasite clearance in vivo However, association of K13 mutations with in vivo artemisinin resistance has been problematic due to the absence of a tractable model.	artemisinin	0-11	keratin 13	Homo sapiens	77-80
33173001-2	2020	Artemisinin resistance is primarily driven by mutations in the P. falciparum K13 protein, which enhance survival of early ring-stage parasites treated with the artemisinin active metabolite dihydroartemisinin in vitro and associate with delayed parasite clearance in vivo However, association of K13 mutations with in vivo artemisinin resistance has been problematic due to the absence of a tractable model.	artemisinin	0-11	keratin 13	Homo sapiens	296-299
33173001-2	2020	Artemisinin resistance is primarily driven by mutations in the P. falciparum K13 protein, which enhance survival of early ring-stage parasites treated with the artemisinin active metabolite dihydroartemisinin in vitro and associate with delayed parasite clearance in vivo However, association of K13 mutations with in vivo artemisinin resistance has been problematic due to the absence of a tractable model.	artemisinin	160-171	keratin 13	Homo sapiens	77-80
33173001-2	2020	Artemisinin resistance is primarily driven by mutations in the P. falciparum K13 protein, which enhance survival of early ring-stage parasites treated with the artemisinin active metabolite dihydroartemisinin in vitro and associate with delayed parasite clearance in vivo However, association of K13 mutations with in vivo artemisinin resistance has been problematic due to the absence of a tractable model.	artemisinin	197-208	keratin 13	Homo sapiens	77-80
33173001-3	2020	Herein, we have employed CRISPR/Cas9 genome editing to engineer selected orthologous P. falciparum K13 mutations into the K13 gene of an artemisinin-sensitive Plasmodium berghei rodent model of malaria.	artemisinin	137-148	keratin 13	Homo sapiens	99-102
33173001-3	2020	Herein, we have employed CRISPR/Cas9 genome editing to engineer selected orthologous P. falciparum K13 mutations into the K13 gene of an artemisinin-sensitive Plasmodium berghei rodent model of malaria.	artemisinin	137-148	keratin 13	Homo sapiens	122-125
32729005-8	2020	The artemisinin-treated myocardial I/R rats demonstrated less severe myocardial I/R injury (smaller infarct size and lower CK-MB, LDH), significant inhibition of cardiac autophagy (decreased LC3II/I and increased p62), improved mitochondrial electron transport chain activity, concomitant with decreased activation of NLRP3 inflammasome (decreased NLRP3, ASC, cleaved caspase-1, IL-1beta).	artemisinin	4-15	KH RNA binding domain containing, signal transduction associated 1	Rattus norvegicus	213-216
32729005-8	2020	The artemisinin-treated myocardial I/R rats demonstrated less severe myocardial I/R injury (smaller infarct size and lower CK-MB, LDH), significant inhibition of cardiac autophagy (decreased LC3II/I and increased p62), improved mitochondrial electron transport chain activity, concomitant with decreased activation of NLRP3 inflammasome (decreased NLRP3, ASC, cleaved caspase-1, IL-1beta).	artemisinin	4-15	NLR family, pyrin domain containing 3	Rattus norvegicus	318-323
32729005-8	2020	The artemisinin-treated myocardial I/R rats demonstrated less severe myocardial I/R injury (smaller infarct size and lower CK-MB, LDH), significant inhibition of cardiac autophagy (decreased LC3II/I and increased p62), improved mitochondrial electron transport chain activity, concomitant with decreased activation of NLRP3 inflammasome (decreased NLRP3, ASC, cleaved caspase-1, IL-1beta).	artemisinin	4-15	NLR family, pyrin domain containing 3	Rattus norvegicus	348-353
32729005-8	2020	The artemisinin-treated myocardial I/R rats demonstrated less severe myocardial I/R injury (smaller infarct size and lower CK-MB, LDH), significant inhibition of cardiac autophagy (decreased LC3II/I and increased p62), improved mitochondrial electron transport chain activity, concomitant with decreased activation of NLRP3 inflammasome (decreased NLRP3, ASC, cleaved caspase-1, IL-1beta).	artemisinin	4-15	PYD and CARD domain containing	Rattus norvegicus	355-358
32729005-8	2020	The artemisinin-treated myocardial I/R rats demonstrated less severe myocardial I/R injury (smaller infarct size and lower CK-MB, LDH), significant inhibition of cardiac autophagy (decreased LC3II/I and increased p62), improved mitochondrial electron transport chain activity, concomitant with decreased activation of NLRP3 inflammasome (decreased NLRP3, ASC, cleaved caspase-1, IL-1beta).	artemisinin	4-15	caspase 1	Rattus norvegicus	368-377
32729005-8	2020	The artemisinin-treated myocardial I/R rats demonstrated less severe myocardial I/R injury (smaller infarct size and lower CK-MB, LDH), significant inhibition of cardiac autophagy (decreased LC3II/I and increased p62), improved mitochondrial electron transport chain activity, concomitant with decreased activation of NLRP3 inflammasome (decreased NLRP3, ASC, cleaved caspase-1, IL-1beta).	artemisinin	4-15	interleukin 1 alpha	Rattus norvegicus	379-387
32729005-9	2020	In conclusion, our findings further confirmed that activation of the NLRP3 inflammasome pathway is involved in myocardial I/R injury, whereas artemisinin preconditioning could effectively protect against myocardial I/R injury through suppression of NLRP3 inflammasome activation.	artemisinin	142-153	NLR family, pyrin domain containing 3	Rattus norvegicus	249-254
32729005-10	2020	Therefore, the NLRP3 inflammasome might serve as a promising therapeutic target providing new mechanisms for understanding the effect of artemisinin during the evolution of myocardial infarction.	artemisinin	137-148	NLR family, pyrin domain containing 3	Rattus norvegicus	15-20
32747827-2	2020	Here we genotyped the P. falciparum K13 (Pfkelch13) propeller domain, mutations in which can mediate artemisinin resistance5,6, in pretreatment samples collected from recent dihydroarteminisin-piperaquine and artemether-lumefantrine efficacy trials in Rwanda7.	artemisinin	101-112	keratin 13	Homo sapiens	36-39
32855235-2	2020	Using a biotin-labeled artemisinin we identified the intermediate filament protein vimentin as an artemisinin target, validated by detailed biochemical and biological assays.	artemisinin	23-34	vimentin	Homo sapiens	83-91
32855235-2	2020	Using a biotin-labeled artemisinin we identified the intermediate filament protein vimentin as an artemisinin target, validated by detailed biochemical and biological assays.	artemisinin	98-109	vimentin	Homo sapiens	83-91
32855235-8	2020	Binding of artesunate, an artemisinin monomer, to vimentin prevents virus-induced vimentin degradation, decreasing vimentin phosphorylation at Ser55 and Ser83 and resisting calpain digestion.	artemisinin	26-37	vimentin	Homo sapiens	50-58
32855235-8	2020	Binding of artesunate, an artemisinin monomer, to vimentin prevents virus-induced vimentin degradation, decreasing vimentin phosphorylation at Ser55 and Ser83 and resisting calpain digestion.	artemisinin	26-37	vimentin	Homo sapiens	82-90
32855235-8	2020	Binding of artesunate, an artemisinin monomer, to vimentin prevents virus-induced vimentin degradation, decreasing vimentin phosphorylation at Ser55 and Ser83 and resisting calpain digestion.	artemisinin	26-37	vimentin	Homo sapiens	82-90
32535079-0	2020	Artemisinin attenuates early renal damage on diabetic nephropathy rats through suppressing TGF-beta1 regulator and activating the Nrf2 signaling pathway.	artemisinin	0-11	transforming growth factor, beta 1	Rattus norvegicus	91-100
32899699-2	2020	It has been reported that artemisinin derivatives can overcome resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in liver and cervical cancer cells.	artemisinin	26-37	TNF superfamily member 10	Homo sapiens	77-132
32899699-2	2020	It has been reported that artemisinin derivatives can overcome resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in liver and cervical cancer cells.	artemisinin	26-37	TNF superfamily member 10	Homo sapiens	134-139
32899699-0	2020	Artemisinin Derivatives Stimulate DR5-Specific TRAIL-Induced Apoptosis by Regulating Wildtype P53.	artemisinin	0-11	TNF receptor superfamily member 10b	Homo sapiens	34-37
32899699-0	2020	Artemisinin Derivatives Stimulate DR5-Specific TRAIL-Induced Apoptosis by Regulating Wildtype P53.	artemisinin	0-11	TNF superfamily member 10	Homo sapiens	47-52
32535079-0	2020	Artemisinin attenuates early renal damage on diabetic nephropathy rats through suppressing TGF-beta1 regulator and activating the Nrf2 signaling pathway.	artemisinin	0-11	NFE2 like bZIP transcription factor 2	Rattus norvegicus	130-134
32118504-3	2020	The results showed that bisdemethoxycurcumin, glycyrrhetnic acid, rotenone, artemisinin, dihydroartemisinin, ligustilide and matrine strongly induced the mRNA levels of PXR.	artemisinin	76-87	nuclear receptor subfamily 1 group I member 2	Homo sapiens	169-172
32598944-0	2020	Artemisinin protects motoneurons against axotomy-induced apoptosis through activation of the PKA-Akt signaling pathway and promotes Neural stem/progenitor cells differentiation into NeuN+ neurons.	artemisinin	0-11	AKT serine/threonine kinase 1	Homo sapiens	97-100
32598944-0	2020	Artemisinin protects motoneurons against axotomy-induced apoptosis through activation of the PKA-Akt signaling pathway and promotes Neural stem/progenitor cells differentiation into NeuN+ neurons.	artemisinin	0-11	RNA binding fox-1 homolog 3	Homo sapiens	182-186
32598944-6	2020	Additionally, artemisinin inhibited the molecular signals of apoptosis, activated signaling pathways related to cell survival and induced NSCPs differentiation into NeuN-positive neurons.	artemisinin	14-25	RNA binding fox-1 homolog 3	Homo sapiens	165-169
32598944-7	2020	Further validation of the involved key signaling molecules, using an in vitro model of hydrogen peroxide-induced neurotoxicity, revealed that both the inhibition of PKA signaling pathway or the silencing of Akt reversed the neuroprotective action of artemisinin on motoneurons.	artemisinin	250-261	AKT serine/threonine kinase 1	Homo sapiens	207-210
32598944-8	2020	Our results indicate that artemisinin provides neuroprotection against axotomy and hydrogen peroxide-induced neurotoxicity, an effect that might be mediated by the PKA-Akt signaling pathway.	artemisinin	26-37	AKT serine/threonine kinase 1	Homo sapiens	168-171
32118504-4	2020	Additionally, the up-regulation of CYP3A30 gene ran parallel with PXR gene after the treatment of demethoxycurcumin, glycyrrhetnic acid, artemisinin, matrine, baicalein, schisantherin A, ligustilide, and dihydroartemisinin.	artemisinin	137-148	nuclear receptor subfamily 1 group I member 2	Homo sapiens	66-69
32696720-0	2021	Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19.	artemisinin	19-30	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	126-131
32657048-0	2020	Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/beta-catenin signaling pathway.	artemisinin	27-38	catenin beta 1	Homo sapiens	122-134
32657048-18	2020	WHAT THIS STUDY ADDS: Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cells through the Wnt/beta-catenin signaling pathway.	artemisinin	49-60	catenin beta 1	Homo sapiens	149-161
32765947-0	2020	Artemisinin Improved Neuronal Functions in Alzheimer"s Disease Animal Model 3xtg Mice and Neuronal Cells via Stimulating the ERK/CREB Signaling Pathway.	artemisinin	0-11	mitogen-activated protein kinase 1	Mus musculus	125-128
32765947-0	2020	Artemisinin Improved Neuronal Functions in Alzheimer"s Disease Animal Model 3xtg Mice and Neuronal Cells via Stimulating the ERK/CREB Signaling Pathway.	artemisinin	0-11	cAMP responsive element binding protein 1	Mus musculus	129-133
32765947-6	2020	Western blot assay showed that artemisinin stimulated the activation of ERK/CREB signaling pathway.	artemisinin	31-42	mitogen-activated protein kinase 1	Mus musculus	72-75
32765947-6	2020	Western blot assay showed that artemisinin stimulated the activation of ERK/CREB signaling pathway.	artemisinin	31-42	cAMP responsive element binding protein 1	Mus musculus	76-80
32765947-8	2020	Artemisinin also stimulated the phosphorylation of ERK1/2 and CREB in SH-SY5Y cells in time and concentration-dependent manner.	artemisinin	0-11	mitogen-activated protein kinase 3	Homo sapiens	51-57
32765947-8	2020	Artemisinin also stimulated the phosphorylation of ERK1/2 and CREB in SH-SY5Y cells in time and concentration-dependent manner.	artemisinin	0-11	cAMP responsive element binding protein 1	Homo sapiens	62-66
32765947-9	2020	Inhibition of ERK/CREB pathway attenuated the protective effect of artemisinin.	artemisinin	67-78	mitogen-activated protein kinase 1	Homo sapiens	14-17
32765947-9	2020	Inhibition of ERK/CREB pathway attenuated the protective effect of artemisinin.	artemisinin	67-78	cAMP responsive element binding protein 1	Homo sapiens	18-22
32765947-10	2020	These data put together suggested that artemisinin has the potential to protect neuronal cells in vitro as well as in vivo animal model 3xTg mice via, at least in part, the activation of the ERK/CREB pathway.	artemisinin	39-50	mitogen-activated protein kinase 1	Mus musculus	191-194
32765947-10	2020	These data put together suggested that artemisinin has the potential to protect neuronal cells in vitro as well as in vivo animal model 3xTg mice via, at least in part, the activation of the ERK/CREB pathway.	artemisinin	39-50	cAMP responsive element binding protein 1	Mus musculus	195-199
32696720-5	2021	Artesunate, artemisinin and artenimol, showed two mode of interactions with Lys353 and Lys31 binding hotspots of the Spike protein.	artemisinin	12-23	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	117-122
32612358-1	2020	Objective: Artemisinin (ART) is a natural anti-malarial sesquiterpene lactone which has the ability to treat and activate the CLRN1 pathway to play a pivotal role in hearing loss and hair cell function.	artemisinin	11-22	clarin 1	Homo sapiens	126-131
32653033-13	2020	Also, high prevalence of dhfr and dhps mutant alleles occurred in the study areas in Lagos, Nigeria five to eight years after the introduction of artemisinin combination therapy underscores the need for continuous monitoring.	artemisinin	146-157	dihydrofolate reductase	Homo sapiens	25-29
32653033-13	2020	Also, high prevalence of dhfr and dhps mutant alleles occurred in the study areas in Lagos, Nigeria five to eight years after the introduction of artemisinin combination therapy underscores the need for continuous monitoring.	artemisinin	146-157	deoxyhypusine synthase	Homo sapiens	34-38
32799228-0	2020	[In vitro and in silico Determination of the Interaction of Artemisinin with Human Serum Albumin].	artemisinin	60-71	albumin	Mus musculus	89-96
32799228-3	2020	The interaction of artemisinin with human serum albumin was studied both in vitro and in silico, and compared with dexamethasone.	artemisinin	19-30	albumin	Mus musculus	42-55
32799228-4	2020	The quenching of the fluorescence emission of human serum albumin with artemisinin at different temperatures proceeded according to a single mechanism and indicated the static nature, which is similar to the effect of dexamethasone.	artemisinin	71-82	albumin	Mus musculus	52-65
32799228-5	2020	Artemisinin and dexamethasone interact with Drug site I on human serum albumin.	artemisinin	0-11	albumin	Mus musculus	65-78
32799228-10	2020	Therefore, we assume that one of the main transporters of artemisinin is human serum albumin.	artemisinin	58-69	albumin	Mus musculus	79-92
32799228-11	2020	Moreover, the interaction parameters of artemisinin with human serum albumin coincide with those of dexamethasone.	artemisinin	40-51	albumin	Mus musculus	63-76
32360483-3	2020	An increasing number of studies report that artemisinin can impact the fibrotic process through various ways, such as TGF-beta, MAPK, Wnt/beta-catenin, PI3K/AKT/mTRO, FRX and Notch signaling pathways, as well as regulation of BMP-7 and cell autophagy.	artemisinin	44-55	transforming growth factor alpha	Homo sapiens	118-126
32360483-3	2020	An increasing number of studies report that artemisinin can impact the fibrotic process through various ways, such as TGF-beta, MAPK, Wnt/beta-catenin, PI3K/AKT/mTRO, FRX and Notch signaling pathways, as well as regulation of BMP-7 and cell autophagy.	artemisinin	44-55	bone morphogenetic protein 7	Homo sapiens	226-231
32304346-0	2020	Artemisinin-Derivative-NHC-gold(I)-Hybrid with enhanced cytotoxic activity through inhibiting NRF2 transcriptional activity.	artemisinin	0-11	NFE2 like bZIP transcription factor 2	Homo sapiens	94-98
32612358-1	2020	Objective: Artemisinin (ART) is a natural anti-malarial sesquiterpene lactone which has the ability to treat and activate the CLRN1 pathway to play a pivotal role in hearing loss and hair cell function.	artemisinin	24-27	clarin 1	Homo sapiens	126-131
31987792-3	2020	We found that artemisinin and clinical artemisinin derivatives are able to compensate for a mutation in the yeast Bcs1 protein, a key chaperon involved in biogenesis of the mitochondrial respiratory complex III.	artemisinin	14-25	bifunctional AAA family ATPase chaperone/translocase BCS1	Saccharomyces cerevisiae S288C	114-118
32532194-10	2021	Treatment with Artemisinin (50 mg/kg) reduced the levels of PAP, LDH, prostate weight and prostatic index to a significant extent and restored the histoarchitectural features of the cells.	artemisinin	15-26	acid phosphatase 3	Rattus norvegicus	60-63
31987792-3	2020	We found that artemisinin and clinical artemisinin derivatives are able to compensate for a mutation in the yeast Bcs1 protein, a key chaperon involved in biogenesis of the mitochondrial respiratory complex III.	artemisinin	39-50	bifunctional AAA family ATPase chaperone/translocase BCS1	Saccharomyces cerevisiae S288C	114-118
32103124-0	2020	Detection of mutations associated with artemisinin resistance at k13-propeller gene and a near complete return of chloroquine susceptible falciparum malaria in Southeast of Tanzania.	artemisinin	39-50	keratin 13	Homo sapiens	65-68
32862573-4	2020	Apoptotic effects of artemisinin were finally confirmed by western blot assay by analysing its effects on Bcl-2 and Bax protein expressions.	artemisinin	21-32	bcl-2	None	106-111
32862573-4	2020	Apoptotic effects of artemisinin were finally confirmed by western blot assay by analysing its effects on Bcl-2 and Bax protein expressions.	artemisinin	21-32	bax	None	116-119
32862573-11	2020	The molecule also targeted G2/M phase cell cycle along with targeting some key cell cycle related proteins including cyclin-B1, cyclin D1 and cyclin E. CONCLUSION: The results show that artemisinin showed strong anticancer effects in MDA-MB-231 cisplatin-resistant cancer cells by triggering apoptosis and autophagy and G2/M phase arrest.	artemisinin	186-197	cyclin-b1	None	117-126
32862573-11	2020	The molecule also targeted G2/M phase cell cycle along with targeting some key cell cycle related proteins including cyclin-B1, cyclin D1 and cyclin E. CONCLUSION: The results show that artemisinin showed strong anticancer effects in MDA-MB-231 cisplatin-resistant cancer cells by triggering apoptosis and autophagy and G2/M phase arrest.	artemisinin	186-197	cyclin d1	None	128-137
32105722-1	2020	OBJECTIVE: The dimeric artesunate phospholipid conjugate (Di-ART-GPC) is a novel amphipathic artemisinin derivative, which can be assembled into liposomes.	artemisinin	93-104	glycophorin C	Rattus norvegicus	65-68
32435422-0	2020	Artemisinin Derivatives with Antimelanoma Activity Show Inhibitory Effect against Human DNA Topoisomerase 1.	artemisinin	0-11	DNA topoisomerase I	Homo sapiens	88-107
32152546-5	2020	This included dependencies involving the transporters SLC11A2/SLC16A1 for artemisinin derivatives and SLC35A2/SLC38A5 for cisplatin.	artemisinin	74-85	solute carrier family 11 member 2	Homo sapiens	54-61
32152546-5	2020	This included dependencies involving the transporters SLC11A2/SLC16A1 for artemisinin derivatives and SLC35A2/SLC38A5 for cisplatin.	artemisinin	74-85	solute carrier family 16 member 1	Homo sapiens	62-69
31945670-10	2020	The result of fluorescence quantitative section showed that artemisinin could down-regulate the expression of notch signaling related factors notch1, Dll4 and Jagged1, and 200 mg/kg dose group had the most significant effect.	artemisinin	60-71	notch 1	Mus musculus	142-148
31945670-10	2020	The result of fluorescence quantitative section showed that artemisinin could down-regulate the expression of notch signaling related factors notch1, Dll4 and Jagged1, and 200 mg/kg dose group had the most significant effect.	artemisinin	60-71	delta like canonical Notch ligand 4	Mus musculus	150-154
31945670-10	2020	The result of fluorescence quantitative section showed that artemisinin could down-regulate the expression of notch signaling related factors notch1, Dll4 and Jagged1, and 200 mg/kg dose group had the most significant effect.	artemisinin	60-71	jagged 1	Mus musculus	159-166
32258150-0	2020	Sequence Analysis of the K13-Propeller Gene in Artemisinin Challenging Plasmodium falciparum Isolates from Malaria Endemic Areas of Odisha, India: A Molecular Surveillance Study.	artemisinin	47-58	keratin 13	Homo sapiens	25-28
32143118-8	2020	ARS compounds selectively inhibit osteoclast differentiation by downregulation of pathways involved in receptor activator of nuclear factor kappa-B ligand (RANKL) -induced osteoclastogenesis, and have no effect on osteogenic differentiation of osteoblasts.	artemisinin	0-3	TNF superfamily member 11	Homo sapiens	103-154
32143118-8	2020	ARS compounds selectively inhibit osteoclast differentiation by downregulation of pathways involved in receptor activator of nuclear factor kappa-B ligand (RANKL) -induced osteoclastogenesis, and have no effect on osteogenic differentiation of osteoblasts.	artemisinin	0-3	TNF superfamily member 11	Homo sapiens	156-161
32310999-0	2020	Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparum K13.	artemisinin	71-82	keratin 13	Homo sapiens	130-133
32310999-9	2020	These data help define the biological properties of K13 and its role in mediating P. falciparum resistance to ART treatment.	artemisinin	110-113	keratin 13	Homo sapiens	52-55
32103124-6	2020	About 422 samples were successful sequenced for K13 gene (marker for artemisinin resistance), the wild type (WT) was found in 391 samples (92.7%) whereby 31 samples (7.3%) had mutations in K13 gene.	artemisinin	69-80	keratin 13	Homo sapiens	48-51
31284865-0	2020	In Silico Screening Reveals Histone Deacetylase 7 and ERK1/2 as Potential Targets for Artemisinin Dimer and Artemisinin Dimer Hemisuccinate.	artemisinin	86-97	histone deacetylase 7	Homo sapiens	28-49
32098816-1	2020	The efficacy of current antimalarial drugs is threatened by reduced susceptibility of Plasmodium falciparum to artemisinin, associated with mutations in pfkelch13 Another gene with variants known to modulate the response to artemisinin encodes the mu subunit of the AP-2 adaptin trafficking complex.	artemisinin	111-122	transcription factor AP-2 alpha	Homo sapiens	266-270
32098816-1	2020	The efficacy of current antimalarial drugs is threatened by reduced susceptibility of Plasmodium falciparum to artemisinin, associated with mutations in pfkelch13 Another gene with variants known to modulate the response to artemisinin encodes the mu subunit of the AP-2 adaptin trafficking complex.	artemisinin	224-235	transcription factor AP-2 alpha	Homo sapiens	266-270
31791643-4	2020	Given the high antitumor activity of artemisinin dimers in comparison to their monomers, we report here the synthesis of simple 1,2,3-triazole conjugated 1,2,4-trioxanes and their potential antitumor activity by studying their inhibitory effect on osteopontin (OPN) expression in MDA-MB-435 breast cancer cells.	artemisinin	37-48	secreted phosphoprotein 1	Homo sapiens	248-259
31791643-4	2020	Given the high antitumor activity of artemisinin dimers in comparison to their monomers, we report here the synthesis of simple 1,2,3-triazole conjugated 1,2,4-trioxanes and their potential antitumor activity by studying their inhibitory effect on osteopontin (OPN) expression in MDA-MB-435 breast cancer cells.	artemisinin	37-48	secreted phosphoprotein 1	Homo sapiens	261-264
31284865-0	2020	In Silico Screening Reveals Histone Deacetylase 7 and ERK1/2 as Potential Targets for Artemisinin Dimer and Artemisinin Dimer Hemisuccinate.	artemisinin	86-97	mitogen-activated protein kinase 3	Homo sapiens	54-60
31284865-0	2020	In Silico Screening Reveals Histone Deacetylase 7 and ERK1/2 as Potential Targets for Artemisinin Dimer and Artemisinin Dimer Hemisuccinate.	artemisinin	108-119	histone deacetylase 7	Homo sapiens	28-49
31284865-0	2020	In Silico Screening Reveals Histone Deacetylase 7 and ERK1/2 as Potential Targets for Artemisinin Dimer and Artemisinin Dimer Hemisuccinate.	artemisinin	108-119	mitogen-activated protein kinase 3	Homo sapiens	54-60
31358588-3	2019	Artemisinin resistance has been associated in Southeast Asia with multiple nonsynonymous single nucleotide polymorphisms (NS-SNPs) in the propeller domain of the gene encoding the Plasmodium falciparum K13 protein (K13PD).	artemisinin	0-11	keratin 13	Homo sapiens	202-205
31636063-2	2019	Mutations in two other genes, ubp1 and ap2mu, are associated with artemisinin resistance in rodent malaria and with clinical failure of combination therapy in African malaria patients.	artemisinin	66-77	upstream binding protein 1	Homo sapiens	30-34
31636063-8	2019	Therefore, variants of the AP2 adaptor complex mu-subunit and of the ubiquitin hydrolase UBP1 reduce in vitro artemisinin susceptibility at the early ring stage in P. falciparum These findings confirm the existence of multiple pathways to perturbation of either the mode of action of artemisinin, the parasite"s adaptive mechanisms of resistance, or both.	artemisinin	110-121	upstream binding protein 1	Homo sapiens	89-93
31636063-8	2019	Therefore, variants of the AP2 adaptor complex mu-subunit and of the ubiquitin hydrolase UBP1 reduce in vitro artemisinin susceptibility at the early ring stage in P. falciparum These findings confirm the existence of multiple pathways to perturbation of either the mode of action of artemisinin, the parasite"s adaptive mechanisms of resistance, or both.	artemisinin	284-295	upstream binding protein 1	Homo sapiens	89-93
31604109-2	2019	MAIN METHODS: Eight-week-old male ApoE-/- mice were treated with ART for eight weeks.	artemisinin	65-68	apolipoprotein E	Mus musculus	34-38
31604109-5	2019	KEY FINDINGS: Artemisinin treatment significantly reduced plaque area in the ApoE-/- mice and increased the expression of contractile phenotypic markers.	artemisinin	14-25	apolipoprotein E	Mus musculus	77-81
31619243-3	2019	Whole-genome sequencing of the artemisinin-resistant parasite line revealed mutations on the k13 gene associated with drug resistance in P. falciparum.	artemisinin	31-42	keratin 13	Homo sapiens	93-96
31619243-4	2019	To understand the artemisinin resistance of the imported P. falciparum cases from Africa, the mutations in the k13 gene in parasites from imported malaria cases in Guangxi Province were detected and the treatment efficiency of artesunate monotherapy was observed.	artemisinin	18-29	keratin 13	Homo sapiens	111-114
31094238-0	2020	Artemisinin alleviates atherosclerotic lesion by reducing macrophage inflammation via regulation of AMPK/NF-kappaB/NLRP3 inflammasomes pathway.	artemisinin	0-11	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	105-114
31094238-0	2020	Artemisinin alleviates atherosclerotic lesion by reducing macrophage inflammation via regulation of AMPK/NF-kappaB/NLRP3 inflammasomes pathway.	artemisinin	0-11	NLR family, pyrin domain containing 3	Mus musculus	115-120
31094238-3	2020	The primary aim of this study was to investigate whether artemisinin could be conferred an anti-atherosclerotic effect in high-fat diet (HFD)-fed ApoE-/- mice and explore the possible mechanism.	artemisinin	57-68	apolipoprotein E	Mus musculus	146-150
31094238-5	2020	Atherosclerotic mice treated with artemisinin showed reduced inflammation by up-regulating adenosine 5"-monophosphate (AMP) activated protein kinase (AMPK) activation and by down-regulating nuclear factor-kappaB (NF-kappaB) phosphorylation and nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome expression in the aortas.	artemisinin	34-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	190-211
31094238-5	2020	Atherosclerotic mice treated with artemisinin showed reduced inflammation by up-regulating adenosine 5"-monophosphate (AMP) activated protein kinase (AMPK) activation and by down-regulating nuclear factor-kappaB (NF-kappaB) phosphorylation and nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome expression in the aortas.	artemisinin	34-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	213-222
31094238-5	2020	Atherosclerotic mice treated with artemisinin showed reduced inflammation by up-regulating adenosine 5"-monophosphate (AMP) activated protein kinase (AMPK) activation and by down-regulating nuclear factor-kappaB (NF-kappaB) phosphorylation and nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome expression in the aortas.	artemisinin	34-45	NLR family, pyrin domain containing 3	Mus musculus	296-301
31094238-7	2020	In conclusion, we demonstrate that artemisinin may protect the aortas from atherosclerotic lesions by suppression of inflammatory reaction via AMPK/NF-kappaB/NLRP3 inflammasomes signalling in macrophages.	artemisinin	35-46	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	148-157
31094238-7	2020	In conclusion, we demonstrate that artemisinin may protect the aortas from atherosclerotic lesions by suppression of inflammatory reaction via AMPK/NF-kappaB/NLRP3 inflammasomes signalling in macrophages.	artemisinin	35-46	NLR family, pyrin domain containing 3	Mus musculus	158-163
31577904-0	2019	Regulation of Artemisinin and Its Derivatives on the Assembly Behavior and Cytotoxicity of Amyloid Polypeptides hIAPP and Abeta.	artemisinin	14-25	islet amyloid polypeptide	Homo sapiens	112-117
31577904-0	2019	Regulation of Artemisinin and Its Derivatives on the Assembly Behavior and Cytotoxicity of Amyloid Polypeptides hIAPP and Abeta.	artemisinin	14-25	amyloid beta precursor protein	Homo sapiens	122-127
31577904-5	2019	In this work, four compounds, namely, artemisinin (1), dihydroartemisinin (2), artesunate (3), and artemether (4), were exploited to inhibit the assembly behavior of hIAPP and compared with that of Abeta.	artemisinin	38-49	islet amyloid polypeptide	Homo sapiens	166-171
31465776-0	2019	Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-kappaB signaling and NLRP3 inflammasome activation by exosomes in rats.	artemisinin	26-37	nuclear factor kappa B subunit 1	Homo sapiens	116-125
31465776-0	2019	Renoprotective effects of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via suppressing NF-kappaB signaling and NLRP3 inflammasome activation by exosomes in rats.	artemisinin	26-37	NLR family, pyrin domain containing 3	Rattus norvegicus	140-145
31358323-0	2019	Anti-inflammatory effect of artemisinin on uric acid-induced NLRP3 inflammasome activation through blocking interaction between NLRP3 and NEK7.	artemisinin	28-39	NLR family pyrin domain containing 3	Homo sapiens	61-66
31358323-0	2019	Anti-inflammatory effect of artemisinin on uric acid-induced NLRP3 inflammasome activation through blocking interaction between NLRP3 and NEK7.	artemisinin	28-39	NLR family pyrin domain containing 3	Homo sapiens	128-133
31358323-9	2019	Enhanced expression of NLRP3, caspase-1, and IL-1beta was noted in macrophages treated with LPS (10 ng/ml) and MSU crystals (0.1 mg/ml), which was markedly suppressed by treatment with artemisinin (1, 10, and 100 muM).	artemisinin	185-196	interleukin 1 beta	Homo sapiens	45-53
31358323-0	2019	Anti-inflammatory effect of artemisinin on uric acid-induced NLRP3 inflammasome activation through blocking interaction between NLRP3 and NEK7.	artemisinin	28-39	NIMA related kinase 7	Homo sapiens	138-142
31358323-9	2019	Enhanced expression of NLRP3, caspase-1, and IL-1beta was noted in macrophages treated with LPS (10 ng/ml) and MSU crystals (0.1 mg/ml), which was markedly suppressed by treatment with artemisinin (1, 10, and 100 muM).	artemisinin	185-196	latexin	Homo sapiens	213-216
31358323-10	2019	Artemisinin significantly inhibited interaction between NLRP3 and NEK7 in NLRP3 inflammasome activation.	artemisinin	0-11	NLR family pyrin domain containing 3	Homo sapiens	56-61
31358323-3	2019	The aim of this study was to clarify the anti-inflammatory effect of artemisinin on activation of uric acid-induced NLRP3 inflammasome through regulation of NEK7.	artemisinin	69-80	NLR family pyrin domain containing 3	Homo sapiens	116-121
31358323-3	2019	The aim of this study was to clarify the anti-inflammatory effect of artemisinin on activation of uric acid-induced NLRP3 inflammasome through regulation of NEK7.	artemisinin	69-80	NIMA related kinase 7	Homo sapiens	157-161
31358323-10	2019	Artemisinin significantly inhibited interaction between NLRP3 and NEK7 in NLRP3 inflammasome activation.	artemisinin	0-11	NIMA related kinase 7	Homo sapiens	66-70
31358323-10	2019	Artemisinin significantly inhibited interaction between NLRP3 and NEK7 in NLRP3 inflammasome activation.	artemisinin	0-11	NLR family pyrin domain containing 3	Homo sapiens	74-79
31358323-9	2019	Enhanced expression of NLRP3, caspase-1, and IL-1beta was noted in macrophages treated with LPS (10 ng/ml) and MSU crystals (0.1 mg/ml), which was markedly suppressed by treatment with artemisinin (1, 10, and 100 muM).	artemisinin	185-196	NLR family pyrin domain containing 3	Homo sapiens	23-28
31358323-11	2019	Artemisinin (10 and 100 muM) attenuated intracellular K+ efflux in macrophages stimulated with LPS and MSU crystals.	artemisinin	0-11	latexin	Homo sapiens	24-27
31112710-0	2019	A novel derivative of artemisinin inhibits cell proliferation and metastasis via down-regulation of cathepsin K in breast cancer.	artemisinin	22-33	cathepsin K	Homo sapiens	100-111
31358323-13	2019	CONCLUSION: This study revealed that artemisinin inhibited activation of NLRP3 inflammasome by suppressing interaction between NEK7 and NLRP3 in uric acid-induced inflammation.	artemisinin	37-48	NLR family pyrin domain containing 3	Homo sapiens	73-78
31358323-13	2019	CONCLUSION: This study revealed that artemisinin inhibited activation of NLRP3 inflammasome by suppressing interaction between NEK7 and NLRP3 in uric acid-induced inflammation.	artemisinin	37-48	NIMA related kinase 7	Homo sapiens	127-131
31358323-13	2019	CONCLUSION: This study revealed that artemisinin inhibited activation of NLRP3 inflammasome by suppressing interaction between NEK7 and NLRP3 in uric acid-induced inflammation.	artemisinin	37-48	NLR family pyrin domain containing 3	Homo sapiens	136-141
31440140-9	2019	Finally, we will also summarize how anti-malarial artemisinin drugs modulate gephyrin-mediated inhibitory neurotransmission.	artemisinin	50-61	gephyrin	Homo sapiens	77-85
31387196-8	2019	RESULT: The skin erythema and histopathological alteration, as well as the elevated pro-inflammatory factors (IL-1beta, IL6, TNFalpha) and TLR2 were significantly ameliorated by ART treatment in LL37-induced rosacea-like mice.	artemisinin	178-181	interleukin 1 alpha	Mus musculus	110-118
31387196-8	2019	RESULT: The skin erythema and histopathological alteration, as well as the elevated pro-inflammatory factors (IL-1beta, IL6, TNFalpha) and TLR2 were significantly ameliorated by ART treatment in LL37-induced rosacea-like mice.	artemisinin	178-181	interleukin 6	Mus musculus	120-123
31387196-8	2019	RESULT: The skin erythema and histopathological alteration, as well as the elevated pro-inflammatory factors (IL-1beta, IL6, TNFalpha) and TLR2 were significantly ameliorated by ART treatment in LL37-induced rosacea-like mice.	artemisinin	178-181	tumor necrosis factor	Mus musculus	125-133
31387196-8	2019	RESULT: The skin erythema and histopathological alteration, as well as the elevated pro-inflammatory factors (IL-1beta, IL6, TNFalpha) and TLR2 were significantly ameliorated by ART treatment in LL37-induced rosacea-like mice.	artemisinin	178-181	toll-like receptor 2	Mus musculus	139-143
31387196-8	2019	RESULT: The skin erythema and histopathological alteration, as well as the elevated pro-inflammatory factors (IL-1beta, IL6, TNFalpha) and TLR2 were significantly ameliorated by ART treatment in LL37-induced rosacea-like mice.	artemisinin	178-181	cathelicidin antimicrobial peptide	Homo sapiens	195-199
31452821-7	2019	By contrast, artemisinin decreased proliferative capacity, decreased migration, decreased vimentin expression and increased E-cadherin expression of EMT model cells, indicating that MET was induced.	artemisinin	13-24	vimentin	Homo sapiens	90-98
31452821-7	2019	By contrast, artemisinin decreased proliferative capacity, decreased migration, decreased vimentin expression and increased E-cadherin expression of EMT model cells, indicating that MET was induced.	artemisinin	13-24	cadherin 1	Homo sapiens	124-134
31523201-2	2019	In the current study, we investigated the role of AMPK in the protective effect of artemisinin, an FDA approved anti-malarial Chinese herbal drug, on RPE cell line D407, against H2O2 induced oxidative stress.	artemisinin	83-94	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	50-54
31009824-1	2019	Mutations in the Kelch domain of the K13 gene (PF3D7_1343700) were previously associated with artemisinin resistance in Plasmodium falciparum.	artemisinin	94-105	kelch like family member 2	Homo sapiens	17-22
30536376-9	2019	Based on our data, we believe that Art can inhibit proliferation of breast cancer cells by activating apoptosis pathways, and inhibit osteoclast formation and differentiation by inhibiting activation of cathepsin K, ATPase H+ transporting V0 subunit D2, nuclear factor of activated T cells 1, calcitonin receptor, and tartrate-resistant acid phosphatase and by inhibiting nuclear factor-kappaB activation.	artemisinin	35-38	cathepsin K	Homo sapiens	203-214
31085516-0	2019	Evolution and Genetic Diversity of the k13 Gene Associated with Artemisinin Delayed Parasite Clearance in Plasmodium falciparum.	artemisinin	64-75	keratin 13	Homo sapiens	39-42
31523201-5	2019	Western blotting showed that artemisinin concentration- and time-dependently stimulated the phosphorylation of AMP-activated protein kinase (AMPK) in D407 cells while AMPK inhibitor Compound C or knock-down of AMPK by si-RNA, inhibited the survival protective effect of artemisinin.	artemisinin	29-40	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	111-139
31523201-5	2019	Western blotting showed that artemisinin concentration- and time-dependently stimulated the phosphorylation of AMP-activated protein kinase (AMPK) in D407 cells while AMPK inhibitor Compound C or knock-down of AMPK by si-RNA, inhibited the survival protective effect of artemisinin.	artemisinin	29-40	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	141-145
31523201-5	2019	Western blotting showed that artemisinin concentration- and time-dependently stimulated the phosphorylation of AMP-activated protein kinase (AMPK) in D407 cells while AMPK inhibitor Compound C or knock-down of AMPK by si-RNA, inhibited the survival protective effect of artemisinin.	artemisinin	29-40	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	167-171
31523201-5	2019	Western blotting showed that artemisinin concentration- and time-dependently stimulated the phosphorylation of AMP-activated protein kinase (AMPK) in D407 cells while AMPK inhibitor Compound C or knock-down of AMPK by si-RNA, inhibited the survival protective effect of artemisinin.	artemisinin	29-40	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	167-171
31523201-5	2019	Western blotting showed that artemisinin concentration- and time-dependently stimulated the phosphorylation of AMP-activated protein kinase (AMPK) in D407 cells while AMPK inhibitor Compound C or knock-down of AMPK by si-RNA, inhibited the survival protective effect of artemisinin.	artemisinin	270-281	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	111-139
31523201-5	2019	Western blotting showed that artemisinin concentration- and time-dependently stimulated the phosphorylation of AMP-activated protein kinase (AMPK) in D407 cells while AMPK inhibitor Compound C or knock-down of AMPK by si-RNA, inhibited the survival protective effect of artemisinin.	artemisinin	270-281	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	141-145
31523201-6	2019	More importantly, artemisinin produced a similar protective effect in primary cultured retinal pigment cells which was also blocked by inhibitors of AMPK.	artemisinin	18-29	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	149-153
31523201-7	2019	Taken together, these results suggested that artemisinin promotes survival of human retinal pigment cells against H2O2-induced cell death at least in part through enhancing the activation of AMPK.	artemisinin	45-56	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	191-195
31097578-6	2019	On expression of GRASP55 mRNA, or on exposure to the drug artemisinin (which activates GCUSP), the localization of CLRN1N48K to the hair bundles was enhanced.	artemisinin	58-69	golgi reassembly stacking protein 2	Homo sapiens	17-24
31263819-0	2019	Identification of HSP90 as a direct target of artemisinin for its anti-inflammatory activity via quantitative chemical proteomics.	artemisinin	46-57	heat shock protein 90 alpha family class A member 1	Homo sapiens	18-23
30869127-0	2019	Plasmodium falciparum K13 expression associated with parasite clearance during artemisinin-based combination therapy.	artemisinin	79-90	keratin 13	Homo sapiens	22-25
30869127-1	2019	BACKGROUND: Delayed parasite clearance and, consequently, reduced efficacy of artemisinin-based combination therapies have been linked with Plasmodium falciparum K13 gene SNPs in Southeast Asia.	artemisinin	78-89	keratin 13	Homo sapiens	162-165
31301971-0	2019	Interactions between artemisinin derivatives and P-glycoprotein.	artemisinin	21-32	ATP binding cassette subfamily B member 1	Homo sapiens	49-63
31301971-4	2019	Interestingly, many artemisinin derivatives exhibit excellent ability to overcome P-gp mediated MDR and even show collateral sensitivity against MDR cancer cells.	artemisinin	20-31	ATP binding cassette subfamily B member 1	Homo sapiens	82-86
31301971-5	2019	Furthermore, some artemisinin derivatives show P-gp-mediated MDR reversal activity.	artemisinin	18-29	ATP binding cassette subfamily B member 1	Homo sapiens	47-51
31301971-6	2019	Therefore, the interaction between P-gp and artemisinin derivatives is important to develop novel combination treatment protocols with artemisinin derivatives and established anticancer drugs that are P-gp substrates.	artemisinin	44-55	ATP binding cassette subfamily B member 1	Homo sapiens	201-205
31301971-6	2019	Therefore, the interaction between P-gp and artemisinin derivatives is important to develop novel combination treatment protocols with artemisinin derivatives and established anticancer drugs that are P-gp substrates.	artemisinin	135-146	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
31301971-7	2019	PURPOSE: This systematic review provides an updated overview on the interaction between artemisinin derivatives and P-gp and the effect of artemisinin derivatives on the P-gp expression level.	artemisinin	88-99	ATP binding cassette subfamily B member 1	Homo sapiens	116-120
31301971-7	2019	PURPOSE: This systematic review provides an updated overview on the interaction between artemisinin derivatives and P-gp and the effect of artemisinin derivatives on the P-gp expression level.	artemisinin	139-150	ATP binding cassette subfamily B member 1	Homo sapiens	170-174
31301971-8	2019	RESULTS: Artemisinin derivatives exhibit multi-specific interactions with P-gp.	artemisinin	9-20	ATP binding cassette subfamily B member 1	Homo sapiens	74-78
31301971-10	2019	However, some of novel synthetized artemisinin derivatives exhibit P-gp substrate properties.	artemisinin	35-46	ATP binding cassette subfamily B member 1	Homo sapiens	67-71
31301971-11	2019	Furthermore, many artemisinin derivatives act as P-gp inhibitors, which exhibit the potential to reverse MDR towards clinically used anticancer drugs.	artemisinin	18-29	ATP binding cassette subfamily B member 1	Homo sapiens	49-53
31301971-12	2019	CONCLUSION: Therefore, studies on the interaction between artemisinin derivatives and P-gp provide important information for the development of novel anti-cancer artemisinin derivatives to reverse P-gp mediated MDR and for the design of rational artemisinin-based combination therapies against cancer.	artemisinin	58-69	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
31301971-12	2019	CONCLUSION: Therefore, studies on the interaction between artemisinin derivatives and P-gp provide important information for the development of novel anti-cancer artemisinin derivatives to reverse P-gp mediated MDR and for the design of rational artemisinin-based combination therapies against cancer.	artemisinin	58-69	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
31301971-12	2019	CONCLUSION: Therefore, studies on the interaction between artemisinin derivatives and P-gp provide important information for the development of novel anti-cancer artemisinin derivatives to reverse P-gp mediated MDR and for the design of rational artemisinin-based combination therapies against cancer.	artemisinin	162-173	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
31301971-12	2019	CONCLUSION: Therefore, studies on the interaction between artemisinin derivatives and P-gp provide important information for the development of novel anti-cancer artemisinin derivatives to reverse P-gp mediated MDR and for the design of rational artemisinin-based combination therapies against cancer.	artemisinin	162-173	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
31301971-12	2019	CONCLUSION: Therefore, studies on the interaction between artemisinin derivatives and P-gp provide important information for the development of novel anti-cancer artemisinin derivatives to reverse P-gp mediated MDR and for the design of rational artemisinin-based combination therapies against cancer.	artemisinin	162-173	ATP binding cassette subfamily B member 1	Homo sapiens	86-90
31301971-12	2019	CONCLUSION: Therefore, studies on the interaction between artemisinin derivatives and P-gp provide important information for the development of novel anti-cancer artemisinin derivatives to reverse P-gp mediated MDR and for the design of rational artemisinin-based combination therapies against cancer.	artemisinin	162-173	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
31269339-5	2019	Each concentration of artemisinin increased the total serum proteins, gamma-globulins and the serum activity of CK and decreased the serum ALP level.	artemisinin	22-33	cytidine/uridine monophosphate kinase 1	Gallus gallus	112-114
31269339-5	2019	Each concentration of artemisinin increased the total serum proteins, gamma-globulins and the serum activity of CK and decreased the serum ALP level.	artemisinin	22-33	PDZ and LIM domain 3	Gallus gallus	139-142
31151322-0	2019	Artemisinin Attenuated Hydrogen Peroxide (H2O2)-Induced Oxidative Injury in SH-SY5Y and Hippocampal Neurons via the Activation of AMPK Pathway.	artemisinin	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	130-134
31151322-6	2019	Further studies showed that artemisinin significantly restored the nuclear morphology, improved the abnormal changes in intracellular reactive oxygen species (ROS), reduced the mitochondrial membrane potential, and caspase-3 activation, thereby attenuating apoptosis.	artemisinin	28-39	caspase 3	Homo sapiens	215-224
31151322-7	2019	Artemisinin also stimulated the phosphorylation of the adenosine monophosphate -activated protein kinase (AMPK) pathway in SH-SY5Y cells in a time- and concentration-dependent manner.	artemisinin	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	55-104
31151322-7	2019	Artemisinin also stimulated the phosphorylation of the adenosine monophosphate -activated protein kinase (AMPK) pathway in SH-SY5Y cells in a time- and concentration-dependent manner.	artemisinin	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	106-110
31151322-8	2019	Inhibition of the AMPK pathway attenuated the protective effect of artemisinin.	artemisinin	67-78	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	18-22
31151322-11	2019	Cumulatively, these results indicated that artemisinin protected neuronal cells from oxidative damage, at least in part through the activation of AMPK.	artemisinin	43-54	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	146-150
31097578-7	2019	Artemisinin treatment also effectively restored hair cell mechanotransduction and attenuated progressive hair cell dysfunction in clrn1 KO/KO larvae that express CLRN1 c.144T>G , highlighting the potential of artemisinin to prevent sensory loss in CLRN1 c.144T>G patients.	artemisinin	0-11	clarin 1	Homo sapiens	130-135
31097578-7	2019	Artemisinin treatment also effectively restored hair cell mechanotransduction and attenuated progressive hair cell dysfunction in clrn1 KO/KO larvae that express CLRN1 c.144T>G , highlighting the potential of artemisinin to prevent sensory loss in CLRN1 c.144T>G patients.	artemisinin	0-11	clarin 1	Homo sapiens	162-167
31097578-7	2019	Artemisinin treatment also effectively restored hair cell mechanotransduction and attenuated progressive hair cell dysfunction in clrn1 KO/KO larvae that express CLRN1 c.144T>G , highlighting the potential of artemisinin to prevent sensory loss in CLRN1 c.144T>G patients.	artemisinin	0-11	clarin 1	Homo sapiens	251-256
30707255-4	2019	In addition to its well-established antimalarial properties, emerging evidence hints that artemisinin family drugs also possess preferential immunoregulatory and anti-inflammation properties, such as modifying T lymphocytes" activation and cytokines release, modulating Th1/Th2 balance, activating regulatory T cells (Tregs), modulating inflammatory signaling pathways, as well as acting on non-specific mechanisms of OLP.	artemisinin	90-101	negative elongation factor complex member C/D	Homo sapiens	270-273
31156427-10	2019	It is also important to highlight that several plant-derived products (compounds, essential oils) from Artemisia plants have shown high inhibitory potential against Leishmania spp., such as artemisinin and its derivatives.	artemisinin	190-201	histocompatibility minor 13	Homo sapiens	176-179
30746754-0	2019	Artemisinin inhibits angiogenesis by regulating p38 MAPK/CREB/TSP-1 signaling pathway in osteosarcoma.	artemisinin	0-11	cAMP responsive element binding protein 1	Homo sapiens	57-61
30934859-0	2019	Possible Role of the Ca2+/Mn2+ P-Type ATPase Pmr1p on Artemisinin Toxicity through an Induction of Intracellular Oxidative Stress.	artemisinin	54-65	Ca(2+)/Mn(2+)-transporting P-type ATPase PMR1	Saccharomyces cerevisiae S288C	45-50
30934859-3	2019	We utilized Saccharomyces cerevisiae as a model to examine the involvement of Pmr1p, a functional homolog of PfATP6, on the toxicity of artemisinin.	artemisinin	136-147	Ca(2+)/Mn(2+)-transporting P-type ATPase PMR1	Saccharomyces cerevisiae S288C	78-83
30934859-4	2019	Our analysis demonstrated that cells lacking Pmr1p are less susceptible to growth inhibition from artemisinin and its derivatives.	artemisinin	98-109	Ca(2+)/Mn(2+)-transporting P-type ATPase PMR1	Saccharomyces cerevisiae S288C	45-50
30934859-9	2019	We propose that loss of function mutations in Pmr1p in yeast cells and PfATP6 in P. falciparum are protective against artemisinin toxicity due to reduced intracellular oxidative damage.	artemisinin	118-129	Ca(2+)/Mn(2+)-transporting P-type ATPase PMR1	Saccharomyces cerevisiae S288C	46-51
30260039-0	2019	Artemisinin attenuates tubulointerstitial inflammation and fibrosis via the NF-kappaB/NLRP3 pathway in rats with 5/6 subtotal nephrectomy.	artemisinin	0-11	NLR family, pyrin domain containing 3	Rattus norvegicus	86-91
30260039-10	2019	Furthermore, Art inhibited the activation of NLRP3 inflammasome and NF-kappaB in the kidneys.	artemisinin	13-16	NLR family, pyrin domain containing 3	Rattus norvegicus	45-50
30790532-3	2019	(2019) demonstrate that artemisinin antimalarial drugs bind to gephyrin at the same site where the receptor interaction occurs.	artemisinin	24-35	gephyrin	Homo sapiens	63-71
30783079-2	2019	Here, we evaluated a library of natural compounds for inhibitors of Axl and identified dihydroartemisinin, the active principle of the anti-malarial drug artemisinin, as an Axl-inhibitor in prostate cancer.	artemisinin	94-105	AXL receptor tyrosine kinase	Homo sapiens	173-176
30746754-0	2019	Artemisinin inhibits angiogenesis by regulating p38 MAPK/CREB/TSP-1 signaling pathway in osteosarcoma.	artemisinin	0-11	thrombospondin 1	Homo sapiens	62-67
30746754-6	2019	In this study, we found that artemisinin could induce both the expression and secretion of thrombospondin-1 (TSP-1) in a dose-dependent way in osteosarcoma cells.	artemisinin	29-40	thrombospondin 1	Homo sapiens	91-107
30746754-6	2019	In this study, we found that artemisinin could induce both the expression and secretion of thrombospondin-1 (TSP-1) in a dose-dependent way in osteosarcoma cells.	artemisinin	29-40	thrombospondin 1	Homo sapiens	109-114
30746754-7	2019	In addition, TSP-1 could effectively restore the artemisinin-induced suppression of angiogenesis in human umbilical vein endothelial cells (HUVECs).	artemisinin	49-60	thrombospondin 1	Homo sapiens	13-18
30746754-9	2019	Moreover, our results showed that artemisinin could induce the phosphorylation of CREB via the activation of p38 mitogen-activated protein kinase (MAPK) signaling pathway in osteosarcoma cells.	artemisinin	34-45	cAMP responsive element binding protein 1	Homo sapiens	82-86
30746754-9	2019	Moreover, our results showed that artemisinin could induce the phosphorylation of CREB via the activation of p38 mitogen-activated protein kinase (MAPK) signaling pathway in osteosarcoma cells.	artemisinin	34-45	mitogen-activated protein kinase 14	Homo sapiens	109-145
30746754-10	2019	In vivo, we also found that artemisinin could inhibit osteosarcoma proliferation and angiogenesis by regulating the p38 MAPK/CREB/TSP-1 signaling pathway.	artemisinin	28-39	cAMP responsive element binding protein 1	Homo sapiens	125-129
30746754-10	2019	In vivo, we also found that artemisinin could inhibit osteosarcoma proliferation and angiogenesis by regulating the p38 MAPK/CREB/TSP-1 signaling pathway.	artemisinin	28-39	thrombospondin 1	Homo sapiens	130-135
30746754-11	2019	Taken together, our findings indicated that artemisinin could inhibit angiogenesis by regulating the p38 MAPK/CREB/TSP-1 signaling pathway in osteosarcoma.	artemisinin	44-55	cAMP responsive element binding protein 1	Homo sapiens	110-114
30746754-11	2019	Taken together, our findings indicated that artemisinin could inhibit angiogenesis by regulating the p38 MAPK/CREB/TSP-1 signaling pathway in osteosarcoma.	artemisinin	44-55	thrombospondin 1	Homo sapiens	115-120
30607137-0	2018	Patients" adherence to artemisinin-based combination therapy and healthcare workers" perception and practice in Savannakhet province, Lao PDR.	artemisinin	23-34	interleukin 4 induced 1	Homo sapiens	134-137
30337251-8	2018	An enhancement of SP1 and CD14 expression was observed in artemisinin treated human monocyte cell line.	artemisinin	58-69	CD14 molecule	Homo sapiens	26-30
30278333-0	2018	Development of high potent and selective Bcl-2 inhibitors bearing the structural elements of natural product artemisinin.	artemisinin	109-120	BCL2 apoptosis regulator	Homo sapiens	41-46
30278333-1	2018	By taking advantage of the apoptosis-inducing capacity of artemisinin derivatives, we developed several series of compounds by merging the basic structural elements of the natural product artemisinin into the P2 interaction pocket of the clinically prescribed Bcl-2 inhibitor venetoclax.	artemisinin	58-69	BCL2 apoptosis regulator	Homo sapiens	260-265
30278333-1	2018	By taking advantage of the apoptosis-inducing capacity of artemisinin derivatives, we developed several series of compounds by merging the basic structural elements of the natural product artemisinin into the P2 interaction pocket of the clinically prescribed Bcl-2 inhibitor venetoclax.	artemisinin	188-199	BCL2 apoptosis regulator	Homo sapiens	260-265
30505200-4	2018	We found that artemisinin inhibited the proliferation in C6 cells and induced cell cycle arrest and a caspase-3-dependent cell apoptosis.	artemisinin	14-25	caspase 3	Rattus norvegicus	102-111
30271498-2	2018	Dihydroartemisinin (DHA), a the effective anti-malarial derivative of artemisinin, demonstrated potent anti-angiogenic activities that closely related to the regulation of vascular endothelial growth factor (VEGF) signaling cascade.	artemisinin	7-18	vascular endothelial growth factor A	Homo sapiens	172-206
30367653-0	2018	A single nucleotide polymorphism in the Plasmodium falciparum atg18 gene associates with artemisinin resistance and confers enhanced parasite survival under nutrient deprivation.	artemisinin	89-100	phosphoinositide binding protein ATG18	Saccharomyces cerevisiae S288C	62-67
30367653-4	2018	RESULTS: A SNP in autophagy-related gene 18 (atg18) was associated with long parasite clearance half-life in patients following artemisinin-based combination therapy.	artemisinin	128-139	phosphoinositide binding protein ATG18	Saccharomyces cerevisiae S288C	45-50
30367653-10	2018	CONCLUSIONS: These results suggest that the atg18 T38I polymorphism may provide additional resistance against artemisinin derivatives, but not partner drugs, even in the absence of kelch13 mutations, and may also be important in parasite survival during nutrient deprivation.	artemisinin	110-121	phosphoinositide binding protein ATG18	Saccharomyces cerevisiae S288C	44-49
30443164-0	2018	Plasmodium falciparum Treated with Artemisinin-based Combined Therapy Exhibits Enhanced Mutation, Heightened Cortisol and TNF-alpha Induction.	artemisinin	35-46	tumor necrosis factor	Homo sapiens	122-131
30271498-2	2018	Dihydroartemisinin (DHA), a the effective anti-malarial derivative of artemisinin, demonstrated potent anti-angiogenic activities that closely related to the regulation of vascular endothelial growth factor (VEGF) signaling cascade.	artemisinin	7-18	vascular endothelial growth factor A	Homo sapiens	208-212
29731711-6	2018	Furthermore, our study demonstrated that artemisinin activated Akt/Bcl-2 signaling and that neuroprotective effect of artemisinin was blocked by Akt-specific inhibitor, MK2206.	artemisinin	41-52	thymoma viral proto-oncogene 1	Mus musculus	63-66
28737446-10	2018	The fm, CYP2B6 values for artemisinin, bupropion, clopidogrel, ketamine, selegiline, sertraline and ticlopidine were 0.46, 0.17, 0.15, 0.60, 0.51, 0.66 and 0.77, respectively, in HLM determined by chemical inhibition method in the presence of BSA (0.5% w/v).	artemisinin	26-37	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	8-14
29991950-2	2018	This study aimed to explore the effects of artemisinin alone or combined with neurectomy of pterygoid canal in ovalbumin-induced AR mouse model and illustrate the underlying mechanisms.	artemisinin	43-54	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	111-120
29991950-10	2018	An increased Treg cell proportion and inhibited ERK phosphorylation were observed in artemisinin-treated groups as compared to those in the AR group.	artemisinin	85-96	mitogen-activated protein kinase 1	Mus musculus	48-51
29991950-12	2018	Conclusions: These results indicated that artemisinin exhibited anti-allergic effect by inhibiting ERK activation and increasing Treg cell proportion, which subsequently decreased the expressions of allergic mediators.	artemisinin	42-53	mitogen-activated protein kinase 1	Mus musculus	99-102
29690890-0	2018	A novel field-based molecular assay to detect validated artemisinin-resistant k13 mutants.	artemisinin	56-67	keratin 13	Homo sapiens	78-81
30159225-1	2018	Objectives: The CYP2B6 is one of the most polymorphic CYP genes in humans that has the potential to modify the pharmacological and toxicological responses to clinically important drugs such as antimalarial artemisinin and its derivatives.	artemisinin	206-217	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	16-22
29967165-3	2018	The beta5 inhibitors synergize with a beta2 inhibitor in vitro and in mice and with artemisinin.	artemisinin	84-95	integrin beta 5	Mus musculus	4-9
30011856-1	2018	According to the precepts that C-10 amino-artemisinins display optimum biological activities for the artemisinin drug class, and that attachment of a sugar enhances specificity of drug delivery, polarity and solubility so as to attenuate toxicity, we assessed the effects of attaching sugars to N-4 of the dihydroartemisinin (DHA)-piperazine derivative prepared in one step from DHA and piperazine.	artemisinin	42-53	homeobox C10	Homo sapiens	31-35
28737446-9	2018	The fm, CYP2B6 values for artemisinin, bupropion, clopidogrel, ketamine, selegiline, sertraline and ticlopidine were 0.24, 0.28, 0.15, 0.45, 0.46, 0.42 and 0.54, respectively, in HLM determined by chemical inhibition method.	artemisinin	26-37	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	8-14
29731711-7	2018	Taken together, our study indicated that artemisinin prevented neuronal HT-22 cell from glutamate-induced oxidative injury by activation of Akt signaling pathway.	artemisinin	41-52	thymoma viral proto-oncogene 1	Mus musculus	140-143
29731711-6	2018	Furthermore, our study demonstrated that artemisinin activated Akt/Bcl-2 signaling and that neuroprotective effect of artemisinin was blocked by Akt-specific inhibitor, MK2206.	artemisinin	41-52	B cell leukemia/lymphoma 2	Mus musculus	67-72
29731711-6	2018	Furthermore, our study demonstrated that artemisinin activated Akt/Bcl-2 signaling and that neuroprotective effect of artemisinin was blocked by Akt-specific inhibitor, MK2206.	artemisinin	41-52	thymoma viral proto-oncogene 1	Mus musculus	145-148
29731711-6	2018	Furthermore, our study demonstrated that artemisinin activated Akt/Bcl-2 signaling and that neuroprotective effect of artemisinin was blocked by Akt-specific inhibitor, MK2206.	artemisinin	118-129	thymoma viral proto-oncogene 1	Mus musculus	145-148
30266137-1	2018	In the present study, a transferrin-conjugated nanostructured lipid carrier (TF-NLCs) for brain delivery of artemisinin (ART) was developed.	artemisinin	108-119	transferrin	Homo sapiens	24-35
29456648-0	2018	Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-kappaB signaling pathway in lupus nephritis mice.	artemisinin	52-63	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	92-113
30562742-0	2018	Artemisinin Ameliorates Osteoarthritis by Inhibiting the Wnt/beta-Catenin Signaling Pathway.	artemisinin	0-11	catenin beta 1	Homo sapiens	61-73
29246124-12	2017	Along with orphan nuclear receptors (ERRalpha, ERRbeta and ERRgamma), artemisinin altered the ERalpha/ERbeta/PR/Her expression status of MCF-7 cells.	artemisinin	70-81	estrogen receptor 1	Homo sapiens	94-101
33525848-8	2017	Alternative candidate markers of artemisinin susceptibility are also described, as K13-independent treatment failure has been observed in African P. falciparum and in the rodent malaria parasite Plasmodium chabaudi.	artemisinin	33-44	keratin 13	Homo sapiens	83-86
29246124-12	2017	Along with orphan nuclear receptors (ERRalpha, ERRbeta and ERRgamma), artemisinin altered the ERalpha/ERbeta/PR/Her expression status of MCF-7 cells.	artemisinin	70-81	estrogen receptor 2	Homo sapiens	102-108
28952817-2	2017	Artemisinin, as an anti-malaria as its agent, has been used widely in the treatment of malaria, shifts the lymphocyte responses from Th1 to Th2.	artemisinin	0-11	heart and neural crest derivatives expressed 2	Mus musculus	140-143
29241036-2	2017	(2017) show that translational repression through eIF2alpha phosphorylation mediated by PK4 kinase activity plays a key role in artemisinin resistance in recrudescent malaria infections.	artemisinin	128-139	eukaryotic translation initiation factor 2A	Homo sapiens	50-59
29241041-0	2017	Inhibiting the Plasmodium eIF2alpha Kinase PK4 Prevents Artemisinin-Induced Latency.	artemisinin	56-67	eukaryotic translation initiation factor 2A	Mus musculus	26-35
28952817-9	2017	The concentration of IFN-gamma in the low dose of artemisinin treated group showed significantly (p value < .05) lower in comparison to the untreated group.	artemisinin	50-61	interferon gamma	Mus musculus	21-30
28952817-11	2017	CONCLUSIONS: Since, artemisinin can shift the immune responses from Th1 to Th2, therefore, it can be helpful in the treatment of MS after more investigation.	artemisinin	20-31	heart and neural crest derivatives expressed 2	Mus musculus	75-78
27931149-0	2017	Chrysosplenetin inhibits artemisinin efflux in P-gp-over-expressing Caco-2 cells and reverses P-gp/MDR1 mRNA up-regulated expression induced by artemisinin in mouse small intestine.	artemisinin	25-36	phosphoglycolate phosphatase	Homo sapiens	47-51
27931149-0	2017	Chrysosplenetin inhibits artemisinin efflux in P-gp-over-expressing Caco-2 cells and reverses P-gp/MDR1 mRNA up-regulated expression induced by artemisinin in mouse small intestine.	artemisinin	144-155	phosphoglycolate phosphatase	Homo sapiens	94-98
27931149-0	2017	Chrysosplenetin inhibits artemisinin efflux in P-gp-over-expressing Caco-2 cells and reverses P-gp/MDR1 mRNA up-regulated expression induced by artemisinin in mouse small intestine.	artemisinin	144-155	ATP binding cassette subfamily B member 1	Homo sapiens	99-103
29387451-3	2017	Herein, we report that dihydroartemisinin, one of the most active derivatives of Artemisinin, directly targets platelet-derived growth factor receptor-alpha (PDGFRalpha) to inhibit ovarian cancer cell growth and metastasis.	artemisinin	81-92	platelet derived growth factor receptor alpha	Homo sapiens	111-156
29178921-1	2017	BACKGROUND: Artemisinin resistance, linked to polymorphisms in the Kelch gene on chromosome 13 of Plasmodium falciparum (k13), has outpaced containment efforts in South East Asia.	artemisinin	12-23	keratin 13	Homo sapiens	121-124
29178921-9	2017	The prevalence of k13 mutations as well as allele diversity varies considerably across short distances, presumably because of historical patterns of artemisinin use and population movements.	artemisinin	149-160	keratin 13	Homo sapiens	18-21
29387451-3	2017	Herein, we report that dihydroartemisinin, one of the most active derivatives of Artemisinin, directly targets platelet-derived growth factor receptor-alpha (PDGFRalpha) to inhibit ovarian cancer cell growth and metastasis.	artemisinin	81-92	platelet derived growth factor receptor alpha	Homo sapiens	158-168
29387451-7	2017	Considering that Artemisinin compounds are currently clinically used drugs with favorable safety profiles, the results from this study will potentiate their use in combination with clinically used PDGFRalpha inhibitors, leading to maximal therapeutic efficacy with minimal adverse effects in PDGFRalpha-positive cancer patients.	artemisinin	17-28	platelet derived growth factor receptor alpha	Homo sapiens	197-207
29387451-7	2017	Considering that Artemisinin compounds are currently clinically used drugs with favorable safety profiles, the results from this study will potentiate their use in combination with clinically used PDGFRalpha inhibitors, leading to maximal therapeutic efficacy with minimal adverse effects in PDGFRalpha-positive cancer patients.	artemisinin	17-28	platelet derived growth factor receptor alpha	Homo sapiens	292-302
28447781-7	2017	Taken together, these results demonstrated that artemisinin promoted the survival of RGC-5 cells from H2O2 toxicity via the activation of the p38 and ERK1/2 pathways.	artemisinin	48-59	mitogen-activated protein kinase 14	Mus musculus	142-145
28341405-0	2017	Synthesis of novel C-9 carbon substituted derivatives of artemisinin.	artemisinin	57-68	complement C9	Homo sapiens	19-22
29078767-0	2017	Correction to: Prevalence of K13 mutation and Day-3 positive parasitaemia in artemisinin-resistant malaria endemic area of Cambodia: a cross-sectional study.	artemisinin	77-88	keratin 13	Homo sapiens	29-32
28708672-0	2017	Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.	artemisinin	0-11	androgen receptor	Homo sapiens	138-155
28708672-3	2017	Artemisinin treatment induced the 26S proteasome-mediated degradation of the receptor protein, without altering AR transcript levels, in androgen-responsive LNCaP prostate cancer cells or PC-3 prostate cancer cells expressing exogenous wild-type AR.	artemisinin	0-11	androgen receptor	Homo sapiens	246-248
28708672-4	2017	Furthermore, artemisinin stimulated AR ubiquitination and AR receptor interactions with the E3 ubiquitin ligase MDM2 in LNCaP cells.	artemisinin	13-24	androgen receptor	Homo sapiens	36-38
28708672-4	2017	Furthermore, artemisinin stimulated AR ubiquitination and AR receptor interactions with the E3 ubiquitin ligase MDM2 in LNCaP cells.	artemisinin	13-24	MDM2 proto-oncogene	Homo sapiens	112-116
28708672-5	2017	The artemisinin-induced loss of AR protein prevented androgen-responsive cell proliferation and ablated total AR transcriptional activity.	artemisinin	4-15	androgen receptor	Homo sapiens	32-34
28708672-5	2017	The artemisinin-induced loss of AR protein prevented androgen-responsive cell proliferation and ablated total AR transcriptional activity.	artemisinin	4-15	androgen receptor	Homo sapiens	110-112
28708672-6	2017	The serine/threonine protein kinase AKT-1 was shown to be highly associated with artemisinin-induced proteasome-mediated degradation of AR protein.	artemisinin	81-92	AKT serine/threonine kinase 1	Homo sapiens	36-41
28708672-6	2017	The serine/threonine protein kinase AKT-1 was shown to be highly associated with artemisinin-induced proteasome-mediated degradation of AR protein.	artemisinin	81-92	androgen receptor	Homo sapiens	136-138
28708672-7	2017	Artemisinin treatment activated AKT-1 enzymatic activity, enhanced receptor association with AKT-1, and induced AR serine phosphorylation.	artemisinin	0-11	AKT serine/threonine kinase 1	Homo sapiens	32-37
28708672-7	2017	Artemisinin treatment activated AKT-1 enzymatic activity, enhanced receptor association with AKT-1, and induced AR serine phosphorylation.	artemisinin	0-11	AKT serine/threonine kinase 1	Homo sapiens	93-98
28708672-7	2017	Artemisinin treatment activated AKT-1 enzymatic activity, enhanced receptor association with AKT-1, and induced AR serine phosphorylation.	artemisinin	0-11	androgen receptor	Homo sapiens	112-114
28708672-8	2017	Treatment of LNCaP cells with the PI3-kinase inhibitor LY294002, which inhibits the PI3-kinase-dependent activation of AKT-1, prevented the artemisinin-induced AR degradation.	artemisinin	140-151	AKT serine/threonine kinase 1	Homo sapiens	119-124
28708672-8	2017	Treatment of LNCaP cells with the PI3-kinase inhibitor LY294002, which inhibits the PI3-kinase-dependent activation of AKT-1, prevented the artemisinin-induced AR degradation.	artemisinin	140-151	androgen receptor	Homo sapiens	160-162
28708672-10	2017	Taken together, our results indicate that artemisinin induces the degradation of AR protein and disrupts androgen responsiveness of human prostate cancer cells, suggesting that this natural compound represents a new potential therapeutic molecule that selectively targets AR levels.	artemisinin	42-53	androgen receptor	Homo sapiens	81-83
28708672-10	2017	Taken together, our results indicate that artemisinin induces the degradation of AR protein and disrupts androgen responsiveness of human prostate cancer cells, suggesting that this natural compound represents a new potential therapeutic molecule that selectively targets AR levels.	artemisinin	42-53	androgen receptor	Homo sapiens	272-274
28903755-0	2017	Prevalence of K13 mutation and Day-3 positive parasitaemia in artemisinin-resistant malaria endemic area of Cambodia: a cross-sectional study.	artemisinin	62-73	keratin 13	Homo sapiens	14-17
28903755-2	2017	In 2013, mutations in the propeller domain of the kelch protein K13 was found to be associated with artemisinin resistance.	artemisinin	100-111	keratin 13	Homo sapiens	64-67
28903755-12	2017	Further investigation should be made to determine if k13 marker remains useful as a tool for tracking artemisinin resistance and predicting the trend of the efficacy of artemisinin combination therapy once the mutant alleles have been well established in the population.	artemisinin	102-113	keratin 13	Homo sapiens	53-56
28447781-4	2017	Western blot analysis showed that artemisinin upregulated the phosphorylation of p38 and extracellular signal-regulated kinases1/2 (ERK1/2) and reversed the inhibitory effect of H2O2 on the phosphorylation of these two kinases.	artemisinin	34-45	mitogen activated protein kinase 14	Rattus norvegicus	81-84
28447781-4	2017	Western blot analysis showed that artemisinin upregulated the phosphorylation of p38 and extracellular signal-regulated kinases1/2 (ERK1/2) and reversed the inhibitory effect of H2O2 on the phosphorylation of these two kinases.	artemisinin	34-45	mitogen activated protein kinase 3	Rattus norvegicus	89-130
28447781-4	2017	Western blot analysis showed that artemisinin upregulated the phosphorylation of p38 and extracellular signal-regulated kinases1/2 (ERK1/2) and reversed the inhibitory effect of H2O2 on the phosphorylation of these two kinases.	artemisinin	34-45	mitogen activated protein kinase 3	Rattus norvegicus	132-138
28447781-5	2017	Moreover, protective effect of artemisinin was blocked by the p38 kinase inhibitor PD169316 or ERK1/2 kinase pathway inhibitor PD98059, respectively.	artemisinin	31-42	mitogen-activated protein kinase 14	Mus musculus	62-65
28447781-5	2017	Moreover, protective effect of artemisinin was blocked by the p38 kinase inhibitor PD169316 or ERK1/2 kinase pathway inhibitor PD98059, respectively.	artemisinin	31-42	mitogen activated protein kinase 3	Rattus norvegicus	95-101
29132370-2	2017	In September 2008, a public-private mix (PPM) strategy was launched initially in four northern and southern provinces in Lao PDR to increase access to rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT), improve quality of care, and collect routine malaria data from the private sector.	artemisinin	185-196	interleukin 4 induced 1	Homo sapiens	121-124
28192150-0	2017	Effect of artemisinin on neuropathic pain mediated by P2X4 receptor in dorsal root ganglia.	artemisinin	10-21	purinergic receptor P2X 4	Homo sapiens	54-58
28192150-7	2017	The results demonstrated that artemisinin relieved pain behaviors in the CCI rats, inhibited the expression of P2X4 receptor in the DRG, and decreased the ATP-activated currents in HEK293 cells transfected with P2X4 plasmid.	artemisinin	30-41	purinergic receptor P2X 4	Homo sapiens	111-115
28192150-7	2017	The results demonstrated that artemisinin relieved pain behaviors in the CCI rats, inhibited the expression of P2X4 receptor in the DRG, and decreased the ATP-activated currents in HEK293 cells transfected with P2X4 plasmid.	artemisinin	30-41	purinergic receptor P2X 4	Homo sapiens	211-215
28192150-9	2017	After CCI rats were treated with artemisinin, the coexpression of P2X4 receptor and GFAP in the DRG was significantly decreased compared to the CCI group.	artemisinin	33-44	purinergic receptor P2X 4	Homo sapiens	66-70
28192150-10	2017	This finding suggested that artemisinin could inhibit the nociceptive transmission mediated by P2X4 receptor in the DRG SGCs and thus relieve pain behaviors in the CCI rats.	artemisinin	28-39	purinergic receptor P2X 4	Homo sapiens	95-99
29225511-6	2017	Trapping of vanillin and (+)-artemisinin elicited single-crystal-to-single-crystal transformations where space group symmetry reduced from C2/c to P1 and C2, respectively, and the absolute configuration of (+)-artemisinin was determined through anomalous dispersion.	artemisinin	25-40	complement C2	Homo sapiens	139-156
28447781-7	2017	Taken together, these results demonstrated that artemisinin promoted the survival of RGC-5 cells from H2O2 toxicity via the activation of the p38 and ERK1/2 pathways.	artemisinin	48-59	mitogen-activated protein kinase 3	Mus musculus	150-156
28476599-5	2017	This up-regulation is not caused by haem but rather by Hz-generated lipoperoxidation products (15-HETE) and fibrinogen associated to Hz, and is, at least in part, triggered by the activation of NF-kappaB, as it was significantly inhibited by artemisinin and other NF-kappaB pathway inhibitors.	artemisinin	242-253	nuclear factor kappa B subunit 1	Homo sapiens	194-203
28806957-2	2017	Although K13 kelch propeller has been assessed for artemisinin resistance molecular marker, most of the mutations need to be validated.	artemisinin	51-62	keratin 13	Homo sapiens	9-12
28806957-3	2017	In this study, artemisinin resistance was assessed by clinical and molecular analysis, including k13 and recently reported markers, pfarps10, pffd and pfmdr2.	artemisinin	15-26	keratin 13	Homo sapiens	97-100
28806957-10	2017	CONCLUSIONS: Apart from k13, pfarps10, pffd and pfmdr2 are also useful for molecular surveillance of artemisinin resistance especially where k13 mutation has not been reported.	artemisinin	101-112	keratin 13	Homo sapiens	141-144
28476599-5	2017	This up-regulation is not caused by haem but rather by Hz-generated lipoperoxidation products (15-HETE) and fibrinogen associated to Hz, and is, at least in part, triggered by the activation of NF-kappaB, as it was significantly inhibited by artemisinin and other NF-kappaB pathway inhibitors.	artemisinin	242-253	nuclear factor kappa B subunit 1	Homo sapiens	264-273
28391183-0	2017	Artemisinin protects PC12 cells against beta-amyloid-induced apoptosis through activation of the ERK1/2 signaling pathway.	artemisinin	0-11	mitogen activated protein kinase 3	Rattus norvegicus	97-103
28391183-8	2017	Western blotting analysis demonstrated that artemisinin activated extracellular regulated kinase ERK1/2 but not Akt survival signaling.	artemisinin	44-55	mitogen activated protein kinase 3	Rattus norvegicus	97-103
28391183-9	2017	Consistent with the role of ERK1/2, preincubation of cells with ERK1/2 pathway inhibitor PD98059 blocked the effect of artemisinin while PI3K inhibitor LY294002 has no effect.	artemisinin	119-130	mitogen activated protein kinase 3	Rattus norvegicus	28-34
28391183-9	2017	Consistent with the role of ERK1/2, preincubation of cells with ERK1/2 pathway inhibitor PD98059 blocked the effect of artemisinin while PI3K inhibitor LY294002 has no effect.	artemisinin	119-130	mitogen activated protein kinase 3	Rattus norvegicus	64-70
28391183-11	2017	Taken together, these results, at the first time, suggest that artemisinin is a potential protectant against beta amyloid insult through activation of the ERK1/2 pathway.	artemisinin	63-74	mitogen activated protein kinase 3	Rattus norvegicus	155-161
28737711-6	2017	Additionally, the artemisinin-enhanced cytotoxic effect of NK-92MI cells on tumor cells was accompanied by the stimulation of granule exocytosis, as evidenced by the detection of CD107a expression in NK cells.	artemisinin	18-29	lysosomal associated membrane protein 1	Homo sapiens	179-185
27825878-6	2017	By virtue of confocal fluorescence imaging, the artemisinin location in lysosome, ROS-triggered LMP and ultimate cell apoptosis can be visualized with the cathepsin B and caspase-3 activatable nanoprobe.	artemisinin	48-59	cathepsin B	Mus musculus	155-166
28454894-0	2017	The antimalarial drug artemisinin induces an additional, Sod1-supressible anti-mitochondrial action in yeast.	artemisinin	22-33	superoxide dismutase SOD1	Saccharomyces cerevisiae S288C	57-61
28289248-5	2017	Single point mutations in the gene coding for the Kelch propeller domain of the K13 protein strongly correlate with artemisinin resistance.	artemisinin	116-127	keratin 13	Homo sapiens	80-83
27825878-6	2017	By virtue of confocal fluorescence imaging, the artemisinin location in lysosome, ROS-triggered LMP and ultimate cell apoptosis can be visualized with the cathepsin B and caspase-3 activatable nanoprobe.	artemisinin	48-59	caspase 3	Mus musculus	171-180
28450175-4	2017	Mutations in the propeller domain of the Kelch 13 gene (K13-propeller, PF3D71343700), such as Y493H, R539T, I543T and C580Y, were recently associated with in vivo and in vitro resistance to artemisinin in Southeast Asia.	artemisinin	190-201	keratin 13	Homo sapiens	56-59
28448816-8	2017	We successfully demonstrated that treatment with high dose of artemisinin significantly decreased the elevated levels of AST (p<0.05) and ALT (p<0.01) in plasma, as well as the liver weight index (p<0.01).	artemisinin	62-73	transmembrane protease, serine 11d	Mus musculus	121-124
28448816-8	2017	We successfully demonstrated that treatment with high dose of artemisinin significantly decreased the elevated levels of AST (p<0.05) and ALT (p<0.01) in plasma, as well as the liver weight index (p<0.01).	artemisinin	62-73	glutamic pyruvic transaminase, soluble	Mus musculus	141-144
28294340-0	2017	Neuroprotective effects of artemisinin against isoflurane-induced cognitive impairments and neuronal cell death involve JNK/ERK1/2 signalling and improved hippocampal histone acetylation in neonatal rats.	artemisinin	27-38	mitogen-activated protein kinase 8	Rattus norvegicus	120-123
28294340-10	2017	CONCLUSIONS: Artemisinin effectively inhibited neuronal apoptosis and improved cognition and memory via regulating histone acetylation and JNK/ERK1/2 signalling.	artemisinin	13-24	mitogen-activated protein kinase 8	Rattus norvegicus	139-142
28294340-10	2017	CONCLUSIONS: Artemisinin effectively inhibited neuronal apoptosis and improved cognition and memory via regulating histone acetylation and JNK/ERK1/2 signalling.	artemisinin	13-24	mitogen activated protein kinase 3	Rattus norvegicus	143-149
28294340-0	2017	Neuroprotective effects of artemisinin against isoflurane-induced cognitive impairments and neuronal cell death involve JNK/ERK1/2 signalling and improved hippocampal histone acetylation in neonatal rats.	artemisinin	27-38	mitogen activated protein kinase 3	Rattus norvegicus	124-130
28294340-5	2017	Western blotting analysis revealed that treatment with artemisinin significantly enhanced the expression of anti-apoptotic proteins (Bcl-2, Bcl-xL, c-IAP-1, c-IAP-2, xIAP and survivin).	artemisinin	55-66	BCL2, apoptosis regulator	Rattus norvegicus	133-138
28294340-5	2017	Western blotting analysis revealed that treatment with artemisinin significantly enhanced the expression of anti-apoptotic proteins (Bcl-2, Bcl-xL, c-IAP-1, c-IAP-2, xIAP and survivin).	artemisinin	55-66	Bcl2-like 1	Rattus norvegicus	140-146
28294340-5	2017	Western blotting analysis revealed that treatment with artemisinin significantly enhanced the expression of anti-apoptotic proteins (Bcl-2, Bcl-xL, c-IAP-1, c-IAP-2, xIAP and survivin).	artemisinin	55-66	X-linked inhibitor of apoptosis	Rattus norvegicus	166-170
28294340-6	2017	Artemisinin increased the acetylation of H3K9 and H4K12 while reducing the expression of histone deacetlyases (HDACs) - HDAC-2 and HDAC-3.	artemisinin	0-11	histone deacetylase 2	Rattus norvegicus	120-126
28294340-6	2017	Artemisinin increased the acetylation of H3K9 and H4K12 while reducing the expression of histone deacetlyases (HDACs) - HDAC-2 and HDAC-3.	artemisinin	0-11	histone deacetylase 3	Rattus norvegicus	131-137
28294340-7	2017	Isoflurane-induced activation of JNK signalling and downregulated ERK1/2 expression was effectively modulated by artemisinin.	artemisinin	113-124	mitogen-activated protein kinase 8	Rattus norvegicus	33-36
28294340-7	2017	Isoflurane-induced activation of JNK signalling and downregulated ERK1/2 expression was effectively modulated by artemisinin.	artemisinin	113-124	mitogen activated protein kinase 3	Rattus norvegicus	66-72
28438155-1	2017	BACKGROUND: In the context of national and regional goals to eliminate malaria by 2030, the Center for Malaria Parasitology and Entomology in the Lao PDR is implementing strategies to ensure all malaria cases are detected and appropriately treated with first-line artemisinin combination therapy, artemether-lumefantrine (AL).	artemisinin	264-275	interleukin 4 induced 1	Homo sapiens	146-149
28249583-2	2017	After discovery of artemisinin resistance marker (K13), molecular surveillance on artemisinin resistance in endemic regions have been conducted.	artemisinin	19-30	keratin 13	Homo sapiens	50-53
28361857-10	2017	The most enhanced increase of miRNA expression under artemisinin influence were found for miRNA-200b in MCF-7/DDP cells (7.1 +- 0.98 fold change), miRNA-320a in MCF-7/Dox cells (2.9 +- 0.45 fold change) and miRNA-34a (1.7 +- 0.15 fold change) in MCF-7/S cells.	artemisinin	53-64	microRNA 34a	Homo sapiens	207-216
28249583-6	2017	Amplification and sequence analysis of artemisinin resistance molecular markers, such as k13, pfarps10, pffd, pfmdr2, pfmrp1, pfrad5, and pfcnbp, were carried out and pfmdr1 copy number analysis was conducted by real-time PCR.	artemisinin	39-50	keratin 13	Homo sapiens	89-92
28000518-0	2017	Artemisinin inhibits inflammatory response via regulating NF-kappaB and MAPK signaling pathways.	artemisinin	0-11	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	58-67
28000518-0	2017	Artemisinin inhibits inflammatory response via regulating NF-kappaB and MAPK signaling pathways.	artemisinin	0-11	mitogen-activated protein kinase 1	Mus musculus	72-76
28000518-4	2017	Then the artemisinin significantly inhibited the expression of NF-kappaB reporter gene induced by TNF-alpha in a dose-dependent manner.	artemisinin	9-20	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	63-72
28000518-4	2017	Then the artemisinin significantly inhibited the expression of NF-kappaB reporter gene induced by TNF-alpha in a dose-dependent manner.	artemisinin	9-20	tumor necrosis factor	Mus musculus	98-107
28000518-5	2017	Artemisinin also inhibited TNF-alpha induced phosphorylation and degradation of IkappaBalpha, p65 nuclear translocation.	artemisinin	0-11	tumor necrosis factor	Mus musculus	27-36
28000518-5	2017	Artemisinin also inhibited TNF-alpha induced phosphorylation and degradation of IkappaBalpha, p65 nuclear translocation.	artemisinin	0-11	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	80-92
28000518-5	2017	Artemisinin also inhibited TNF-alpha induced phosphorylation and degradation of IkappaBalpha, p65 nuclear translocation.	artemisinin	0-11	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	94-97
28000518-6	2017	Artemisinin also has an impact on upstream signaling of IKK through the inhibition of expression of adaptor proteins, TNF receptor-associated factor 2 (TRAF2) and receptor interacting protein 1 (RIP1).	artemisinin	0-11	TNF receptor-associated factor 2	Mus musculus	118-150
28000518-6	2017	Artemisinin also has an impact on upstream signaling of IKK through the inhibition of expression of adaptor proteins, TNF receptor-associated factor 2 (TRAF2) and receptor interacting protein 1 (RIP1).	artemisinin	0-11	TNF receptor-associated factor 2	Mus musculus	152-157
28000518-6	2017	Artemisinin also has an impact on upstream signaling of IKK through the inhibition of expression of adaptor proteins, TNF receptor-associated factor 2 (TRAF2) and receptor interacting protein 1 (RIP1).	artemisinin	0-11	receptor (TNFRSF)-interacting serine-threonine kinase 1	Mus musculus	163-193
28000518-6	2017	Artemisinin also has an impact on upstream signaling of IKK through the inhibition of expression of adaptor proteins, TNF receptor-associated factor 2 (TRAF2) and receptor interacting protein 1 (RIP1).	artemisinin	0-11	receptor (TNFRSF)-interacting serine-threonine kinase 1	Mus musculus	195-199
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	tumor necrosis factor	Mus musculus	66-75
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	98-107
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	baculoviral IAP repeat-containing 3	Mus musculus	146-152
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	B cell leukemia/lymphoma 2	Mus musculus	154-159
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	cytochrome c oxidase II, mitochondrial	Mus musculus	187-192
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	cyclin D1	Mus musculus	194-202
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	matrix metallopeptidase 9	Mus musculus	215-220
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	vascular endothelial growth factor A	Mus musculus	237-241
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	tumor necrosis factor	Mus musculus	278-287
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	nitric oxide synthase 2, inducible	Mus musculus	289-293
28000518-7	2017	Furthermore, pretreatment of cells with artemisinin prevented the TNF-alpha-induced expression of NF-kappaB target genes, such as anti-apoptosis (c-IAP1, Bcl-2, and FLIP), proliferation (COX-2, cyclinD1), invasion (MMP-9), angiogenesis (VEGF), and major inflammatory cytokines (TNF-alpha, iNOS, and MCP1).	artemisinin	40-51	mast cell protease 1	Mus musculus	299-303
28000518-8	2017	We also proved that artemisinin potentiated TNF-alpha-induced apoptosis.	artemisinin	20-31	tumor necrosis factor	Mus musculus	44-53
28000518-9	2017	Moreover, artemisinin significantly impaired the ROS production and phosphorylation of p38 and ERK, but did not affect the phosphorylation of JNK.	artemisinin	10-21	mitogen-activated protein kinase 14	Mus musculus	87-90
28000518-9	2017	Moreover, artemisinin significantly impaired the ROS production and phosphorylation of p38 and ERK, but did not affect the phosphorylation of JNK.	artemisinin	10-21	mitogen-activated protein kinase 1	Mus musculus	95-98
27515812-0	2016	Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations.	artemisinin	12-23	deoxyhypusine synthase	Homo sapiens	147-151
27736063-1	2016	A series of novel Smo antagonists were developed either by directly incorporating the basic skeleton of the natural product artemisinin or by first breaking artemisinin into structurally simpler and stable intermediates and then reconstructing into diversified heterocyclic derivatives, equipped with a Smo-targeting bullet.	artemisinin	124-135	smoothened, frizzled class receptor	Homo sapiens	18-21
27736063-1	2016	A series of novel Smo antagonists were developed either by directly incorporating the basic skeleton of the natural product artemisinin or by first breaking artemisinin into structurally simpler and stable intermediates and then reconstructing into diversified heterocyclic derivatives, equipped with a Smo-targeting bullet.	artemisinin	157-168	smoothened, frizzled class receptor	Homo sapiens	18-21
27660233-0	2016	Role of K13 Mutations in Artemisinin-Based Combination Therapy.	artemisinin	25-36	keratin 13	Homo sapiens	8-11
27515812-0	2016	Efficacy of artemisinin-based combination therapies for the treatment of falciparum malaria in Pakistan (2007-2015): In vivo response and dhfr and dhps mutations.	artemisinin	12-23	dihydrofolate reductase	Homo sapiens	138-142
27732639-10	2016	For canine CAR3, 50 muM artemisinin proved to be the best activator (7.3 +- 1.8 and 10.5 +- 2.2 fold) while clotrimazole (10 muM) was the primary activator of the rat variant (13.7 +- 0.8 and 26.9 +- 1.3 fold).	artemisinin	24-35	carbonic anhydrase 3	Rattus norvegicus	11-15
27372058-0	2016	Artemisinin protects human retinal pigment epithelial cells from hydrogen peroxide-induced oxidative damage through activation of ERK/CREB signaling.	artemisinin	0-11	mitogen-activated protein kinase 1	Homo sapiens	130-133
27012321-1	2016	In this study, we used a self-contrast method, which excluded the individual difference, to evaluate the inhibitory effect of chrysosplentin (CHR) in the presence or absence of artemisinin (ART) on the P-glycoprotein (P-gp) transport activity.	artemisinin	190-193	ATP-binding cassette, subfamily B (MDR/TAP), member 1B	Rattus norvegicus	202-216
27372058-0	2016	Artemisinin protects human retinal pigment epithelial cells from hydrogen peroxide-induced oxidative damage through activation of ERK/CREB signaling.	artemisinin	0-11	cAMP responsive element binding protein 1	Homo sapiens	134-138
27372058-5	2016	Western blotting analysis showed that Artemisinin was able to activate extracellular regulated ERK/CREB survival signaling.	artemisinin	38-49	mitogen-activated protein kinase 1	Homo sapiens	95-98
27372058-5	2016	Western blotting analysis showed that Artemisinin was able to activate extracellular regulated ERK/CREB survival signaling.	artemisinin	38-49	cAMP responsive element binding protein 1	Homo sapiens	99-103
27372058-7	2016	Taken together, these results suggest that Artemisinin is a potential protectant with the pro-survival effects against H2O2 insult through activation of the ERK/CREB pathway.	artemisinin	43-54	mitogen-activated protein kinase 1	Homo sapiens	157-160
27372058-7	2016	Taken together, these results suggest that Artemisinin is a potential protectant with the pro-survival effects against H2O2 insult through activation of the ERK/CREB pathway.	artemisinin	43-54	cAMP responsive element binding protein 1	Homo sapiens	161-165
27039397-0	2016	25-methoxyl-dammarane-3beta, 12beta, 20-triol and artemisinin synergistically inhibit MDA-MB-231 cell proliferation through downregulation of testes-specific protease 50 (TSP50) expression.	artemisinin	50-61	serine protease 50	Homo sapiens	142-169
27590543-5	2016	The relative standard deviation is 4.83% for the determination of 10 muM artemisinin.	artemisinin	73-84	latexin	Homo sapiens	69-72
27713827-7	2016	Induction of CYP3A4 by PB, artemisinin, and phenytoin was also much reduced in PXR-KO cells, while the response to CITCO was maintained.	artemisinin	27-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19
27713827-7	2016	Induction of CYP3A4 by PB, artemisinin, and phenytoin was also much reduced in PXR-KO cells, while the response to CITCO was maintained.	artemisinin	27-38	nuclear receptor subfamily 1 group I member 2	Homo sapiens	79-82
27313266-2	2016	The role of Plasmodium falciparum K13 mutations (a marker of artemisinin resistance) in reducing treatment efficacy remains controversial.	artemisinin	61-72	keratin 13	Homo sapiens	34-37
27313266-5	2016	K13 mutations conferring moderate artemisinin resistance (notably E252Q) predominated initially but were later overtaken by propeller mutations associated with slower parasite clearance (notably C580Y).	artemisinin	34-45	keratin 13	Homo sapiens	0-3
27313266-10	2016	CONCLUSIONS: The increasing prevalence of K13 mutations was the decisive factor for the recent and rapid decline in efficacy of artemisinin-based combination (MAS3) on the Thailand-Myanmar border.	artemisinin	128-139	keratin 13	Homo sapiens	42-45
27039397-0	2016	25-methoxyl-dammarane-3beta, 12beta, 20-triol and artemisinin synergistically inhibit MDA-MB-231 cell proliferation through downregulation of testes-specific protease 50 (TSP50) expression.	artemisinin	50-61	serine protease 50	Homo sapiens	171-176
27039397-5	2016	We identified the compound 7P3A, which consists of 70 % 25-methoxyl-dammarane-3beta, 12beta, 20-triol and 30 % artemisinin, as being capable of inhibiting the TSP50-3"-UTR reporter activity, as well as the expression of TSP50.	artemisinin	111-122	serine protease 50	Homo sapiens	159-164
27480521-4	2016	We found that artesunate (ART), a small molecular derivative of artemisinin, had a significant inhibitory effect on ocular NV by downregulating the expression of VEGFR2, PKCalpha, and PDGFR.	artemisinin	64-75	kinase insert domain receptor	Homo sapiens	162-168
26999297-0	2016	Enhanced Efficacy of Artemisinin Loaded in Transferrin-Conjugated Liposomes versus Stealth Liposomes against HCT-8 Colon Cancer Cells.	artemisinin	21-32	transferrin	Homo sapiens	43-54
27385212-0	2016	Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1.	artemisinin	17-28	cyclin dependent kinase inhibitor 1A	Homo sapiens	100-107
27385212-0	2016	Halofuginone and artemisinin synergistically arrest cancer cells at the G1/G0 phase by upregulating p21Cip1 and p27Kip1.	artemisinin	17-28	cyclin dependent kinase inhibitor 1B	Homo sapiens	112-119
27480521-4	2016	We found that artesunate (ART), a small molecular derivative of artemisinin, had a significant inhibitory effect on ocular NV by downregulating the expression of VEGFR2, PKCalpha, and PDGFR.	artemisinin	64-75	protein kinase C alpha	Homo sapiens	170-178
27480521-4	2016	We found that artesunate (ART), a small molecular derivative of artemisinin, had a significant inhibitory effect on ocular NV by downregulating the expression of VEGFR2, PKCalpha, and PDGFR.	artemisinin	64-75	platelet derived growth factor receptor beta	Homo sapiens	184-189
25789847-4	2016	Real-time PCR and western blot analysis of extracted RNA and total protein revealed artemsinin and artesunate increased miR-34a expression in a dose-dependent manner correlating with down-regulation of the miR-34a target gene, CDK4.	artemisinin	84-94	microRNA 34a	Homo sapiens	120-127
27242266-0	2016	Artemisinin conferred ERK mediated neuroprotection to PC12 cells and cortical neurons exposed to sodium nitroprusside-induced oxidative insult.	artemisinin	0-11	Eph receptor B1	Rattus norvegicus	22-25
27242266-3	2016	Pretreatment of PC12 cells with artemisinin significantly suppressed SNP-induced cell death by decreasing the extent of oxidation, preventing the decline of mitochondrial membrane potential, restoring abnormal changes in nuclear morphology and reducing lactate dehydrogenase release and inhibiting caspase 3/7 activities.	artemisinin	32-43	caspase 3	Rattus norvegicus	298-307
27242266-4	2016	Western blotting analysis revealed that artemisinin was able to activate extracellular regulated protein kinases (ERK) pathway.	artemisinin	40-51	Eph receptor B1	Rattus norvegicus	73-112
27242266-4	2016	Western blotting analysis revealed that artemisinin was able to activate extracellular regulated protein kinases (ERK) pathway.	artemisinin	40-51	Eph receptor B1	Rattus norvegicus	114-117
27242266-5	2016	Furthermore, the ERK inhibitor PD98059 blocked the neuroprotective effect of artemisinin whereas the PI3K inhibitor LY294002 had no effect.	artemisinin	77-88	Eph receptor B1	Rattus norvegicus	17-20
27242266-6	2016	Cumulatively these findings support the notion that artemisinin confers neuroprotection from SNP-induce neuronal cell death insult, a phenomenon coincidentally related to activation of ERK phosphorylation.	artemisinin	52-63	Eph receptor B1	Rattus norvegicus	185-188
27337450-6	2016	Specifically, these studies have established that artemisinin resistance manifests as slow parasite clearance in patients and increased survival of early-ring-stage parasites in vitro; is caused by single nucleotide polymorphisms in the parasite"s K13 gene, is associated with an upregulated "unfolded protein response" pathway that may antagonize the pro-oxidant activity of artemisinins, and selects for partner drug resistance that rapidly leads to ACT failures.	artemisinin	50-61	keratin 13	Homo sapiens	248-251
26830216-0	2016	Artemisinin protects mice against burn sepsis through inhibiting NLRP3 inflammasome activation.	artemisinin	0-11	NLR family, pyrin domain containing 3	Mus musculus	65-70
26830216-13	2016	Artemisinin down-regulated protein levels of NLRP3 and caspase 1 and inhibited the increases of IL-1beta and IL-18 messenger RNA expression from Raw 264.7 cells that were stimulated with burn sepsis serum.	artemisinin	0-11	NLR family, pyrin domain containing 3	Mus musculus	45-50
26830216-13	2016	Artemisinin down-regulated protein levels of NLRP3 and caspase 1 and inhibited the increases of IL-1beta and IL-18 messenger RNA expression from Raw 264.7 cells that were stimulated with burn sepsis serum.	artemisinin	0-11	caspase 1	Mus musculus	55-64
26830216-13	2016	Artemisinin down-regulated protein levels of NLRP3 and caspase 1 and inhibited the increases of IL-1beta and IL-18 messenger RNA expression from Raw 264.7 cells that were stimulated with burn sepsis serum.	artemisinin	0-11	interleukin 1 beta	Mus musculus	96-104
26830216-13	2016	Artemisinin down-regulated protein levels of NLRP3 and caspase 1 and inhibited the increases of IL-1beta and IL-18 messenger RNA expression from Raw 264.7 cells that were stimulated with burn sepsis serum.	artemisinin	0-11	interleukin 18	Mus musculus	109-114
25789847-5	2016	I3C stimulation of miR-34a expression required functional p53, whereas, both artemisinin and artesunate up-regulated miR-34a expression regardless of p53 mutational status or in the presence of dominant negative p53.	artemisinin	77-88	microRNA 34a	Homo sapiens	117-124
25789847-7	2016	Our results suggest that miR-34a is an essential component of the anti-proliferative activities of I3C, artemisinin, and artesunate and demonstrate that both wild-type p53 dependent and independent pathways are responsible for miR-34a induction.	artemisinin	104-115	microRNA 34a	Homo sapiens	25-32
27434054-3	2016	Eight of 20 patients with uncomplicated malaria who were given oral artemisinin-based combination therapy met the definition of posttreatment hemolysis (low haptoglobin level and increased lactate dehydrogenase level on day 14).	artemisinin	68-79	haptoglobin	Homo sapiens	157-168
27122190-0	2016	Artemisinin inhibits monocyte adhesion to HUVECs through the NF-kappaB and MAPK pathways in vitro.	artemisinin	0-11	nuclear factor kappa B subunit 1	Homo sapiens	61-70
27122190-4	2016	In the present study, we found that artemisinin significantly decreased the adhesion of monocytes to tumor necrosis factor-alpha (TNF-alpha)-stimulated HUVECs in a dose-dependent manner and suppressed the mRNA and protein level of ICAM-1 and VCAM-1 in the TNF-alpha-stimulated HUVECs.	artemisinin	36-47	tumor necrosis factor	Homo sapiens	101-128
27122190-4	2016	In the present study, we found that artemisinin significantly decreased the adhesion of monocytes to tumor necrosis factor-alpha (TNF-alpha)-stimulated HUVECs in a dose-dependent manner and suppressed the mRNA and protein level of ICAM-1 and VCAM-1 in the TNF-alpha-stimulated HUVECs.	artemisinin	36-47	tumor necrosis factor	Homo sapiens	130-139
27122190-4	2016	In the present study, we found that artemisinin significantly decreased the adhesion of monocytes to tumor necrosis factor-alpha (TNF-alpha)-stimulated HUVECs in a dose-dependent manner and suppressed the mRNA and protein level of ICAM-1 and VCAM-1 in the TNF-alpha-stimulated HUVECs.	artemisinin	36-47	intercellular adhesion molecule 1	Homo sapiens	231-237
27122190-4	2016	In the present study, we found that artemisinin significantly decreased the adhesion of monocytes to tumor necrosis factor-alpha (TNF-alpha)-stimulated HUVECs in a dose-dependent manner and suppressed the mRNA and protein level of ICAM-1 and VCAM-1 in the TNF-alpha-stimulated HUVECs.	artemisinin	36-47	vascular cell adhesion molecule 1	Homo sapiens	242-248
27122190-4	2016	In the present study, we found that artemisinin significantly decreased the adhesion of monocytes to tumor necrosis factor-alpha (TNF-alpha)-stimulated HUVECs in a dose-dependent manner and suppressed the mRNA and protein level of ICAM-1 and VCAM-1 in the TNF-alpha-stimulated HUVECs.	artemisinin	36-47	tumor necrosis factor	Homo sapiens	256-265
27122190-6	2016	Moreover, artemisinin impeded the activation of the NF-kappaB and MAPK signaling pathways.	artemisinin	10-21	nuclear factor kappa B subunit 1	Homo sapiens	52-61
27122190-8	2016	Taken together, the findings of our study indicated that artemisinin blocked monocyte adhesion to TNF-alpha-stimulated to HUVECs by downregulating ICAM-1 and VCAM-1 expression in the TNF-alpha-stimulated HUVECs.	artemisinin	57-68	tumor necrosis factor	Homo sapiens	98-107
27122190-8	2016	Taken together, the findings of our study indicated that artemisinin blocked monocyte adhesion to TNF-alpha-stimulated to HUVECs by downregulating ICAM-1 and VCAM-1 expression in the TNF-alpha-stimulated HUVECs.	artemisinin	57-68	intercellular adhesion molecule 1	Homo sapiens	147-153
27122190-8	2016	Taken together, the findings of our study indicated that artemisinin blocked monocyte adhesion to TNF-alpha-stimulated to HUVECs by downregulating ICAM-1 and VCAM-1 expression in the TNF-alpha-stimulated HUVECs.	artemisinin	57-68	vascular cell adhesion molecule 1	Homo sapiens	158-164
27122190-8	2016	Taken together, the findings of our study indicated that artemisinin blocked monocyte adhesion to TNF-alpha-stimulated to HUVECs by downregulating ICAM-1 and VCAM-1 expression in the TNF-alpha-stimulated HUVECs.	artemisinin	57-68	tumor necrosis factor	Homo sapiens	183-192
27119499-0	2016	Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/beta-catenin signaling.	artemisinin	0-11	catenin beta 1	Homo sapiens	110-122
26830216-15	2016	CONCLUSION: Artemisinin protects mice from burn sepsis by attenuating the inflammatory response and alleviating inflammatory infiltration in vital organs, likely through inhibiting the activation of NLRP3 inflammasome.	artemisinin	12-23	NLR family, pyrin domain containing 3	Mus musculus	199-204
25789847-4	2016	Real-time PCR and western blot analysis of extracted RNA and total protein revealed artemsinin and artesunate increased miR-34a expression in a dose-dependent manner correlating with down-regulation of the miR-34a target gene, CDK4.	artemisinin	84-94	cyclin dependent kinase 4	Homo sapiens	227-231
25789847-4	2016	Real-time PCR and western blot analysis of extracted RNA and total protein revealed artemsinin and artesunate increased miR-34a expression in a dose-dependent manner correlating with down-regulation of the miR-34a target gene, CDK4.	artemisinin	84-94	microRNA 34a	Homo sapiens	206-213
27035431-7	2016	Western blot analysis indicated that artemisinin induced the expression of p16, while down-regulating phosphorylated extracellular signal-regulated kinase (ERK)1/2, CDK4 and cyclin D1 expression, leading to inhibition of the ERK1/2 pathway.	artemisinin	37-48	mitogen-activated protein kinase 3	Homo sapiens	225-231
27035431-8	2016	Furthermore, flow cytometry and western blot analysis showed that artemisinin caused G1-phase arrest of the cell cycle, promoted the generation of reactive oxygen species (ROS), led to a collapse of the mitochondrial membrane potential and to triggered cytochrome c release from the mitochondria into the cytoplasm, which finally activated caspase-3-mediated apoptosis.	artemisinin	66-77	cytochrome c, somatic	Homo sapiens	253-265
27035431-7	2016	Western blot analysis indicated that artemisinin induced the expression of p16, while down-regulating phosphorylated extracellular signal-regulated kinase (ERK)1/2, CDK4 and cyclin D1 expression, leading to inhibition of the ERK1/2 pathway.	artemisinin	37-48	cyclin dependent kinase inhibitor 2A	Homo sapiens	75-78
27035431-8	2016	Furthermore, flow cytometry and western blot analysis showed that artemisinin caused G1-phase arrest of the cell cycle, promoted the generation of reactive oxygen species (ROS), led to a collapse of the mitochondrial membrane potential and to triggered cytochrome c release from the mitochondria into the cytoplasm, which finally activated caspase-3-mediated apoptosis.	artemisinin	66-77	caspase 3	Homo sapiens	340-349
27035431-7	2016	Western blot analysis indicated that artemisinin induced the expression of p16, while down-regulating phosphorylated extracellular signal-regulated kinase (ERK)1/2, CDK4 and cyclin D1 expression, leading to inhibition of the ERK1/2 pathway.	artemisinin	37-48	mitogen-activated protein kinase 1	Homo sapiens	117-163
26518641-5	2015	The dosage of 5 ppm of artemisinin improved the WG and FCR for the chickens infected with E. acervulina.	artemisinin	23-34	FCR	Gallus gallus	55-58
27035431-7	2016	Western blot analysis indicated that artemisinin induced the expression of p16, while down-regulating phosphorylated extracellular signal-regulated kinase (ERK)1/2, CDK4 and cyclin D1 expression, leading to inhibition of the ERK1/2 pathway.	artemisinin	37-48	cyclin dependent kinase 4	Homo sapiens	165-169
27035431-7	2016	Western blot analysis indicated that artemisinin induced the expression of p16, while down-regulating phosphorylated extracellular signal-regulated kinase (ERK)1/2, CDK4 and cyclin D1 expression, leading to inhibition of the ERK1/2 pathway.	artemisinin	37-48	cyclin D1	Homo sapiens	174-183
26932893-10	2016	Cytochrome C was released from mitochondria to cytoplasm leading to the activation of caspase-3 and PARP after dealt with artemisinin(P<0.05).	artemisinin	122-133	cytochrome c, somatic	Homo sapiens	0-12
26932893-10	2016	Cytochrome C was released from mitochondria to cytoplasm leading to the activation of caspase-3 and PARP after dealt with artemisinin(P<0.05).	artemisinin	122-133	caspase 3	Homo sapiens	86-95
26932893-10	2016	Cytochrome C was released from mitochondria to cytoplasm leading to the activation of caspase-3 and PARP after dealt with artemisinin(P<0.05).	artemisinin	122-133	collagen type XI alpha 2 chain	Homo sapiens	100-104
26932893-11	2016	CONCLUSION: The inhibition effect of artemisinin on the proliferation gallbladder cancer cells is accompanied by down-regulation of ERK1/2 signaling pathway, G1 phase arrest and triggering caspase-3-mediate apoptosis.	artemisinin	37-48	mitogen-activated protein kinase 3	Homo sapiens	132-138
26932893-11	2016	CONCLUSION: The inhibition effect of artemisinin on the proliferation gallbladder cancer cells is accompanied by down-regulation of ERK1/2 signaling pathway, G1 phase arrest and triggering caspase-3-mediate apoptosis.	artemisinin	37-48	caspase 3	Homo sapiens	189-198
26932893-9	2016	In addition, expression of p16 was increased, and expressions of p-ERK1/2, CDK4 and cyclin D1 were down-regulated by artemisinin(all P<0.05).	artemisinin	117-128	cyclin dependent kinase inhibitor 2A	Homo sapiens	27-30
26932893-9	2016	In addition, expression of p16 was increased, and expressions of p-ERK1/2, CDK4 and cyclin D1 were down-regulated by artemisinin(all P<0.05).	artemisinin	117-128	mitogen-activated protein kinase 3	Homo sapiens	67-73
26932893-9	2016	In addition, expression of p16 was increased, and expressions of p-ERK1/2, CDK4 and cyclin D1 were down-regulated by artemisinin(all P<0.05).	artemisinin	117-128	cyclin dependent kinase 4	Homo sapiens	75-79
26932893-9	2016	In addition, expression of p16 was increased, and expressions of p-ERK1/2, CDK4 and cyclin D1 were down-regulated by artemisinin(all P<0.05).	artemisinin	117-128	cyclin D1	Homo sapiens	84-93
26655404-13	2015	The high expression of MYC, TFR, and VEGFC in the patient biopsy corresponded with high expression of these markers in the artemisinin-sensitive PC-3 cells compared to artemisinin-resistant DU-145 cells.	artemisinin	123-134	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	23-26
26655404-13	2015	The high expression of MYC, TFR, and VEGFC in the patient biopsy corresponded with high expression of these markers in the artemisinin-sensitive PC-3 cells compared to artemisinin-resistant DU-145 cells.	artemisinin	123-134	transferrin receptor	Homo sapiens	28-31
26655404-13	2015	The high expression of MYC, TFR, and VEGFC in the patient biopsy corresponded with high expression of these markers in the artemisinin-sensitive PC-3 cells compared to artemisinin-resistant DU-145 cells.	artemisinin	123-134	vascular endothelial growth factor C	Homo sapiens	37-42
26655404-13	2015	The high expression of MYC, TFR, and VEGFC in the patient biopsy corresponded with high expression of these markers in the artemisinin-sensitive PC-3 cells compared to artemisinin-resistant DU-145 cells.	artemisinin	168-179	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	23-26
26655404-13	2015	The high expression of MYC, TFR, and VEGFC in the patient biopsy corresponded with high expression of these markers in the artemisinin-sensitive PC-3 cells compared to artemisinin-resistant DU-145 cells.	artemisinin	168-179	transferrin receptor	Homo sapiens	28-31
26655404-13	2015	The high expression of MYC, TFR, and VEGFC in the patient biopsy corresponded with high expression of these markers in the artemisinin-sensitive PC-3 cells compared to artemisinin-resistant DU-145 cells.	artemisinin	168-179	vascular endothelial growth factor C	Homo sapiens	37-42
26084957-0	2015	Stereoselective chlorothiolation of artemisinin-derived C-10 oxa terminal alkynes.	artemisinin	36-47	homeobox C10	Homo sapiens	56-60
26695060-9	2015	Artemisinin-resistant K13 mutants with ex vivo PSA survival rates >=10% were associated with 32-fold higher risk of recrudescence (95% CI, 4.5-224; P = 0.0005).	artemisinin	0-11	keratin 13	Homo sapiens	22-25
26695060-11	2015	Combined ex vivo PSA and K13 genotyping provides a convenient monitor for both artemisinin and piperaquine resistance where dihydroartemisinin-piperaquine is used.	artemisinin	79-90	keratin 13	Homo sapiens	25-28
31157126-1	2015	Objective: To determine if oral artemisinin is safe and has a short-term effect on prostate specific antigen (PSA) kinetics in patients with prostate cancer (CaP).	artemisinin	32-43	kallikrein related peptidase 3	Homo sapiens	83-108
26084957-1	2015	A mild and efficient strategy is explored on the highly sensitive artemisinin-derived C-10 oxa terminal alkynes.	artemisinin	66-77	homeobox C10	Homo sapiens	86-90
25862844-0	2015	Quantitative structure-activity relationship and molecular docking of artemisinin derivatives to vascular endothelial growth factor receptor 1.	artemisinin	70-81	fms related receptor tyrosine kinase 1	Homo sapiens	97-142
25936561-8	2015	The protection was associated with a Th1-biased immune response as evident from a positive delayed-type hypersensitivity reaction, escalated IgG2a levels, augmented lymphoproliferation and enhancement in proinflammatory cytokines (IFN-gamma and IL-2) with significant suppression of Th2 cytokines (IL-10 and IL-4) after in vitro recall, compared to infected control and free artemisinin treatment.	artemisinin	375-386	negative elongation factor complex member C/D, Th1l	Mus musculus	37-40
26237549-3	2015	RECENT FINDINGS: Multiple international collaborations have established that artemisinin resistance is associated with slow parasite clearance in patients, increased survival of early-ring-stage parasites in vitro, single-nucleotide polymorphisms (SNPs) in the parasite"s kelch protein gene (K13), parasite "founder" populations sharing a genetic background of four additional SNPs, parasite transcriptional profiles reflecting an "unfolded protein response" and decelerated parasite development, and elevated parasite phosphatidylinositol-3-kinase activity.	artemisinin	77-88	keratin 13	Homo sapiens	292-295
26390866-7	2015	In areas with artemisinin-sensitive parasites, the median PC1/2 following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of patients with PC1/2 >5 h from 0 to 10 %.	artemisinin	14-25	polycystin 1, transient receptor potential channel interacting	Homo sapiens	58-63
26390866-7	2015	In areas with artemisinin-sensitive parasites, the median PC1/2 following three-day artesunate treatment (4 mg/kg/day) ranged from 1.8 to 3.0 h and the proportion of patients with PC1/2 >5 h from 0 to 10 %.	artemisinin	14-25	polycystin 1, transient receptor potential channel interacting	Homo sapiens	180-185
26390866-13	2015	As substantial heterogeneity in parasite clearance exists between locations, early detection of artemisinin resistance requires reference PC1/2 data.	artemisinin	96-107	polycystin 1, transient receptor potential channel interacting	Homo sapiens	138-143
25755006-2	2015	In the present study, we have investigated the anticancer effects of artemisinin in human cervical cancer cells, with special emphasis on its role in inducing apoptosis and repressing cell proliferation by inhibiting the telomerase subunits, ERalpha which is essential for maintenance of the cervix, and downstream components like VEGF, which is known to activate angiogenesis.	artemisinin	69-80	estrogen receptor 1	Homo sapiens	242-249
25755006-2	2015	In the present study, we have investigated the anticancer effects of artemisinin in human cervical cancer cells, with special emphasis on its role in inducing apoptosis and repressing cell proliferation by inhibiting the telomerase subunits, ERalpha which is essential for maintenance of the cervix, and downstream components like VEGF, which is known to activate angiogenesis.	artemisinin	69-80	vascular endothelial growth factor A	Homo sapiens	331-335
25755006-5	2015	Our findings demonstrated that artemisinin significantly downregulated the expression of ERalpha and its downstream component, VEGF.	artemisinin	31-42	estrogen receptor 1	Homo sapiens	89-96
25755006-5	2015	Our findings demonstrated that artemisinin significantly downregulated the expression of ERalpha and its downstream component, VEGF.	artemisinin	31-42	vascular endothelial growth factor A	Homo sapiens	127-131
25755006-8	2015	Artemisinin-induced apoptosis was confirmed by FACS, nuclear chromatin condensation, annexin V staining.	artemisinin	0-11	annexin A5	Homo sapiens	85-94
25755006-9	2015	Increased expression of p53 with concomitant decrease in expression of the p53 inhibitor Mdm2 further supported that artemisinin-induced apoptosis was p53-dependent.	artemisinin	117-128	tumor protein p53	Homo sapiens	24-27
25755006-9	2015	Increased expression of p53 with concomitant decrease in expression of the p53 inhibitor Mdm2 further supported that artemisinin-induced apoptosis was p53-dependent.	artemisinin	117-128	tumor protein p53	Homo sapiens	75-78
25755006-9	2015	Increased expression of p53 with concomitant decrease in expression of the p53 inhibitor Mdm2 further supported that artemisinin-induced apoptosis was p53-dependent.	artemisinin	117-128	MDM2 proto-oncogene	Homo sapiens	89-93
25755006-9	2015	Increased expression of p53 with concomitant decrease in expression of the p53 inhibitor Mdm2 further supported that artemisinin-induced apoptosis was p53-dependent.	artemisinin	117-128	tumor protein p53	Homo sapiens	75-78
25897065-4	2015	All 1,737 ACAs contained the labeled artemisinin derivative, with 4.1% being outside the 85-115% artemisinin API range defined as acceptable quality.	artemisinin	37-48	ALL1	Homo sapiens	0-5
25707499-1	2015	The aim of this study was to evaluate the effect of artemisinin (ART) on rat vascular smooth muscle cell (VSMC) proliferation induced by tumour necrosis factor (TNF)-alpha, cell cycle arrest, and apoptosis, and its effect on neointima formation after balloon injury of rat carotid artery.	artemisinin	52-63	tumor necrosis factor	Rattus norvegicus	137-171
25707499-8	2015	The results suggest that ART can effectively inhibit the proliferation of VSMC induced by TNF-alpha through the apoptotic induction pathway and cell cycle arrest.	artemisinin	25-28	tumor necrosis factor	Rattus norvegicus	90-99
26109756-8	2015	At 2 h after treatment, the intravenous administration of artemisinin and transferrin-loaded magnetic nanoliposomes followed using the magnetic field approximately produced 10- and 5.5-fold higher levels of artemisinin and transferrin in the tumors, respectively, compared with free artemisinin and transferrin.	artemisinin	58-69	transferrin	Mus musculus	223-234
26109756-8	2015	At 2 h after treatment, the intravenous administration of artemisinin and transferrin-loaded magnetic nanoliposomes followed using the magnetic field approximately produced 10- and 5.5-fold higher levels of artemisinin and transferrin in the tumors, respectively, compared with free artemisinin and transferrin.	artemisinin	58-69	transferrin	Mus musculus	223-234
26109756-8	2015	At 2 h after treatment, the intravenous administration of artemisinin and transferrin-loaded magnetic nanoliposomes followed using the magnetic field approximately produced 10- and 5.5-fold higher levels of artemisinin and transferrin in the tumors, respectively, compared with free artemisinin and transferrin.	artemisinin	207-218	transferrin	Mus musculus	74-85
26109756-8	2015	At 2 h after treatment, the intravenous administration of artemisinin and transferrin-loaded magnetic nanoliposomes followed using the magnetic field approximately produced 10- and 5.5-fold higher levels of artemisinin and transferrin in the tumors, respectively, compared with free artemisinin and transferrin.	artemisinin	207-218	transferrin	Mus musculus	74-85
25836766-3	2015	A total of 417 patient samples from the year 2007, collected during malaria surveillance studies across ten provinces in Thailand, were genotyped for the candidate Plasmodium falciparum molecular marker of artemisinin resistance K13.	artemisinin	206-217	keratin 13	Homo sapiens	229-232
25836766-7	2015	The most prevalent artemisinin resistance-associated K13 mutation, C580Y, carried two distinct haplotype profiles that were separated based on geography, along the Thai-Cambodia and Thai-Myanmar borders.	artemisinin	19-30	keratin 13	Homo sapiens	53-56
25836766-9	2015	In summary, parasites with K13 propeller mutations associated with artemisinin resistance were widely present along the Thai-Cambodia and Thai-Myanmar borders prior to the implementation of the artemisinin resistance containment project in the region.	artemisinin	67-78	keratin 13	Homo sapiens	27-30
25836766-9	2015	In summary, parasites with K13 propeller mutations associated with artemisinin resistance were widely present along the Thai-Cambodia and Thai-Myanmar borders prior to the implementation of the artemisinin resistance containment project in the region.	artemisinin	194-205	keratin 13	Homo sapiens	27-30
25862844-3	2015	MATERIAL AND METHODS: We performed molecular docking of 52 artemisinin derivatives to vascular endothelial growth factor receptors (VEGFR1, VEGFR2), and VEGFA ligand using Autodock4 and AutodockTools-1.5.7.rc1 using the Lamarckian genetic algorithm.	artemisinin	59-70	fms related receptor tyrosine kinase 1	Homo sapiens	132-138
25862844-3	2015	MATERIAL AND METHODS: We performed molecular docking of 52 artemisinin derivatives to vascular endothelial growth factor receptors (VEGFR1, VEGFR2), and VEGFA ligand using Autodock4 and AutodockTools-1.5.7.rc1 using the Lamarckian genetic algorithm.	artemisinin	59-70	kinase insert domain receptor	Homo sapiens	140-146
25862844-5	2015	RESULTS: A statistically significant inverse relationship was obtained between in silico binding energies to VEGFR1 and anti-angiogenic activity in vivo of a test-set of artemisinin derivatives (R=-0.843; p=0.035).	artemisinin	170-181	fms related receptor tyrosine kinase 1	Homo sapiens	109-115
25862844-7	2015	Furthermore, 52 artemisinin derivatives were docked to VEGFR1 and in selected examples also to VEGFR2 and VEGFA.	artemisinin	16-27	fms related receptor tyrosine kinase 1	Homo sapiens	55-61
25862844-7	2015	Furthermore, 52 artemisinin derivatives were docked to VEGFR1 and in selected examples also to VEGFR2 and VEGFA.	artemisinin	16-27	kinase insert domain receptor	Homo sapiens	95-101
25862844-7	2015	Furthermore, 52 artemisinin derivatives were docked to VEGFR1 and in selected examples also to VEGFR2 and VEGFA.	artemisinin	16-27	vascular endothelial growth factor A	Homo sapiens	106-111
25862844-9	2015	The best binding affinities to VEGFR1 were found for an artemisinin dimer, 10-dihydroartemisinyl-2-propylpentanoate, and dihydroartemisinin alpha-hemisuccinate sodium salt.	artemisinin	56-67	fms related receptor tyrosine kinase 1	Homo sapiens	31-37
25584867-5	2015	Furthermore, artemisinin induced apoptosis in erythrocytes in zebrafish embryos, as assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling assay, and preferentially acted on differentiated erythrocytes by elevating caspase 8 and caspase 9 activity in differentiated human K562 cells.	artemisinin	13-24	caspase 8, apoptosis-related cysteine peptidase	Danio rerio	233-242
25584867-5	2015	Furthermore, artemisinin induced apoptosis in erythrocytes in zebrafish embryos, as assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling assay, and preferentially acted on differentiated erythrocytes by elevating caspase 8 and caspase 9 activity in differentiated human K562 cells.	artemisinin	13-24	caspase 9, apoptosis-related cysteine peptidase	Danio rerio	247-256
25584867-4	2015	RNA-Seq revealed that artemisinin suppressed a cluster of genes in the heme biosynthesis and globin synthesis pathways.	artemisinin	22-33	hemoglobin alpha embryonic-3	Danio rerio	93-99
25502316-3	2015	Polymorphisms in the kelch domain-carrying protein K13 are associated with artemisinin resistance, but the underlying molecular mechanisms are unknown.	artemisinin	75-86	keratin 13	Homo sapiens	51-54
25575733-0	2015	Artemisinin inhibits the proliferation, migration, and inflammatory reaction induced by tumor necrosis factor-alpha in vascular smooth muscle cells through nuclear factor kappa B pathway.	artemisinin	0-11	tumor necrosis factor	Rattus norvegicus	88-115
25575733-2	2015	The aim of this study was to evaluate the effect of artemisinin (ART) on the proliferation, migration, and inflammation induced by tumor necrosis factor-alpha (TNF-alpha) of rat vascular smooth muscle cells (VSMCs).	artemisinin	52-63	tumor necrosis factor	Rattus norvegicus	131-158
25575733-2	2015	The aim of this study was to evaluate the effect of artemisinin (ART) on the proliferation, migration, and inflammation induced by tumor necrosis factor-alpha (TNF-alpha) of rat vascular smooth muscle cells (VSMCs).	artemisinin	52-63	tumor necrosis factor	Rattus norvegicus	160-169
25575733-2	2015	The aim of this study was to evaluate the effect of artemisinin (ART) on the proliferation, migration, and inflammation induced by tumor necrosis factor-alpha (TNF-alpha) of rat vascular smooth muscle cells (VSMCs).	artemisinin	65-68	tumor necrosis factor	Rattus norvegicus	131-158
25575733-2	2015	The aim of this study was to evaluate the effect of artemisinin (ART) on the proliferation, migration, and inflammation induced by tumor necrosis factor-alpha (TNF-alpha) of rat vascular smooth muscle cells (VSMCs).	artemisinin	65-68	tumor necrosis factor	Rattus norvegicus	160-169
25575733-9	2015	RESULTS: The proliferation, migration, and inflammation of VSMCs induced by TNF-alpha were significantly inhibited by ART treatment in a dose-dependent manner.	artemisinin	118-121	tumor necrosis factor	Rattus norvegicus	76-85
25354548-5	2015	Western blot analysis revealed that QH induced apoptosis in human prostate cancer cells via activation of caspase-3 and cleavage of poly(adenosine diphosphate ribose) polymerase.	artemisinin	36-38	caspase 3	Homo sapiens	106-115
25760540-0	2015	Effect of CAR polymorphism on the pharmacokinetics of artemisinin in healthy Chinese subjects.	artemisinin	54-65	nuclear receptor subfamily 1 group I member 3	Homo sapiens	10-13
25760540-1	2015	Repeated pretreatment with the antimalarial drug artemisinin (QHS) could lead to reduced exposure to the parent drug, which is mainly mediated by auto-induction of CYP2B6 activity.	artemisinin	49-60	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	164-170
25502316-4	2015	We analyzed the in vivo transcriptomes of 1043 P. falciparum isolates from patients with acute malaria and found that artemisinin resistance is associated with increased expression of unfolded protein response (UPR) pathways involving the major PROSC and TRiC chaperone complexes.	artemisinin	118-129	pyridoxal phosphate binding protein	Homo sapiens	245-250
25313206-3	2015	While several artemisinin-type antimalarial drugs have been shown to activate PXR, data on nonartemisinin-type antimalarials are still missing.	artemisinin	14-25	nuclear receptor subfamily 1 group I member 2	Homo sapiens	78-81
24876631-6	2015	Artemisinin significantly increased hydrogen peroxide (H2O2) and malondialdehyde (MDA) levels and decreased catalase, glutathione peroxidase and superoxide dismutase activities in erythrocytes and uterus of rats compared with control group (p < 0.05).	artemisinin	0-11	catalase	Rattus norvegicus	108-116
25754587-0	2015	Enhancement of cytotoxicity of artemisinin toward cancer cells by transferrin-mediated carbon nanotubes nanoparticles.	artemisinin	31-42	transferrin	Homo sapiens	66-77
25263705-0	2014	Improper protein trafficking contributes to artemisinin sensitivity in cells lacking the KDAC Rpd3p.	artemisinin	44-55	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	94-99
24804646-1	2014	The interactions of dihydroartemisinin (DHA) and artemisinin (ART) with bovine serum albumin (BSA) have been investigated using fluorescence, UV/vis absorption and Fourier transform infrared (FTIR) spectra under simulated physiological conditions.	artemisinin	27-38	albumin	Homo sapiens	79-98
25263705-3	2014	Deletion of RPD3, but not other KDAC genes, resulted in strong sensitivity to artemisinin, which was also observed in sit4Delta mutants with impaired endoplasmic reticulum (ER) to Golgi protein trafficking.	artemisinin	78-89	histone deacetylase RPD3	Saccharomyces cerevisiae S288C	12-16
25363545-0	2014	Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations.	artemisinin	121-132	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	0-15
25110145-0	2014	Artemisinin prevents electric remodeling following myocardial infarction possibly by upregulating the expression of connexin 43.	artemisinin	0-11	gap junction protein, alpha 1	Rattus norvegicus	116-127
24079412-4	2014	However, increased hydrogen peroxide and lipid peroxidation levels were accompanied by a concomitant decrease in glutathione peroxidase and glutathione-S-transferase activities as well as glutathione level in spermatozoon of rats administered with overdose of artemisinin.	artemisinin	260-271	hematopoietic prostaglandin D synthase	Rattus norvegicus	140-165
25110145-5	2014	The electrophysiological improvement of the VFT was accompanied by increased immunofluorescence-stained connexin 43 (Cx43), myocardial Cx43 protein and mRNA levels in artemisinin-treated rats.	artemisinin	167-178	gap junction protein, alpha 1	Rattus norvegicus	135-139
25110145-6	2014	The present study also demonstrated that artemisinin significantly decreased tissue tumor necrosis factor (TNF)-alpha levels at the infarcted border zone.	artemisinin	41-52	tumor necrosis factor	Rattus norvegicus	84-117
25110145-8	2014	Although the precise mechanism by which artemisinin modulates the dephosphorylation of Cx43 is unknown, it is likely that artemisinin increased the expression of Cx43 via the inhibition of TNF-alpha.	artemisinin	40-51	gap junction protein, alpha 1	Rattus norvegicus	87-91
25110145-8	2014	Although the precise mechanism by which artemisinin modulates the dephosphorylation of Cx43 is unknown, it is likely that artemisinin increased the expression of Cx43 via the inhibition of TNF-alpha.	artemisinin	122-133	gap junction protein, alpha 1	Rattus norvegicus	162-166
25110145-8	2014	Although the precise mechanism by which artemisinin modulates the dephosphorylation of Cx43 is unknown, it is likely that artemisinin increased the expression of Cx43 via the inhibition of TNF-alpha.	artemisinin	122-133	tumor necrosis factor	Rattus norvegicus	189-198
24400699-0	2014	Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies.	artemisinin	11-22	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-55
25074847-0	2014	A semi-synthetic derivative of artemisinin, artesunate inhibits prostaglandin E2 production in LPS/IFNgamma-activated BV2 microglia.	artemisinin	31-42	interferon gamma	Homo sapiens	99-107
24886881-0	2014	Artemisinin protects against dextran sulfate-sodium-induced inflammatory bowel disease, which is associated with activation of the pregnane X receptor.	artemisinin	0-11	nuclear receptor subfamily 1 group I member 2	Homo sapiens	131-150
24886881-2	2014	In the present study, the effects of artemisinin on pregnane X receptor (PXR)-mediated CYP3A expression and its therapeutic role in inflammatory bowel disease were investigated.	artemisinin	37-48	nuclear receptor subfamily 1 group I member 2	Homo sapiens	52-71
24886881-2	2014	In the present study, the effects of artemisinin on pregnane X receptor (PXR)-mediated CYP3A expression and its therapeutic role in inflammatory bowel disease were investigated.	artemisinin	37-48	nuclear receptor subfamily 1 group I member 2	Homo sapiens	73-76
24886881-2	2014	In the present study, the effects of artemisinin on pregnane X receptor (PXR)-mediated CYP3A expression and its therapeutic role in inflammatory bowel disease were investigated.	artemisinin	37-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	87-92
24886881-3	2014	LS174T cells exposed to artemisinin at various concentrations and for different periods of time were examined with respect to the specific induction of CYP3A4 and PXR mRNA expression.	artemisinin	24-35	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	152-158
24886881-3	2014	LS174T cells exposed to artemisinin at various concentrations and for different periods of time were examined with respect to the specific induction of CYP3A4 and PXR mRNA expression.	artemisinin	24-35	nuclear receptor subfamily 1 group I member 2	Homo sapiens	163-166
24886881-4	2014	Transient transfection experiments showed transcriptional activation of the CYP3A4 gene through artemisinin to be PXR-dependent.	artemisinin	96-107	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	76-82
24886881-4	2014	Transient transfection experiments showed transcriptional activation of the CYP3A4 gene through artemisinin to be PXR-dependent.	artemisinin	96-107	nuclear receptor subfamily 1 group I member 2	Homo sapiens	114-117
24886881-5	2014	An electrophoretic-mobility shift assay (EMSA) showed that artemisinin activates the DNA-binding capacity of the PXR for the CYP3A4 element.	artemisinin	59-70	nuclear receptor subfamily 1 group I member 2	Homo sapiens	113-116
24886881-5	2014	An electrophoretic-mobility shift assay (EMSA) showed that artemisinin activates the DNA-binding capacity of the PXR for the CYP3A4 element.	artemisinin	59-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	125-131
24886881-6	2014	These results indicate that the induction of CYP3A4 by artemisinin is mediated through the activation of PXR.	artemisinin	55-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
24886881-6	2014	These results indicate that the induction of CYP3A4 by artemisinin is mediated through the activation of PXR.	artemisinin	55-66	nuclear receptor subfamily 1 group I member 2	Homo sapiens	105-108
24886881-9	2014	Artemisinin was found to prevent or reduce the severity of colonic inflammation by inducing CYP3A expression by activation of PXR.	artemisinin	0-11	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	92-97
24886881-9	2014	Artemisinin was found to prevent or reduce the severity of colonic inflammation by inducing CYP3A expression by activation of PXR.	artemisinin	0-11	nuclear receptor subfamily 1 group I member 2	Homo sapiens	126-129
25017372-5	2014	Annexin V-FITC/PI staining assay revealed that artemisinin markedly induced apoptosis.	artemisinin	47-58	annexin A5	Homo sapiens	0-9
25116436-9	2014	These results identify GC B cells as a target of artesunate and provide a new rationale for using artemisinin analogues to treat autoimmune diseases mediated by autoantibodies.	artemisinin	98-109	natriuretic peptide receptor 2	Mus musculus	23-27
24400699-5	2014	Effects of the antimalarial agent artemisinin and its structural analogues, artemether, artesunate and dihydroartemisinin, on seven of the major human liver CYP isoforms (CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6 and 3A4) were evaluated using recombinant enzymes (fluorometric assay) and human liver microsomes (LC-MS/MS analysis).	artemisinin	34-45	peptidylprolyl isomerase G	Homo sapiens	157-160
24400699-5	2014	Effects of the antimalarial agent artemisinin and its structural analogues, artemether, artesunate and dihydroartemisinin, on seven of the major human liver CYP isoforms (CYP1A2, 2A6, 2B6, 2C9, 2C19, 2D6 and 3A4) were evaluated using recombinant enzymes (fluorometric assay) and human liver microsomes (LC-MS/MS analysis).	artemisinin	34-45	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	171-177
24400699-10	2014	A high risk of interaction in vivo was predicted if artemisinin is coadministrated with CYP1A2 or 2C19 substrates.	artemisinin	52-63	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	88-94
24974584-4	2014	Treatment with artemisinin was also associated with activation of AMP kinase and inhibition of mTOR/p70S6K/pS6 signaling in SHSY5Y cells.	artemisinin	15-26	mechanistic target of rapamycin kinase	Homo sapiens	95-99
24661944-0	2014	Enhanced delivery of artemisinin and its analogues to cancer cells by their adducts with human serum transferrin.	artemisinin	21-32	transferrin	Homo sapiens	101-112
24974584-4	2014	Treatment with artemisinin was also associated with activation of AMP kinase and inhibition of mTOR/p70S6K/pS6 signaling in SHSY5Y cells.	artemisinin	15-26	ribosomal protein S6 kinase B1	Homo sapiens	100-106
24721719-0	2014	Fetal bovine serum and human constitutive androstane receptor: evidence for activation of the SV23 splice variant by artemisinin, artemether, and arteether in a serum-free cell culture system.	artemisinin	117-128	nuclear receptor subfamily 1 group I member 3	Homo sapiens	29-61
24661969-6	2014	MATERIALS AND METHODS: Healthy and Plasmodium chabaudi-infected mice were oral gavaged with pACT to deliver a 100 mg kg(-1) body weight dose of artemisinin.	artemisinin	144-155	retinoblastoma binding protein 6, ubiquitin ligase	Mus musculus	92-96
24887240-1	2014	BACKGROUND: Artemisinin is the major sesquiterpene lactones in sweet wormwood (Artemisia annua L.), and its combination with transferrin exhibits versatile anti-cancer activities.	artemisinin	12-23	transferrin	Homo sapiens	125-136
24721719-7	2014	Under this condition, artemisinin, artemether, and arteether increased hCAR-SV23 activity, whereas they decreased it in cells cultured in medium supplemented with 10% regular FBS.	artemisinin	22-33	CXADR Ig-like cell adhesion molecule	Homo sapiens	71-75
24661969-8	2014	RESULTS: The first order elimination rate constant for artemisinin in pACT-treated healthy mice was estimated to be 0.80 h(-1) with an elimination half-life (T1/2) of 51.6 min.	artemisinin	55-66	retinoblastoma binding protein 6, ubiquitin ligase	Mus musculus	70-74
24661969-19	2014	The results have implications for possible therapeutic use of pACT in treating malaria and other artemisinin-susceptible diseases.	artemisinin	97-108	retinoblastoma binding protein 6, ubiquitin ligase	Mus musculus	62-66
24333126-3	2014	The single compound and the combined doping experiments at 0, 25 and 50 mug mL-1 doping levels showed that artemetin (50 mug mL-1) caused a reduction in the amount of artemisinin crystallized by ca.	artemisinin	167-178	L1 cell adhesion molecule	Mus musculus	125-129
24296733-6	2014	Artemisinin treatment stimulated the cellular levels of IkappaB-alpha protein without altering the level of IkappaB-alpha transcripts.	artemisinin	0-11	NFKB inhibitor alpha	Homo sapiens	56-69
24296733-7	2014	Finally, expression of exogenous p65 resulted in the accumulation of this NF-kappaB subunit in the nucleus of artemisinin-treated and artemisinin-untreated cells, reversed the artemisinin downregulation of CDK4 protein expression and promoter activity, and prevented the artemisinin-induced G1 cell cycle arrest.	artemisinin	110-121	RELA proto-oncogene, NF-kB subunit	Homo sapiens	33-36
24296733-7	2014	Finally, expression of exogenous p65 resulted in the accumulation of this NF-kappaB subunit in the nucleus of artemisinin-treated and artemisinin-untreated cells, reversed the artemisinin downregulation of CDK4 protein expression and promoter activity, and prevented the artemisinin-induced G1 cell cycle arrest.	artemisinin	110-121	cyclin dependent kinase 4	Homo sapiens	206-210
24296733-7	2014	Finally, expression of exogenous p65 resulted in the accumulation of this NF-kappaB subunit in the nucleus of artemisinin-treated and artemisinin-untreated cells, reversed the artemisinin downregulation of CDK4 protein expression and promoter activity, and prevented the artemisinin-induced G1 cell cycle arrest.	artemisinin	134-145	RELA proto-oncogene, NF-kB subunit	Homo sapiens	33-36
24296733-7	2014	Finally, expression of exogenous p65 resulted in the accumulation of this NF-kappaB subunit in the nucleus of artemisinin-treated and artemisinin-untreated cells, reversed the artemisinin downregulation of CDK4 protein expression and promoter activity, and prevented the artemisinin-induced G1 cell cycle arrest.	artemisinin	134-145	cyclin dependent kinase 4	Homo sapiens	206-210
24296733-7	2014	Finally, expression of exogenous p65 resulted in the accumulation of this NF-kappaB subunit in the nucleus of artemisinin-treated and artemisinin-untreated cells, reversed the artemisinin downregulation of CDK4 protein expression and promoter activity, and prevented the artemisinin-induced G1 cell cycle arrest.	artemisinin	134-145	RELA proto-oncogene, NF-kB subunit	Homo sapiens	33-36
24296733-7	2014	Finally, expression of exogenous p65 resulted in the accumulation of this NF-kappaB subunit in the nucleus of artemisinin-treated and artemisinin-untreated cells, reversed the artemisinin downregulation of CDK4 protein expression and promoter activity, and prevented the artemisinin-induced G1 cell cycle arrest.	artemisinin	134-145	cyclin dependent kinase 4	Homo sapiens	206-210
24296733-7	2014	Finally, expression of exogenous p65 resulted in the accumulation of this NF-kappaB subunit in the nucleus of artemisinin-treated and artemisinin-untreated cells, reversed the artemisinin downregulation of CDK4 protein expression and promoter activity, and prevented the artemisinin-induced G1 cell cycle arrest.	artemisinin	134-145	RELA proto-oncogene, NF-kB subunit	Homo sapiens	33-36
24296733-7	2014	Finally, expression of exogenous p65 resulted in the accumulation of this NF-kappaB subunit in the nucleus of artemisinin-treated and artemisinin-untreated cells, reversed the artemisinin downregulation of CDK4 protein expression and promoter activity, and prevented the artemisinin-induced G1 cell cycle arrest.	artemisinin	134-145	cyclin dependent kinase 4	Homo sapiens	206-210
24296733-8	2014	Taken together, our results demonstrate that a key event in the artemisinin antiproliferative effects in endometrial cancer cells is the transcriptional downregulation of CDK4 expression by disruption of NF-kappaB interactions with the CDK4 promoter.	artemisinin	64-75	cyclin dependent kinase 4	Homo sapiens	171-175
24296733-8	2014	Taken together, our results demonstrate that a key event in the artemisinin antiproliferative effects in endometrial cancer cells is the transcriptional downregulation of CDK4 expression by disruption of NF-kappaB interactions with the CDK4 promoter.	artemisinin	64-75	cyclin dependent kinase 4	Homo sapiens	236-240
24296733-0	2014	Artemisinin triggers a G1 cell cycle arrest of human Ishikawa endometrial cancer cells and inhibits cyclin-dependent kinase-4 promoter activity and expression by disrupting nuclear factor-kappaB transcriptional signaling.	artemisinin	0-11	cyclin dependent kinase 4	Homo sapiens	100-125
24296733-2	2014	Artemisinin induced a G1 cell cycle arrest in cultured human Ishikawa endometrial cancer cells and downregulated cyclin-dependent kinase-2 (CDK2) and CDK4 transcript and protein levels.	artemisinin	0-11	cyclin dependent kinase 2	Homo sapiens	113-138
24296733-2	2014	Artemisinin induced a G1 cell cycle arrest in cultured human Ishikawa endometrial cancer cells and downregulated cyclin-dependent kinase-2 (CDK2) and CDK4 transcript and protein levels.	artemisinin	0-11	cyclin dependent kinase 2	Homo sapiens	140-144
24296733-2	2014	Artemisinin induced a G1 cell cycle arrest in cultured human Ishikawa endometrial cancer cells and downregulated cyclin-dependent kinase-2 (CDK2) and CDK4 transcript and protein levels.	artemisinin	0-11	cyclin dependent kinase 4	Homo sapiens	150-154
24296733-3	2014	Analysis of CDK4 promoter-luciferase reporter constructs showed that the artemisinin ablation of CDK4 gene expression was accounted for by the loss of CDK4 promoter activity.	artemisinin	73-84	cyclin dependent kinase 4	Homo sapiens	12-16
24296733-3	2014	Analysis of CDK4 promoter-luciferase reporter constructs showed that the artemisinin ablation of CDK4 gene expression was accounted for by the loss of CDK4 promoter activity.	artemisinin	73-84	cyclin dependent kinase 4	Homo sapiens	97-101
24296733-3	2014	Analysis of CDK4 promoter-luciferase reporter constructs showed that the artemisinin ablation of CDK4 gene expression was accounted for by the loss of CDK4 promoter activity.	artemisinin	73-84	cyclin dependent kinase 4	Homo sapiens	97-101
24296733-4	2014	Chromatin immunoprecipitation demonstrated that artemisinin inhibited nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) subunit p65 and p50 interactions with the endogenous Ishikawa cell CDK4 promoter.	artemisinin	48-59	RELA proto-oncogene, NF-kB subunit	Homo sapiens	153-156
24296733-4	2014	Chromatin immunoprecipitation demonstrated that artemisinin inhibited nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) subunit p65 and p50 interactions with the endogenous Ishikawa cell CDK4 promoter.	artemisinin	48-59	nuclear factor kappa B subunit 1	Homo sapiens	161-164
24296733-4	2014	Chromatin immunoprecipitation demonstrated that artemisinin inhibited nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) subunit p65 and p50 interactions with the endogenous Ishikawa cell CDK4 promoter.	artemisinin	48-59	cyclin dependent kinase 4	Homo sapiens	212-216
24296733-5	2014	Coimmunoprecipitation revealed that artemisinin disrupts endogenous p65 and p50 nuclear translocation through increased protein-protein interactions with IkappaB-alpha, an NF-kappaB inhibitor, and disrupts its interaction with the CDK4 promoter, leading to a loss of CDK4 gene expression.	artemisinin	36-47	RELA proto-oncogene, NF-kB subunit	Homo sapiens	68-71
24296733-5	2014	Coimmunoprecipitation revealed that artemisinin disrupts endogenous p65 and p50 nuclear translocation through increased protein-protein interactions with IkappaB-alpha, an NF-kappaB inhibitor, and disrupts its interaction with the CDK4 promoter, leading to a loss of CDK4 gene expression.	artemisinin	36-47	nuclear factor kappa B subunit 1	Homo sapiens	76-79
24296733-5	2014	Coimmunoprecipitation revealed that artemisinin disrupts endogenous p65 and p50 nuclear translocation through increased protein-protein interactions with IkappaB-alpha, an NF-kappaB inhibitor, and disrupts its interaction with the CDK4 promoter, leading to a loss of CDK4 gene expression.	artemisinin	36-47	NFKB inhibitor alpha	Homo sapiens	154-167
24296733-5	2014	Coimmunoprecipitation revealed that artemisinin disrupts endogenous p65 and p50 nuclear translocation through increased protein-protein interactions with IkappaB-alpha, an NF-kappaB inhibitor, and disrupts its interaction with the CDK4 promoter, leading to a loss of CDK4 gene expression.	artemisinin	36-47	cyclin dependent kinase 4	Homo sapiens	231-235
24296733-5	2014	Coimmunoprecipitation revealed that artemisinin disrupts endogenous p65 and p50 nuclear translocation through increased protein-protein interactions with IkappaB-alpha, an NF-kappaB inhibitor, and disrupts its interaction with the CDK4 promoter, leading to a loss of CDK4 gene expression.	artemisinin	36-47	cyclin dependent kinase 4	Homo sapiens	267-271
25102693-0	2014	Artemisinin ameliorated proteinuria in rats with adriamycin-induced nephropathy through regulating nephrin and podocin expressions.	artemisinin	0-11	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	99-106
25102693-9	2014	CONCLUSION: Artemisinin might have an effect on the nephropathy in rats caused by adriamycin, which may be at least partly correlated with attenu- ation of the severity of foot process effacement and fusion, up-regulation of the expressions of Nephrin and Podocin in the glomeruli in the rats.	artemisinin	12-23	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	244-251
25102693-0	2014	Artemisinin ameliorated proteinuria in rats with adriamycin-induced nephropathy through regulating nephrin and podocin expressions.	artemisinin	0-11	NPHS2 stomatin family member, podocin	Rattus norvegicus	111-118
25102693-7	2014	Compared with adriamycin group, artemisinin could reduce uric protein excretion, decrease the serum TC, TG elevation, increase the serum Alb level, up-regulate the expressions of Nephrin and Podocin (P < 0.05 or P < 0.01), but no statistical significance effects on the levels of BUN, Scr in artemisinin group (P > 0.05).	artemisinin	32-43	albumin	Rattus norvegicus	137-140
25102693-9	2014	CONCLUSION: Artemisinin might have an effect on the nephropathy in rats caused by adriamycin, which may be at least partly correlated with attenu- ation of the severity of foot process effacement and fusion, up-regulation of the expressions of Nephrin and Podocin in the glomeruli in the rats.	artemisinin	12-23	NPHS2 stomatin family member, podocin	Rattus norvegicus	256-263
25102693-7	2014	Compared with adriamycin group, artemisinin could reduce uric protein excretion, decrease the serum TC, TG elevation, increase the serum Alb level, up-regulate the expressions of Nephrin and Podocin (P < 0.05 or P < 0.01), but no statistical significance effects on the levels of BUN, Scr in artemisinin group (P > 0.05).	artemisinin	32-43	NPHS1 adhesion molecule, nephrin	Rattus norvegicus	179-186
25102693-7	2014	Compared with adriamycin group, artemisinin could reduce uric protein excretion, decrease the serum TC, TG elevation, increase the serum Alb level, up-regulate the expressions of Nephrin and Podocin (P < 0.05 or P < 0.01), but no statistical significance effects on the levels of BUN, Scr in artemisinin group (P > 0.05).	artemisinin	32-43	NPHS2 stomatin family member, podocin	Rattus norvegicus	191-198
24381053-0	2013	A SAR and QSAR study of new artemisinin compounds with antimalarial activity.	artemisinin	28-39	sarcosine dehydrogenase	Homo sapiens	2-5
24078446-0	2014	Artemisinin inhibits gastric cancer cell proliferation through upregulation of p53.	artemisinin	0-11	tumor protein p53	Homo sapiens	79-82
24078446-4	2014	Treatment with artemisinin was also associated with induction of p27 kip1 and p21 kip1, two negative cell-cycle regulators.	artemisinin	15-26	cyclin dependent kinase inhibitor 1B	Homo sapiens	65-73
24078446-5	2014	Furthermore, we revealed that artemisinin treatment led to an increased expression of p53.	artemisinin	30-41	tumor protein p53	Homo sapiens	86-89
23661289-0	2013	Artemisinin induces A549 cell apoptosis dominantly via a reactive oxygen species-mediated amplification activation loop among caspase-9, -8 and -3.	artemisinin	0-11	caspase 9	Homo sapiens	126-146
24337849-7	2013	The induction of apoptosis and inhibition of colony formation in SMMC-7721 cells treated with artemisinin were determined by TdT-mediated dUTP nick end labeling (TUNEL) and colony formation assay, respectively.	artemisinin	94-105	DNA nucleotidylexotransferase	Homo sapiens	125-128
23661289-1	2013	This report is designed to explore the roles of caspase-8, -9 and -3 in artemisinin (ARTE)-induced apoptosis in non-small cell lung cancer cells (A549 cells).	artemisinin	72-83	caspase 8	Homo sapiens	48-68
23661289-1	2013	This report is designed to explore the roles of caspase-8, -9 and -3 in artemisinin (ARTE)-induced apoptosis in non-small cell lung cancer cells (A549 cells).	artemisinin	85-89	caspase 8	Homo sapiens	48-68
23406388-0	2013	Antimalarial drug artemisinin extenuates amyloidogenesis and neuroinflammation in APPswe/PS1dE9 transgenic mice via inhibition of nuclear factor-kappaB and NLRP3 inflammasome activation.	artemisinin	18-29	NLR family, pyrin domain containing 3	Mus musculus	156-161
23782869-1	2013	BACKGROUND: This case study describes how a public-private partnership between Medicines for Malaria Venture (MMV) and Sigma-Tau Industrie Farmaceutiche Riunite SpA achieved international regulatory approval for use of the fixed-dose artemisinin-based combination therapy dihydroartemisinin-piperaquine (Eurartesim ) for the treatment of malaria, enabling more widespread access to the medicine in malaria-endemic countries.	artemisinin	234-245	surfactant protein A2	Homo sapiens	161-164
23684544-0	2013	Differential interactions of the broad spectrum drugs artemisinin, dihydroartemisinin and artesunate with serum albumin.	artemisinin	54-65	albumin	Homo sapiens	106-119
23684544-2	2013	As the binding affinity of artemisinin and its derivatives dihydroartemisinin and artesunate to blood serum proteins might influence the effectiveness of the drug, binding of artemisinin and derivatives to serum albumin was studied under near physiological conditions.	artemisinin	27-38	albumin	Homo sapiens	206-219
23979886-2	2013	Considering the lack of data regarding the genotoxic effects of these compounds in human cells, the objective of this study was to evaluate the cytotoxicity and genotoxicity, and expressions of the CASP3 and SOD1 genes in a cultured human hepatocellular liver carcinoma cell line (HepG2 cells) treated with artemisinin and artesunate.	artemisinin	307-318	caspase 3	Homo sapiens	198-203
23560676-3	2013	To elucidate the potential pathways to Ft recovery, repair of oxidative damage to horse spleen apoferritin (apoFt) and Ft by quercetin (QH) or rutin (RH) was studied in the presence and absence of oxygen.	artemisinin	136-138	ferritin heavy chain	Equus caballus	95-106
23406388-5	2013	RESULTS: We found that artemisinin treatment (1) decreased neuritic plaque burden; (2) did not alter Abeta transport across the blood-brain barrier; (3) regulated APP processing via inhibiting beta-secretase activity; (4) inhibited NF-kappaB activity and NALP3 inflammasome activation in APPswe/PS1dE9 double transgenic mice.	artemisinin	23-34	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	232-241
23406388-5	2013	RESULTS: We found that artemisinin treatment (1) decreased neuritic plaque burden; (2) did not alter Abeta transport across the blood-brain barrier; (3) regulated APP processing via inhibiting beta-secretase activity; (4) inhibited NF-kappaB activity and NALP3 inflammasome activation in APPswe/PS1dE9 double transgenic mice.	artemisinin	23-34	NLR family, pyrin domain containing 3	Mus musculus	255-260
23406388-6	2013	CONCLUSIONS: The in vivo study clearly demonstrates that artemisinin has protective effects on AD pathology due to its effects on suppressing NF-kappaB activity and NALP3 inflammasome activation.	artemisinin	57-68	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	142-151
23406388-6	2013	CONCLUSIONS: The in vivo study clearly demonstrates that artemisinin has protective effects on AD pathology due to its effects on suppressing NF-kappaB activity and NALP3 inflammasome activation.	artemisinin	57-68	NLR family, pyrin domain containing 3	Mus musculus	165-170
23497071-7	2013	RESULTS: Over 80% of health workers interviewed were able to correctly identify the malaria M&E forms; 25.4% knew the basis for categorizing Artemisinin-based combination therapy (ACT) into ACT1 - ACT4; 97.6% of the respondents felt there was need to keep proper records to have information available and 7.5% of them kept records because they were asked to do so.	artemisinin	145-156	TRAF3 interacting protein 2	Homo sapiens	194-198
23229480-0	2013	Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.	artemisinin	124-135	N-acetyltransferase 2	Homo sapiens	75-96
23467454-3	2013	Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone.	artemisinin	43-54	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
23201011-4	2013	In present research, we demonstrated that dihydroartemisinin (DHA), a safe and effective antimalarial analog of artemisinin, could significantly inhibit the Bcr/Abl fusion gene at the mRNA level in CML cells sensitive or resistant to imatinib (including the primary CML cells with T315I mutation) and induce cell death.	artemisinin	49-60	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	157-164
23287027-0	2013	Mutation analysis in pfmdr1 and pfmrp1 as potential candidate genes for artemisinin resistance in Plasmodium falciparum clinical isolates 4years after implementation of artemisinin combination therapy in Iran.	artemisinin	72-83	multidrug resistance protein 1	Plasmodium falciparum 3D7	21-27
23287027-3	2013	Also, the copy number of pfmdr1 gene was screened for its association with pfmdr1 mutations to incriminate artemisinin resistance.	artemisinin	107-118	multidrug resistance protein 1	Plasmodium falciparum 3D7	25-31
23287027-8	2013	In addition, the copy number of pfmdr1 gene (N = 1) was similar as a sensitive isolate, 3D7, to artemisinin.	artemisinin	96-107	multidrug resistance protein 1	Plasmodium falciparum 3D7	32-38
23123209-0	2013	Induction of neurite outgrowth in PC12 cells by artemisinin through activation of ERK and p38 MAPK signaling pathways.	artemisinin	48-59	Eph receptor B1	Rattus norvegicus	82-85
23123209-0	2013	Induction of neurite outgrowth in PC12 cells by artemisinin through activation of ERK and p38 MAPK signaling pathways.	artemisinin	48-59	mitogen activated protein kinase 14	Rattus norvegicus	90-93
23123209-8	2013	Artemisinin upregulated phosphorylation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK), critical signaling molecules in neuronal differentiation.	artemisinin	0-11	Eph receptor B1	Rattus norvegicus	43-80
23123209-8	2013	Artemisinin upregulated phosphorylation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK), critical signaling molecules in neuronal differentiation.	artemisinin	0-11	Eph receptor B1	Rattus norvegicus	82-85
23123209-8	2013	Artemisinin upregulated phosphorylation of extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (MAPK), critical signaling molecules in neuronal differentiation.	artemisinin	0-11	mitogen activated protein kinase 14	Rattus norvegicus	91-127
23123209-9	2013	Consistent with activation of the two MAPKs, neurite outgrowth induced by artemisinin was inhibited by the MAPK/ERK kinase inhibitor PD98059 and the p38 MAPK inhibitor SB203580.	artemisinin	74-85	Eph receptor B1	Rattus norvegicus	112-115
23123209-9	2013	Consistent with activation of the two MAPKs, neurite outgrowth induced by artemisinin was inhibited by the MAPK/ERK kinase inhibitor PD98059 and the p38 MAPK inhibitor SB203580.	artemisinin	74-85	mitogen activated protein kinase 14	Rattus norvegicus	149-152
23123209-10	2013	Artemisinin also induced phosphorylation of cyclic AMP response element-binding protein (CREB) that was almost completely attenuated by PD98059 but not by SB203580.	artemisinin	0-11	cAMP responsive element binding protein 1	Rattus norvegicus	44-87
23123209-10	2013	Artemisinin also induced phosphorylation of cyclic AMP response element-binding protein (CREB) that was almost completely attenuated by PD98059 but not by SB203580.	artemisinin	0-11	cAMP responsive element binding protein 1	Rattus norvegicus	89-93
23123209-11	2013	Taken together, our results indicate that artemisinin and its derivatives containing the endoperoxide bridge induced differentiation of PC12 cells toward a neuronal phenotype and suggest that both activation of ERK signaling pathway, which leads to CREB phosphorylation, and activation of p38 MAPK signaling pathway are involved in this process.	artemisinin	42-53	Eph receptor B1	Rattus norvegicus	211-214
23123209-11	2013	Taken together, our results indicate that artemisinin and its derivatives containing the endoperoxide bridge induced differentiation of PC12 cells toward a neuronal phenotype and suggest that both activation of ERK signaling pathway, which leads to CREB phosphorylation, and activation of p38 MAPK signaling pathway are involved in this process.	artemisinin	42-53	cAMP responsive element binding protein 1	Rattus norvegicus	249-253
23123209-11	2013	Taken together, our results indicate that artemisinin and its derivatives containing the endoperoxide bridge induced differentiation of PC12 cells toward a neuronal phenotype and suggest that both activation of ERK signaling pathway, which leads to CREB phosphorylation, and activation of p38 MAPK signaling pathway are involved in this process.	artemisinin	42-53	mitogen activated protein kinase 14	Rattus norvegicus	289-292
23267137-0	2013	Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines.	artemisinin	37-48	transferrin	Homo sapiens	11-22
23267137-0	2013	Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines.	artemisinin	53-64	transferrin	Homo sapiens	11-22
23267137-1	2013	Transferrin (Tf) conjugates of monomeric artemisinin (ART) and artemisinin dimer were synthesized.	artemisinin	41-52	transferrin	Homo sapiens	0-11
23267137-1	2013	Transferrin (Tf) conjugates of monomeric artemisinin (ART) and artemisinin dimer were synthesized.	artemisinin	63-74	transferrin	Homo sapiens	0-11
23267137-5	2013	To our knowledge, this is the first demonstration that an ART derivative can cause a decline of ERBB2 in a human cancer cell line.	artemisinin	58-61	erb-b2 receptor tyrosine kinase 2	Homo sapiens	96-101
23041519-0	2012	Artemisinin inhibits lipopolysaccharide-induced interferon-beta production in RAW 264.7 cells: implications on signal transducer and activator of transcription-1 signaling and nitric oxide production.	artemisinin	0-11	signal transducer and activator of transcription 1	Mus musculus	111-161
23516601-6	2013	We demonstrate for the first time, for any ART derivative, that ADP NPs can down regulate the oncogenic protein HER2, and its counterpart, HER3 in a HER2+ cell line.	artemisinin	43-46	erb-b2 receptor tyrosine kinase 2	Mus musculus	112-116
23516601-6	2013	We demonstrate for the first time, for any ART derivative, that ADP NPs can down regulate the oncogenic protein HER2, and its counterpart, HER3 in a HER2+ cell line.	artemisinin	43-46	erb-b2 receptor tyrosine kinase 3	Mus musculus	139-143
23041519-2	2012	In this study, we investigated the effect of artemisinin on lipopolysaccharide (LPS)-induced production of IFN-beta and characterized the potential relationship between artemisinin-mediated inhibition of IFN-beta and NO production.	artemisinin	169-180	interferon beta 1, fibroblast	Mus musculus	204-212
23041519-3	2012	Artemisinin suppressed IFN-beta production and mRNA expression in a dose-dependent manner in LPS-stimulated RAW 264.7 cells.	artemisinin	0-11	interferon beta 1, fibroblast	Mus musculus	23-31
23041519-4	2012	LPS-induced phosphorylation of signal transducer and activator of transcription-1 (STAT-1) was also inhibited by artemisinin treatment in RAW 264.7 cells.	artemisinin	113-124	signal transducer and activator of transcription 1	Mus musculus	31-81
23041519-4	2012	LPS-induced phosphorylation of signal transducer and activator of transcription-1 (STAT-1) was also inhibited by artemisinin treatment in RAW 264.7 cells.	artemisinin	113-124	signal transducer and activator of transcription 1	Mus musculus	83-89
23041519-6	2012	Further study demonstrated that artemisinin-mediated inhibition of NO production and STAT-1 phosphorylation was reversed by addition of exogenous IFN-beta.	artemisinin	32-43	signal transducer and activator of transcription 1	Mus musculus	85-91
23041519-6	2012	Further study demonstrated that artemisinin-mediated inhibition of NO production and STAT-1 phosphorylation was reversed by addition of exogenous IFN-beta.	artemisinin	32-43	interferon beta 1, fibroblast	Mus musculus	146-154
23041519-8	2012	Collectively, these results suggest that the inhibition of IFN-beta production by artemisinin and concomitant attenuation of STAT-1 activation might be involved in artemisinin-mediated inhibition of NO production in macrophages.	artemisinin	82-93	interferon beta 1, fibroblast	Mus musculus	59-67
23041519-8	2012	Collectively, these results suggest that the inhibition of IFN-beta production by artemisinin and concomitant attenuation of STAT-1 activation might be involved in artemisinin-mediated inhibition of NO production in macrophages.	artemisinin	164-175	interferon beta 1, fibroblast	Mus musculus	59-67
23041519-8	2012	Collectively, these results suggest that the inhibition of IFN-beta production by artemisinin and concomitant attenuation of STAT-1 activation might be involved in artemisinin-mediated inhibition of NO production in macrophages.	artemisinin	164-175	signal transducer and activator of transcription 1	Mus musculus	125-131
22922993-4	2012	Our results show that artemisinin significantly inhibited IL-1beta and TNF-alpha protein expression and the infiltration of macrophages.	artemisinin	22-33	interleukin 1 beta	Homo sapiens	58-66
22922993-4	2012	Our results show that artemisinin significantly inhibited IL-1beta and TNF-alpha protein expression and the infiltration of macrophages.	artemisinin	22-33	tumor necrosis factor	Homo sapiens	71-80
22922993-5	2012	Artemisinin significantly decreased the protein expression of NGF, GAP43, and TH compared with the control group, which was related to sympathetic nerve remodeling.	artemisinin	0-11	nerve growth factor	Homo sapiens	62-65
22922993-5	2012	Artemisinin significantly decreased the protein expression of NGF, GAP43, and TH compared with the control group, which was related to sympathetic nerve remodeling.	artemisinin	0-11	growth associated protein 43	Homo sapiens	67-72
22922993-7	2012	In addition, the densities of both GAP-43- and TH-immunoreactive nerves in the peri-infarct zone were significantly attenuated by artemisinin treatment.	artemisinin	130-141	growth associated protein 43	Homo sapiens	35-41
23212638-0	2012	Enhanced IL-12p40 production in LPS-stimulated macrophages by inhibiting JNK activation by artemisinin.	artemisinin	91-102	interleukin 12b	Mus musculus	9-17
23212638-0	2012	Enhanced IL-12p40 production in LPS-stimulated macrophages by inhibiting JNK activation by artemisinin.	artemisinin	91-102	mitogen-activated protein kinase 8	Mus musculus	73-76
23212638-2	2012	In this study, we investigated the effect of artemisinin on the production of IL-12p40, which is important in the generation of T helper 1 responses.	artemisinin	45-56	interleukin 12b	Mus musculus	78-86
23212638-3	2012	Artemisinin significantly induced IL-12p40 production in LPS-stimulated RAW264.7 macrophage cells.	artemisinin	0-11	interleukin 12b	Mus musculus	34-42
23212638-4	2012	To elucidate the signaling molecules regulated by artemisinin in induced IL-12p40 production, the DNA-binding activity of several transcription factors and activation of mitogen-activated protein kinase (MAPK)s were investigated.	artemisinin	50-61	interleukin 12b	Mus musculus	73-81
23212638-6	2012	However, the induced phosphorylation of JNK was significantly decreased by artemisinin, and inhibition of the JNK signaling pathway further increased IL-12p40 production in LPS-stimulated RAW264.7 macrophage cells.	artemisinin	75-86	mitogen-activated protein kinase 8	Mus musculus	40-43
23212638-7	2012	Taken together, these data suggest that artemisinin induces the production of IL-12p40 in LPS-stimulated macrophage cells by inhibiting JNK activity.	artemisinin	40-51	interleukin 12b	Mus musculus	78-86
23212638-7	2012	Taken together, these data suggest that artemisinin induces the production of IL-12p40 in LPS-stimulated macrophage cells by inhibiting JNK activity.	artemisinin	40-51	mitogen-activated protein kinase 8	Mus musculus	136-139
22679214-4	2012	To better understand the autoinduction and metabolic drug-drug interactions (DDIs), we evaluated the P450s (particularly CYP2B6 and CYP3A4) inhibited or induced by two artemisinin drugs, Qing-hao-su (QHS) and dihydroartemisinin (DHA) using human liver microsome, recombinant P450 enzymes, and primary human hepatocytes.	artemisinin	168-179	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	121-127
22853186-0	2012	LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics.	artemisinin	42-53	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	0-5
22577882-5	2012	KEY RESULTS: Only two artemisinin derivatives arteether and artemether, the metabolite deoxyartemisinin and artemisinin itself demonstrated agonist binding to the major isoforms CAR1 and CAR3, while arteether and artemether were also inverse agonists of CAR2.	artemisinin	22-33	nuclear receptor subfamily 1 group I member 3	Homo sapiens	178-182
22577882-5	2012	KEY RESULTS: Only two artemisinin derivatives arteether and artemether, the metabolite deoxyartemisinin and artemisinin itself demonstrated agonist binding to the major isoforms CAR1 and CAR3, while arteether and artemether were also inverse agonists of CAR2.	artemisinin	22-33	carbonic anhydrase 3	Homo sapiens	187-191
22577882-5	2012	KEY RESULTS: Only two artemisinin derivatives arteether and artemether, the metabolite deoxyartemisinin and artemisinin itself demonstrated agonist binding to the major isoforms CAR1 and CAR3, while arteether and artemether were also inverse agonists of CAR2.	artemisinin	22-33	nuclear receptor subfamily 1 group I member 4	Homo sapiens	254-258
22577882-5	2012	KEY RESULTS: Only two artemisinin derivatives arteether and artemether, the metabolite deoxyartemisinin and artemisinin itself demonstrated agonist binding to the major isoforms CAR1 and CAR3, while arteether and artemether were also inverse agonists of CAR2.	artemisinin	92-103	nuclear receptor subfamily 1 group I member 3	Homo sapiens	178-182
22577882-7	2012	While arteether showed the highest activities in vitro, it was less active than artemisinin in inducing hepatic CYP3A4 gene expression in hepatocytes.	artemisinin	80-91	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	112-118
22577882-8	2012	CONCLUSIONS AND IMPLICATIONS: Artemisinin derivatives and metabolites differentially affect the activities of CAR isoforms and of the pregnane X receptor (PXR).	artemisinin	30-41	nuclear receptor subfamily 1 group I member 3	Homo sapiens	110-113
22577882-8	2012	CONCLUSIONS AND IMPLICATIONS: Artemisinin derivatives and metabolites differentially affect the activities of CAR isoforms and of the pregnane X receptor (PXR).	artemisinin	30-41	nuclear receptor subfamily 1 group I member 2	Homo sapiens	134-153
22577882-8	2012	CONCLUSIONS AND IMPLICATIONS: Artemisinin derivatives and metabolites differentially affect the activities of CAR isoforms and of the pregnane X receptor (PXR).	artemisinin	30-41	nuclear receptor subfamily 1 group I member 2	Homo sapiens	155-158
22577882-9	2012	This negates a common effect of these drugs on CAR/PXR-dependent induction of drug metabolism and further provides an explanation for artemisinin consistently inducing cytochrome P450 genes in vivo, whereas arteether and artemether do not.	artemisinin	134-145	nuclear receptor subfamily 1 group I member 3	Homo sapiens	47-50
22577882-9	2012	This negates a common effect of these drugs on CAR/PXR-dependent induction of drug metabolism and further provides an explanation for artemisinin consistently inducing cytochrome P450 genes in vivo, whereas arteether and artemether do not.	artemisinin	134-145	nuclear receptor subfamily 1 group I member 2	Homo sapiens	51-54
22679214-4	2012	To better understand the autoinduction and metabolic drug-drug interactions (DDIs), we evaluated the P450s (particularly CYP2B6 and CYP3A4) inhibited or induced by two artemisinin drugs, Qing-hao-su (QHS) and dihydroartemisinin (DHA) using human liver microsome, recombinant P450 enzymes, and primary human hepatocytes.	artemisinin	168-179	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-138
22679214-4	2012	To better understand the autoinduction and metabolic drug-drug interactions (DDIs), we evaluated the P450s (particularly CYP2B6 and CYP3A4) inhibited or induced by two artemisinin drugs, Qing-hao-su (QHS) and dihydroartemisinin (DHA) using human liver microsome, recombinant P450 enzymes, and primary human hepatocytes.	artemisinin	168-179	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	101-105
22552829-9	2012	Analyses of G2-checkpoint-related proteins, the activation of Wee 1 and depression of cyclin B1 expression induced by radiation, could be restored to the control level by artemisinin.	artemisinin	171-182	WEE1 G2 checkpoint kinase	Homo sapiens	62-67
23252279-6	2012	The activity and expression level of Caspase-3 were significantly increased when treated with galactosylated artemisinin for 36 h and 72 h. The expression of BAX was also increased markedly, while BCL-2 was reduced after treatment with the drug.	artemisinin	109-120	caspase 3	Homo sapiens	37-46
23252279-6	2012	The activity and expression level of Caspase-3 were significantly increased when treated with galactosylated artemisinin for 36 h and 72 h. The expression of BAX was also increased markedly, while BCL-2 was reduced after treatment with the drug.	artemisinin	109-120	BCL2 associated X, apoptosis regulator	Homo sapiens	158-161
23252279-6	2012	The activity and expression level of Caspase-3 were significantly increased when treated with galactosylated artemisinin for 36 h and 72 h. The expression of BAX was also increased markedly, while BCL-2 was reduced after treatment with the drug.	artemisinin	109-120	BCL2 apoptosis regulator	Homo sapiens	197-202
23252279-8	2012	CONCLUSION: Galactosylated artemisinin exhibits great antitumor activities, which may be ralated to triggering cytochrome C apoptotic pathway which mediated by BCL-2 family.	artemisinin	27-38	BCL2 apoptosis regulator	Homo sapiens	160-165
23236763-7	2012	Artemisinin only inhibited the IL-6 release to a certain extent.	artemisinin	0-11	interleukin 6	Mus musculus	31-35
21547369-9	2012	Taken together, these data demonstrate that metastatic melanoma cells display a specific vulnerability to DHA-induced NOXA-dependent apoptosis and suggest feasibility of future anti-melanoma intervention using artemisinin-derived clinical redox antimalarials.	artemisinin	210-221	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	118-122
22434375-0	2012	Amplification activation loop between caspase-8 and -9 dominates artemisinin-induced apoptosis of ASTC-a-1 cells.	artemisinin	65-76	caspase 8	Homo sapiens	38-54
22434375-1	2012	Although caspases have been demonstrated to be involved in artemisinin (ARTE)-induced apoptosis, their exact functions are not well understood.	artemisinin	59-70	caspase 8	Homo sapiens	9-17
22434375-1	2012	Although caspases have been demonstrated to be involved in artemisinin (ARTE)-induced apoptosis, their exact functions are not well understood.	artemisinin	72-76	caspase 8	Homo sapiens	9-17
22434375-3	2012	ARTE treatment induces a rapid generation of reactive oxygen species (ROS), and ROS-dependent apoptosis as well as the activation of caspase-8, -9 and -3 via time- and dose-dependent fashion.	artemisinin	0-4	caspase 8	Homo sapiens	133-153
22434375-8	2012	Our findings imply a potential to develop new derivatives from artemisinin to effectively initiate the amplification activation loop of caspases.	artemisinin	63-74	caspase 8	Homo sapiens	136-144
22552829-9	2012	Analyses of G2-checkpoint-related proteins, the activation of Wee 1 and depression of cyclin B1 expression induced by radiation, could be restored to the control level by artemisinin.	artemisinin	171-182	cyclin B1	Homo sapiens	86-95
22552829-10	2012	CONCLUSIONS: Given the unique cytotoxic profile of artemisinin on cancer cells and normal cells, artemisinin may be a potentially promising radiosensitizer through the regulation of the expression of G2 checkpoint-related proteins like Wee 1 and cyclin B1, and improve therapeutic ratios for the combination of artemisinin and ionizing irradiation in the treatment of patients with cervical cancer.	artemisinin	97-108	WEE1 G2 checkpoint kinase	Homo sapiens	236-241
22552829-10	2012	CONCLUSIONS: Given the unique cytotoxic profile of artemisinin on cancer cells and normal cells, artemisinin may be a potentially promising radiosensitizer through the regulation of the expression of G2 checkpoint-related proteins like Wee 1 and cyclin B1, and improve therapeutic ratios for the combination of artemisinin and ionizing irradiation in the treatment of patients with cervical cancer.	artemisinin	97-108	cyclin B1	Homo sapiens	246-255
22552829-10	2012	CONCLUSIONS: Given the unique cytotoxic profile of artemisinin on cancer cells and normal cells, artemisinin may be a potentially promising radiosensitizer through the regulation of the expression of G2 checkpoint-related proteins like Wee 1 and cyclin B1, and improve therapeutic ratios for the combination of artemisinin and ionizing irradiation in the treatment of patients with cervical cancer.	artemisinin	97-108	WEE1 G2 checkpoint kinase	Homo sapiens	236-241
22552829-10	2012	CONCLUSIONS: Given the unique cytotoxic profile of artemisinin on cancer cells and normal cells, artemisinin may be a potentially promising radiosensitizer through the regulation of the expression of G2 checkpoint-related proteins like Wee 1 and cyclin B1, and improve therapeutic ratios for the combination of artemisinin and ionizing irradiation in the treatment of patients with cervical cancer.	artemisinin	97-108	cyclin B1	Homo sapiens	246-255
22252826-0	2012	PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin.	artemisinin	148-159	nuclear receptor subfamily 1 group I member 2	Homo sapiens	0-3
22185819-0	2012	Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes.	artemisinin	29-40	E2F transcription factor 1	Homo sapiens	153-157
22185819-0	2012	Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes.	artemisinin	29-40	E2F transcription factor 1	Homo sapiens	115-119
22252826-0	2012	PXR variants and artemisinin use in Vietnamese subjects: frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin.	artemisinin	148-159	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-134
22185819-4	2012	Concurrent with the cell cycle arrest of MCF7 cells, artemisinin selectively downregulated the transcript and protein levels of the CDK2 and CDK4 cyclin-dependent kinases, cyclin E, cyclin D1, and the E2F1 transcription factor.	artemisinin	53-64	cyclin dependent kinase 2	Homo sapiens	132-136
22252826-2	2012	Here, we report the resequencing and genotyping of PXR variants in 75 Vietnamese individuals previously characterized for CYP3A enzyme activity after artemisinin exposure.	artemisinin	150-161	nuclear receptor subfamily 1 group I member 2	Homo sapiens	51-54
22252826-2	2012	Here, we report the resequencing and genotyping of PXR variants in 75 Vietnamese individuals previously characterized for CYP3A enzyme activity after artemisinin exposure.	artemisinin	150-161	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	122-127
22185819-4	2012	Concurrent with the cell cycle arrest of MCF7 cells, artemisinin selectively downregulated the transcript and protein levels of the CDK2 and CDK4 cyclin-dependent kinases, cyclin E, cyclin D1, and the E2F1 transcription factor.	artemisinin	53-64	cyclin E1 L homeolog	Xenopus laevis	172-180
22252826-4	2012	A trend of significance was observed between the level of CYP3A4 induction by artemisinin and two PXR variants, the 8118C T (Y328Y) and 10719A G variants.	artemisinin	78-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	58-64
22185819-4	2012	Concurrent with the cell cycle arrest of MCF7 cells, artemisinin selectively downregulated the transcript and protein levels of the CDK2 and CDK4 cyclin-dependent kinases, cyclin E, cyclin D1, and the E2F1 transcription factor.	artemisinin	53-64	cyclin D1	Homo sapiens	182-191
22252826-4	2012	A trend of significance was observed between the level of CYP3A4 induction by artemisinin and two PXR variants, the 8118C T (Y328Y) and 10719A G variants.	artemisinin	78-89	nuclear receptor subfamily 1 group I member 2	Homo sapiens	98-101
22185819-4	2012	Concurrent with the cell cycle arrest of MCF7 cells, artemisinin selectively downregulated the transcript and protein levels of the CDK2 and CDK4 cyclin-dependent kinases, cyclin E, cyclin D1, and the E2F1 transcription factor.	artemisinin	53-64	E2F transcription factor 1	Homo sapiens	201-205
22185819-5	2012	Analysis of CDK2 promoter-luciferase reporter constructs showed that the artemisinin ablation of CDK2 gene expression was accounted for by the loss of CDK2 promoter activity.	artemisinin	73-84	cyclin dependent kinase 2	Homo sapiens	12-16
23506555-0	2012	The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes.	artemisinin	39-50	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	18-24
22185819-5	2012	Analysis of CDK2 promoter-luciferase reporter constructs showed that the artemisinin ablation of CDK2 gene expression was accounted for by the loss of CDK2 promoter activity.	artemisinin	73-84	cyclin dependent kinase 2	Homo sapiens	97-101
22185819-5	2012	Analysis of CDK2 promoter-luciferase reporter constructs showed that the artemisinin ablation of CDK2 gene expression was accounted for by the loss of CDK2 promoter activity.	artemisinin	73-84	cyclin dependent kinase 2	Homo sapiens	97-101
22185819-6	2012	Chromatin immunoprecipitation revealed that artemisinin inhibited E2F1 interactions with the endogenous MCF7 cell CDK2 and cyclin E promoters.	artemisinin	44-55	E2F transcription factor 1	Homo sapiens	66-70
22185819-6	2012	Chromatin immunoprecipitation revealed that artemisinin inhibited E2F1 interactions with the endogenous MCF7 cell CDK2 and cyclin E promoters.	artemisinin	44-55	cyclin dependent kinase 2	Homo sapiens	114-118
22185819-6	2012	Chromatin immunoprecipitation revealed that artemisinin inhibited E2F1 interactions with the endogenous MCF7 cell CDK2 and cyclin E promoters.	artemisinin	44-55	cyclin E1 L homeolog	Xenopus laevis	123-131
22185819-7	2012	Moreover, constitutive expression of exogenous E2F1 prevented the artemisinin-induced cell cycle arrest and downregulation of CDK2 and cyclin E gene expression.	artemisinin	66-77	E2F transcription factor 1 L homeolog	Xenopus laevis	47-51
22185819-7	2012	Moreover, constitutive expression of exogenous E2F1 prevented the artemisinin-induced cell cycle arrest and downregulation of CDK2 and cyclin E gene expression.	artemisinin	66-77	cyclin-dependent kinase 2 S homeolog	Xenopus laevis	126-130
22185819-7	2012	Moreover, constitutive expression of exogenous E2F1 prevented the artemisinin-induced cell cycle arrest and downregulation of CDK2 and cyclin E gene expression.	artemisinin	66-77	cyclin E1 L homeolog	Xenopus laevis	135-143
22185819-8	2012	Taken together, our results demonstrate that the artemisinin disruption of E2F1 transcription factor expression mediates the cell cycle arrest of human breast cancer cells and represents a critical transcriptional pathway by which artemisinin controls human reproductive cancer cell growth.	artemisinin	49-60	E2F transcription factor 1	Homo sapiens	75-79
22185819-8	2012	Taken together, our results demonstrate that the artemisinin disruption of E2F1 transcription factor expression mediates the cell cycle arrest of human breast cancer cells and represents a critical transcriptional pathway by which artemisinin controls human reproductive cancer cell growth.	artemisinin	231-242	E2F transcription factor 1	Homo sapiens	75-79
23019910-0	2012	[Effect of artemisinin on the expressions of GRalpha mRNA, GRbeta mRNA and P300/CBP protein in lupus nephritis mice].	artemisinin	11-22	CREB binding protein	Mus musculus	75-83
23019910-1	2012	OBJECTIVE: To investigate the effects of Artemisinin on the expressions of GRalpha mRNA, GRbeta mRNA and P300/CBP protein in lupus nephritis mice.	artemisinin	41-52	CREB binding protein	Mus musculus	105-113
22359336-1	2012	Artemisinin (QHS) is one of the first-line antimalarials, and autoinduction of CYP-mediated metabolism can result in its reduced exposure.	artemisinin	0-11	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	79-82
23506555-2	2012	Some artemisinin compounds and anti-retroviral drugs have been shown to be metabolized by CYP2B6.	artemisinin	5-16	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	90-96
23506555-4	2012	This study aimed to investigate whether artemisinin compounds inhibit CYP2B6 activity in vitro using recombinant CYP2B6 (rCYP2B6) and human liver microsomes (HLM).	artemisinin	40-51	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	70-76
23506555-4	2012	This study aimed to investigate whether artemisinin compounds inhibit CYP2B6 activity in vitro using recombinant CYP2B6 (rCYP2B6) and human liver microsomes (HLM).	artemisinin	40-51	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	113-119
23506555-4	2012	This study aimed to investigate whether artemisinin compounds inhibit CYP2B6 activity in vitro using recombinant CYP2B6 (rCYP2B6) and human liver microsomes (HLM).	artemisinin	40-51	cytochrome P450, family 2, subfamily b, polypeptide 3	Rattus norvegicus	121-128
23506555-7	2012	Artemisinin and artemether were shown to inhibit CYP2B6 in vitro through a partial mixed type of inhibition, while dihydroartemisinin did not inhibit the enzymatic activity.	artemisinin	0-11	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	49-55
23506555-8	2012	IC50 values for artemisinin were 9.5 and 9.1 microM for rCYP2B6 and HLM, respectively, after 30 min of incubation.	artemisinin	16-27	cytochrome P450, family 2, subfamily b, polypeptide 3	Rattus norvegicus	56-63
23506555-11	2012	Based on the [I]/Ki approach using rCYP2B6, the risk of DDIs for artemisinin was indicated to be medium to high, while artemether had a low risk.	artemisinin	65-76	cytochrome P450, family 2, subfamily b, polypeptide 3	Rattus norvegicus	35-42
21411308-1	2011	Protein engineering of cytochrome P450 monooxygenases (P450s) has been very successful in generating valuable non-natural activities and properties, allowing these powerful catalysts to be used for the synthesis of drug metabolites and in biosynthetic pathways for the production of precursors of artemisinin and paclitaxel.	artemisinin	297-308	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	23-38
22724024-8	2012	Inhibition of both routes through selected molecules (SB203580, quercetin, artemisinin, parthenolide) prevented HZ-dependent lysozyme release.	artemisinin	75-86	lysozyme	Homo sapiens	125-133
22615874-5	2012	In contrast, RNA interference depletion of intrinsic Sp1 or treatment with artemisinin, a Sp1 inhibitor, reduced expression of LEDGF/p75, suggesting Sp1-mediated regulation of LEDGF/p75.	artemisinin	75-86	Chromatin assembly factor 1, p105 subunit	Drosophila melanogaster	127-136
22615874-5	2012	In contrast, RNA interference depletion of intrinsic Sp1 or treatment with artemisinin, a Sp1 inhibitor, reduced expression of LEDGF/p75, suggesting Sp1-mediated regulation of LEDGF/p75.	artemisinin	75-86	Chromatin assembly factor 1, p105 subunit	Drosophila melanogaster	176-185
22514713-4	2012	Our results show that artemisinin significantly inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1) and nitric oxide (NO).	artemisinin	22-33	tumor necrosis factor	Homo sapiens	84-111
22514713-4	2012	Our results show that artemisinin significantly inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1) and nitric oxide (NO).	artemisinin	22-33	tumor necrosis factor	Homo sapiens	113-122
22514713-4	2012	Our results show that artemisinin significantly inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1) and nitric oxide (NO).	artemisinin	22-33	interleukin 6	Homo sapiens	125-138
22514713-4	2012	Our results show that artemisinin significantly inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1) and nitric oxide (NO).	artemisinin	22-33	interleukin 6	Homo sapiens	140-144
22514713-4	2012	Our results show that artemisinin significantly inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1) and nitric oxide (NO).	artemisinin	22-33	C-C motif chemokine ligand 2	Homo sapiens	147-177
22514713-4	2012	Our results show that artemisinin significantly inhibited LPS-induced production of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1) and nitric oxide (NO).	artemisinin	22-33	C-C motif chemokine ligand 2	Homo sapiens	179-184
22514713-5	2012	Artemisinin significantly decreased both the mRNA and the protein levels of these pro-inflammatory cytokines and inducible nitric oxide synthase (iNOS) and increased the protein levels of IkappaB-alpha, which forms a cytoplasmic inactive complex with the p65-p50 heterodimeric complex.	artemisinin	0-11	nitric oxide synthase 2	Homo sapiens	113-144
22514713-5	2012	Artemisinin significantly decreased both the mRNA and the protein levels of these pro-inflammatory cytokines and inducible nitric oxide synthase (iNOS) and increased the protein levels of IkappaB-alpha, which forms a cytoplasmic inactive complex with the p65-p50 heterodimeric complex.	artemisinin	0-11	nitric oxide synthase 2	Homo sapiens	146-150
22514713-5	2012	Artemisinin significantly decreased both the mRNA and the protein levels of these pro-inflammatory cytokines and inducible nitric oxide synthase (iNOS) and increased the protein levels of IkappaB-alpha, which forms a cytoplasmic inactive complex with the p65-p50 heterodimeric complex.	artemisinin	0-11	NFKB inhibitor alpha	Homo sapiens	188-201
22514713-8	2012	The inhibitory effects of artemisinin on LPS-stimulated microglia were blocked after IkappaB-alpha was silenced with IkappaB-alpha siRNA.	artemisinin	26-37	NFKB inhibitor alpha	Homo sapiens	85-98
22514713-8	2012	The inhibitory effects of artemisinin on LPS-stimulated microglia were blocked after IkappaB-alpha was silenced with IkappaB-alpha siRNA.	artemisinin	26-37	NFKB inhibitor alpha	Homo sapiens	117-130
22389703-10	2012	CONCLUSIONS/SIGNIFICANCE: The results of this study demonstrated that artemisinin analogue SM934 had therapeutic effects on lupus-prone female NZB/W F(1) mice by inhibiting the pathogenic helper T cell development and enhancing anti-inflammatory cytokine IL-10 production.	artemisinin	70-81	interleukin 10	Mus musculus	255-260
21719297-1	2011	The indole alkaloid cyclopiazonic acid (CPA) is one of the few known nanomolar inhibitors of sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) besides the anticancer drug thapsigargin and the antiplasmoidal terpenoid artemisinin.	artemisinin	216-227	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	93-133
21854775-6	2011	Artemisinin, primaquine, and quinine down-regulated GTP-cyclohydrolase 1 gene expression 1.26-, 1.29-, and 1.63-fold, respectively.	artemisinin	0-11	GTP cyclohydrolase 1	Homo sapiens	52-72
21484768-0	2011	Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses.	artemisinin	23-34	negative elongation factor complex member C/D, Th1l	Mus musculus	106-109
21484768-9	2011	CONCLUSION: Taken together, the results of this study demonstrated that the artemisinin analog SM934 had therapeutic effects in lupus-prone female MRL/lpr mice by inhibiting both Th1 cell and Th17 cell responses.	artemisinin	76-87	negative elongation factor complex member C/D, Th1l	Mus musculus	179-182
21309636-1	2011	The cytotoxicity of dihydroartemisinin (DHART; an active metabolite of artemisinin or ART) was investigated using murine GT1-7 hypothalamic neurons.	artemisinin	27-38	retinoic acid induced 1	Mus musculus	121-124
21445878-0	2011	Down-regulation of BMI-1 cooperates with artemisinin on growth inhibition of nasopharyngeal carcinoma cells.	artemisinin	41-52	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	19-24
21445878-7	2011	Artemisinin inhibited BMI-1 both in protein and transcript levels.	artemisinin	0-11	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	22-27
21445878-8	2011	BMI-1 knockdown made the cells more sensitive to artemisinin with an increase in G1 phase, but over-expression of BMI-1 partially reversed the artemisinin-induced G1 cell cycle arrest.	artemisinin	49-60	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	0-5
21445878-8	2011	BMI-1 knockdown made the cells more sensitive to artemisinin with an increase in G1 phase, but over-expression of BMI-1 partially reversed the artemisinin-induced G1 cell cycle arrest.	artemisinin	143-154	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	114-119
21445878-9	2011	Depletion of BMI-1 was able to intensifying the increment of p16 and the reduction of CDK4 induced by artemisinin.	artemisinin	102-113	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	13-18
21445878-9	2011	Depletion of BMI-1 was able to intensifying the increment of p16 and the reduction of CDK4 induced by artemisinin.	artemisinin	102-113	cyclin dependent kinase 4	Homo sapiens	86-90
21445878-10	2011	In addition, over-expression of BMI-1 was capable of attenuating the increasing p16 and decreasing CDK4 in cells treated with artemisinin.	artemisinin	126-137	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	32-37
21445878-10	2011	In addition, over-expression of BMI-1 was capable of attenuating the increasing p16 and decreasing CDK4 in cells treated with artemisinin.	artemisinin	126-137	cyclin dependent kinase inhibitor 2A	Homo sapiens	80-83
21445878-10	2011	In addition, over-expression of BMI-1 was capable of attenuating the increasing p16 and decreasing CDK4 in cells treated with artemisinin.	artemisinin	126-137	cyclin dependent kinase 4	Homo sapiens	99-103
21445878-11	2011	Taking together, the BMI1-p16/CDK4 axis was involved in the artemisinin-driven G1 arrest in nasopharyngeal carcinoma cells, and these results indicated that a potential treatment that the combination of artemisinin and BMI-1 downregulation could enhance the growth inhibitory affects on nasopharyngeal carcinoma cells.	artemisinin	60-71	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	21-25
21445878-11	2011	Taking together, the BMI1-p16/CDK4 axis was involved in the artemisinin-driven G1 arrest in nasopharyngeal carcinoma cells, and these results indicated that a potential treatment that the combination of artemisinin and BMI-1 downregulation could enhance the growth inhibitory affects on nasopharyngeal carcinoma cells.	artemisinin	60-71	cyclin dependent kinase inhibitor 2A	Homo sapiens	26-29
21445878-11	2011	Taking together, the BMI1-p16/CDK4 axis was involved in the artemisinin-driven G1 arrest in nasopharyngeal carcinoma cells, and these results indicated that a potential treatment that the combination of artemisinin and BMI-1 downregulation could enhance the growth inhibitory affects on nasopharyngeal carcinoma cells.	artemisinin	60-71	cyclin dependent kinase 4	Homo sapiens	30-34
21445878-11	2011	Taking together, the BMI1-p16/CDK4 axis was involved in the artemisinin-driven G1 arrest in nasopharyngeal carcinoma cells, and these results indicated that a potential treatment that the combination of artemisinin and BMI-1 downregulation could enhance the growth inhibitory affects on nasopharyngeal carcinoma cells.	artemisinin	60-71	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	219-224
21445878-11	2011	Taking together, the BMI1-p16/CDK4 axis was involved in the artemisinin-driven G1 arrest in nasopharyngeal carcinoma cells, and these results indicated that a potential treatment that the combination of artemisinin and BMI-1 downregulation could enhance the growth inhibitory affects on nasopharyngeal carcinoma cells.	artemisinin	203-214	BMI1 proto-oncogene, polycomb ring finger	Homo sapiens	21-25
21445878-11	2011	Taking together, the BMI1-p16/CDK4 axis was involved in the artemisinin-driven G1 arrest in nasopharyngeal carcinoma cells, and these results indicated that a potential treatment that the combination of artemisinin and BMI-1 downregulation could enhance the growth inhibitory affects on nasopharyngeal carcinoma cells.	artemisinin	203-214	cyclin dependent kinase inhibitor 2A	Homo sapiens	26-29
21445878-11	2011	Taking together, the BMI1-p16/CDK4 axis was involved in the artemisinin-driven G1 arrest in nasopharyngeal carcinoma cells, and these results indicated that a potential treatment that the combination of artemisinin and BMI-1 downregulation could enhance the growth inhibitory affects on nasopharyngeal carcinoma cells.	artemisinin	203-214	cyclin dependent kinase 4	Homo sapiens	30-34
21320288-4	2011	Here it is shown that, in the absence of reducing agents, artemisinin and artesunate targeted the S. cerevisiae calcium channels Pmr1p and Pmc1p.	artemisinin	58-69	Ca(2+)/Mn(2+)-transporting P-type ATPase PMR1	Saccharomyces cerevisiae S288C	129-134
21509671-0	2011	Effect of artemisinin combined with glucocorticoid on the expressions of glucocorticoid receptor alpha mRNA, glucocorticoid receptor beta mRNA and P300/CBP protein in lupus nephritis mice.	artemisinin	10-21	CREB binding protein	Mus musculus	147-155
21320288-4	2011	Here it is shown that, in the absence of reducing agents, artemisinin and artesunate targeted the S. cerevisiae calcium channels Pmr1p and Pmc1p.	artemisinin	58-69	calcium-transporting ATPase PMC1	Saccharomyces cerevisiae S288C	139-144
28299053-4	2011	During its work in Chad, Sierra Leone and Mali in the period 2004 to 2008, Medecins Sans Frontieres showed that it was possible to significantly improve access to effective malaria treatment through: i) the removal of health centre level user fees for essential healthcare for vulnerable population groups, ii) the introduction of free community based treatment for children using malaria village workers to diagnose and treat simple malaria in communities where geographical and financial barriers limited access to effective malaria care, iii) the improved diagnosis and treatment of malaria using rapid diagnosis tests and artemisinin based combination therapy, at both health facilities and in the community.	artemisinin	626-637	chondroadherin	Homo sapiens	19-23
21039753-8	2011	Artemisinin (20-80 mug/mL) significantly inhibited the induction of EMMPRIN and MMP-9 at both the transcriptional and translational levels in a dose-dependent manner in PMA-induced macrophages.	artemisinin	0-11	basigin (Ok blood group)	Homo sapiens	68-75
21165548-3	2011	In the present study, we demonstrate that artemisinin inhibits the secretion and the mRNA levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1ss, and IL-6 in a dose-dependent manner in phorbol 12-myristate 13-acetate (PMA)-induced THP-1 human monocytes.	artemisinin	42-53	tumor necrosis factor	Homo sapiens	100-133
21165548-3	2011	In the present study, we demonstrate that artemisinin inhibits the secretion and the mRNA levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1ss, and IL-6 in a dose-dependent manner in phorbol 12-myristate 13-acetate (PMA)-induced THP-1 human monocytes.	artemisinin	42-53	interleukin 6	Homo sapiens	161-165
21039753-0	2011	Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cdelta/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages.	artemisinin	0-11	basigin (Ok blood group)	Homo sapiens	21-67
21039753-8	2011	Artemisinin (20-80 mug/mL) significantly inhibited the induction of EMMPRIN and MMP-9 at both the transcriptional and translational levels in a dose-dependent manner in PMA-induced macrophages.	artemisinin	0-11	matrix metallopeptidase 9	Homo sapiens	80-85
21039753-0	2011	Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cdelta/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages.	artemisinin	0-11	basigin (Ok blood group)	Homo sapiens	69-76
21039753-0	2011	Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cdelta/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages.	artemisinin	0-11	matrix metallopeptidase 9	Homo sapiens	82-108
21039753-9	2011	In addition, artemisinin (20-80 mug/mL) strongly blocked PKCdelta/JNK/p38/ERK MAPK phosphorylation.	artemisinin	13-24	protein kinase C delta	Homo sapiens	57-65
21039753-0	2011	Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cdelta/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages.	artemisinin	0-11	mitogen-activated protein kinase 1	Homo sapiens	148-151
21039753-0	2011	Artemisinin inhibits extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase-9 expression via a protein kinase Cdelta/p38/extracellular signal-regulated kinase pathway in phorbol myristate acetate-induced THP-1 macrophages.	artemisinin	0-11	GLI family zinc finger 2	Homo sapiens	235-240
21039753-9	2011	In addition, artemisinin (20-80 mug/mL) strongly blocked PKCdelta/JNK/p38/ERK MAPK phosphorylation.	artemisinin	13-24	mitogen-activated protein kinase 8	Homo sapiens	66-69
21039753-3	2011	The aim of the present study was to explore whether artemisinin, a natural extract from Artemisia annua, could decrease EMMPRIN and MMP-9 expression in phorbol myristate acetate (PMA)-induced macrophages by regulating the protein kinase (PK) Cdelta/c-Jun N-terminal kinase (JNK)/p38/extracellular signal-regulated kinase (ERK) pathway.	artemisinin	52-63	basigin (Ok blood group)	Homo sapiens	120-127
21039753-3	2011	The aim of the present study was to explore whether artemisinin, a natural extract from Artemisia annua, could decrease EMMPRIN and MMP-9 expression in phorbol myristate acetate (PMA)-induced macrophages by regulating the protein kinase (PK) Cdelta/c-Jun N-terminal kinase (JNK)/p38/extracellular signal-regulated kinase (ERK) pathway.	artemisinin	52-63	matrix metallopeptidase 9	Homo sapiens	132-137
21039753-9	2011	In addition, artemisinin (20-80 mug/mL) strongly blocked PKCdelta/JNK/p38/ERK MAPK phosphorylation.	artemisinin	13-24	mitogen-activated protein kinase 1	Homo sapiens	70-73
21039753-3	2011	The aim of the present study was to explore whether artemisinin, a natural extract from Artemisia annua, could decrease EMMPRIN and MMP-9 expression in phorbol myristate acetate (PMA)-induced macrophages by regulating the protein kinase (PK) Cdelta/c-Jun N-terminal kinase (JNK)/p38/extracellular signal-regulated kinase (ERK) pathway.	artemisinin	52-63	mitogen-activated protein kinase 8	Homo sapiens	274-277
21039753-3	2011	The aim of the present study was to explore whether artemisinin, a natural extract from Artemisia annua, could decrease EMMPRIN and MMP-9 expression in phorbol myristate acetate (PMA)-induced macrophages by regulating the protein kinase (PK) Cdelta/c-Jun N-terminal kinase (JNK)/p38/extracellular signal-regulated kinase (ERK) pathway.	artemisinin	52-63	mitogen-activated protein kinase 1	Homo sapiens	279-282
21039753-3	2011	The aim of the present study was to explore whether artemisinin, a natural extract from Artemisia annua, could decrease EMMPRIN and MMP-9 expression in phorbol myristate acetate (PMA)-induced macrophages by regulating the protein kinase (PK) Cdelta/c-Jun N-terminal kinase (JNK)/p38/extracellular signal-regulated kinase (ERK) pathway.	artemisinin	52-63	mitogen-activated protein kinase 1	Homo sapiens	322-325
21039753-9	2011	In addition, artemisinin (20-80 mug/mL) strongly blocked PKCdelta/JNK/p38/ERK MAPK phosphorylation.	artemisinin	13-24	mitogen-activated protein kinase 1	Homo sapiens	74-77
21039753-9	2011	In addition, artemisinin (20-80 mug/mL) strongly blocked PKCdelta/JNK/p38/ERK MAPK phosphorylation.	artemisinin	13-24	mitogen-activated protein kinase 1	Homo sapiens	78-82
21039753-12	2011	The results of the present study suggest that artemisinin inhibits EMMPRIN and MMP-9 expression and activity by suppressing the PKCdelta/ERK/p38 cascade in PMA-induced macrophages.	artemisinin	46-57	basigin (Ok blood group)	Homo sapiens	67-74
21039753-12	2011	The results of the present study suggest that artemisinin inhibits EMMPRIN and MMP-9 expression and activity by suppressing the PKCdelta/ERK/p38 cascade in PMA-induced macrophages.	artemisinin	46-57	matrix metallopeptidase 9	Homo sapiens	79-84
21039753-12	2011	The results of the present study suggest that artemisinin inhibits EMMPRIN and MMP-9 expression and activity by suppressing the PKCdelta/ERK/p38 cascade in PMA-induced macrophages.	artemisinin	46-57	protein kinase C delta	Homo sapiens	128-136
21039753-12	2011	The results of the present study suggest that artemisinin inhibits EMMPRIN and MMP-9 expression and activity by suppressing the PKCdelta/ERK/p38 cascade in PMA-induced macrophages.	artemisinin	46-57	mitogen-activated protein kinase 1	Homo sapiens	137-140
21039753-12	2011	The results of the present study suggest that artemisinin inhibits EMMPRIN and MMP-9 expression and activity by suppressing the PKCdelta/ERK/p38 cascade in PMA-induced macrophages.	artemisinin	46-57	mitogen-activated protein kinase 1	Homo sapiens	141-144
21106771-4	2010	These results proved that it is reliable and effective to use Art to treat LN mice, and its therapeutic mechanisms should closely be related to the fact that Art can obviously decrease the serum levels of TNF-alpha and IL-6 and down-regulate the expression of the NF-kappaBp65 protein and NF-kappaB and TGF-beta1 mRNA in renal tissues.	artemisinin	62-65	tumor necrosis factor	Mus musculus	205-214
21695271-2	2011	Anti-malarial drug artesunate is a semi-synthetic derivative of artemisinin, the principal active component of a medicinal plant Artemisia annua, and has been shown to inhibit PI3K/Akt activity.	artemisinin	64-75	thymoma viral proto-oncogene 1	Mus musculus	181-184
20863781-5	2010	Artemisinin blocked angiotensin II-induced cardiac hypertrophy in vitro in a concentration-dependent manner.	artemisinin	0-11	angiotensinogen	Rattus norvegicus	20-34
20863781-8	2010	Banded rats treated with oral artemisinin, compared with untreated rats, showed significantly decreased the levels of IL-6, TNF-alpha and MCP-1 mRNA expression and increased protein levels of IkappaB-alpha, which forms a cytoplasmic inactive complex with the p65-p50 heterodimeric complex.	artemisinin	30-41	interleukin 6	Rattus norvegicus	118-122
20863781-8	2010	Banded rats treated with oral artemisinin, compared with untreated rats, showed significantly decreased the levels of IL-6, TNF-alpha and MCP-1 mRNA expression and increased protein levels of IkappaB-alpha, which forms a cytoplasmic inactive complex with the p65-p50 heterodimeric complex.	artemisinin	30-41	tumor necrosis factor	Rattus norvegicus	124-133
20863781-8	2010	Banded rats treated with oral artemisinin, compared with untreated rats, showed significantly decreased the levels of IL-6, TNF-alpha and MCP-1 mRNA expression and increased protein levels of IkappaB-alpha, which forms a cytoplasmic inactive complex with the p65-p50 heterodimeric complex.	artemisinin	30-41	mast cell protease 1-like 1	Rattus norvegicus	138-143
20863781-8	2010	Banded rats treated with oral artemisinin, compared with untreated rats, showed significantly decreased the levels of IL-6, TNF-alpha and MCP-1 mRNA expression and increased protein levels of IkappaB-alpha, which forms a cytoplasmic inactive complex with the p65-p50 heterodimeric complex.	artemisinin	30-41	NFKB inhibitor alpha	Rattus norvegicus	192-205
20863781-9	2010	The effect of artemisinin on cardiac hypertrophy was blocked after IkappaB-alpha was silenced by transfection of cardiomyocytes with IkappaB-alpha siRNA.	artemisinin	14-25	NFKB inhibitor alpha	Rattus norvegicus	67-80
20863781-9	2010	The effect of artemisinin on cardiac hypertrophy was blocked after IkappaB-alpha was silenced by transfection of cardiomyocytes with IkappaB-alpha siRNA.	artemisinin	14-25	NFKB inhibitor alpha	Rattus norvegicus	133-146
25214386-0	2011	Artemisinin induces caspase-8/9-mediated and Bax/Bak-independent apoptosis in human lung adenocarcinoma (ASTC-a-1) cells.	artemisinin	0-11	caspase 8	Homo sapiens	20-29
25214386-0	2011	Artemisinin induces caspase-8/9-mediated and Bax/Bak-independent apoptosis in human lung adenocarcinoma (ASTC-a-1) cells.	artemisinin	0-11	BCL2 associated X, apoptosis regulator	Homo sapiens	45-48
25214386-0	2011	Artemisinin induces caspase-8/9-mediated and Bax/Bak-independent apoptosis in human lung adenocarcinoma (ASTC-a-1) cells.	artemisinin	0-11	BCL2 antagonist/killer 1	Homo sapiens	49-52
21106771-4	2010	These results proved that it is reliable and effective to use Art to treat LN mice, and its therapeutic mechanisms should closely be related to the fact that Art can obviously decrease the serum levels of TNF-alpha and IL-6 and down-regulate the expression of the NF-kappaBp65 protein and NF-kappaB and TGF-beta1 mRNA in renal tissues.	artemisinin	62-65	interleukin 6	Mus musculus	219-223
21106771-4	2010	These results proved that it is reliable and effective to use Art to treat LN mice, and its therapeutic mechanisms should closely be related to the fact that Art can obviously decrease the serum levels of TNF-alpha and IL-6 and down-regulate the expression of the NF-kappaBp65 protein and NF-kappaB and TGF-beta1 mRNA in renal tissues.	artemisinin	62-65	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	264-273
21106771-4	2010	These results proved that it is reliable and effective to use Art to treat LN mice, and its therapeutic mechanisms should closely be related to the fact that Art can obviously decrease the serum levels of TNF-alpha and IL-6 and down-regulate the expression of the NF-kappaBp65 protein and NF-kappaB and TGF-beta1 mRNA in renal tissues.	artemisinin	62-65	transforming growth factor, beta 1	Mus musculus	303-312
18463201-7	2008	Parthenolide and artemisinin prevented all of the statin effects by inducing RhoA/Rho kinase activation.	artemisinin	17-28	ras homolog family member A	Homo sapiens	77-81
20678173-5	2010	All HZ/trophozoite/15-HETE effects on MMP-9 activity and TNF/IL-1beta production were abrogated by quercetin, artemisinin and parthenolide, inhibitors of IkappaBalpha phosphorylation and subsequent degradation, NF-kappaB nuclear translocation, and NF-kappaB-p65 binding to DNA respectively.	artemisinin	110-121	matrix metallopeptidase 9	Homo sapiens	38-43
20678173-5	2010	All HZ/trophozoite/15-HETE effects on MMP-9 activity and TNF/IL-1beta production were abrogated by quercetin, artemisinin and parthenolide, inhibitors of IkappaBalpha phosphorylation and subsequent degradation, NF-kappaB nuclear translocation, and NF-kappaB-p65 binding to DNA respectively.	artemisinin	110-121	tumor necrosis factor	Homo sapiens	57-60
20678173-5	2010	All HZ/trophozoite/15-HETE effects on MMP-9 activity and TNF/IL-1beta production were abrogated by quercetin, artemisinin and parthenolide, inhibitors of IkappaBalpha phosphorylation and subsequent degradation, NF-kappaB nuclear translocation, and NF-kappaB-p65 binding to DNA respectively.	artemisinin	110-121	interleukin 1 beta	Homo sapiens	61-69
20678173-5	2010	All HZ/trophozoite/15-HETE effects on MMP-9 activity and TNF/IL-1beta production were abrogated by quercetin, artemisinin and parthenolide, inhibitors of IkappaBalpha phosphorylation and subsequent degradation, NF-kappaB nuclear translocation, and NF-kappaB-p65 binding to DNA respectively.	artemisinin	110-121	NFKB inhibitor alpha	Homo sapiens	154-166
20335983-2	2010	Reduction of artemisinin by NaBH4 produced dihydroartemisinin (DHA), and yielded a new stereochemically labile centre at C-10, which, in turn, provided two interconverting lactol hemiacetal epimers (namely alpha and beta), whose rate of interconversion depends on buffer, pH, and solvent polarity.	artemisinin	13-24	homeobox C10	Homo sapiens	121-125
20681308-0	2010	[Effects of artemisinin on proliferation, apoptosis and Caspase-3 expression of rat mesangial cell].	artemisinin	12-23	caspase 3	Rattus norvegicus	56-65
20681308-1	2010	OBJECTIVE: To study the effects of artemisinin on proliferation, apoptosis and Caspase-3 active of rat mesangial cell.	artemisinin	35-46	caspase 3	Rattus norvegicus	79-88
20681308-6	2010	CONCLUSION: Artemisinin could inhibit the proliferation of mesangial cell, enhance the expression of Caspase-3 and promote the apoptosis in a dose-dependent manner.	artemisinin	12-23	caspase 3	Rattus norvegicus	101-110
18956140-6	2009	In addition, artemisinin affected the migratory ability of A375M cells by reducing metalloproteinase 2 (MMP-2) production and down-regulating alpha v beta 3 integrin expression.	artemisinin	13-24	matrix metallopeptidase 2	Homo sapiens	104-109
19017637-0	2009	Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.	artemisinin	0-11	cyclin dependent kinase 4	Homo sapiens	109-134
19017637-0	2009	Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.	artemisinin	0-11	cyclin dependent kinase 4	Homo sapiens	136-140
19017637-0	2009	Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression.	artemisinin	0-11	cyclin dependent kinase 4	Homo sapiens	166-170
19017637-2	2009	We have observed that artemisinin treatment triggers a stringent G1 cell cycle arrest of LNCaP (lymph node carcinoma of the prostate) human prostate cancer cells that is accompanied by a rapid down-regulation of CDK2 and CDK4 protein and transcript levels.	artemisinin	22-33	cyclin dependent kinase 2	Homo sapiens	212-216
19017637-2	2009	We have observed that artemisinin treatment triggers a stringent G1 cell cycle arrest of LNCaP (lymph node carcinoma of the prostate) human prostate cancer cells that is accompanied by a rapid down-regulation of CDK2 and CDK4 protein and transcript levels.	artemisinin	22-33	cyclin dependent kinase 4	Homo sapiens	221-225
19017637-3	2009	Transient transfection with promoter-linked luciferase reporter plasmids revealed that artemisinin strongly inhibits CDK2 and CDK4 promoter activity.	artemisinin	87-98	cyclin dependent kinase 2	Homo sapiens	117-121
19017637-3	2009	Transient transfection with promoter-linked luciferase reporter plasmids revealed that artemisinin strongly inhibits CDK2 and CDK4 promoter activity.	artemisinin	87-98	cyclin dependent kinase 4	Homo sapiens	126-130
19017637-4	2009	Deletion analysis of the CDK4 promoter revealed a 231-bp artemisinin-responsive region between -1737 and -1506.	artemisinin	57-68	cyclin dependent kinase 4	Homo sapiens	25-29
19017637-5	2009	Site-specific mutations revealed that the Sp1 site at -1531 was necessary for artemisinin responsiveness in the context of the CDK4 promoter.	artemisinin	78-89	cyclin dependent kinase 4	Homo sapiens	127-131
19017637-6	2009	DNA binding assays as well as chromatin immunoprecipitation assays demonstrated that this Sp1-binding site in the CDK4 promoter forms a specific artemisinin-responsive DNA-protein complex that contains the Sp1 transcription factor.	artemisinin	145-156	cyclin dependent kinase 4	Homo sapiens	114-118
19017637-7	2009	Artemisinin reduced phosphorylation of Sp1, and when dephosphorylation of Sp1 was inhibited by treatment of cells with the phosphatase inhibitor okadaic acid, the ability of artemisinin to down-regulate Sp1 interactions with the CDK4 promoter was ablated, rendering the CDK4 promoter unresponsive to artemisinin.	artemisinin	174-185	cyclin dependent kinase 4	Homo sapiens	229-233
19017637-7	2009	Artemisinin reduced phosphorylation of Sp1, and when dephosphorylation of Sp1 was inhibited by treatment of cells with the phosphatase inhibitor okadaic acid, the ability of artemisinin to down-regulate Sp1 interactions with the CDK4 promoter was ablated, rendering the CDK4 promoter unresponsive to artemisinin.	artemisinin	174-185	cyclin dependent kinase 4	Homo sapiens	270-274
19017637-8	2009	Finally, overexpression of Sp1 mostly reversed the artemisinin down-regulation of CDK4 promoter activity and partially reversed the cell cycle arrest.	artemisinin	51-62	cyclin dependent kinase 4	Homo sapiens	82-86
19017637-9	2009	Taken together, our results demonstrate that a key event in the artemisinin anti-proliferative effects in prostate cancer cells is the transcriptional down-regulation of CDK4 expression by disruption of Sp1 interactions with the CDK4 promoter.	artemisinin	64-75	cyclin dependent kinase 4	Homo sapiens	170-174
19017637-9	2009	Taken together, our results demonstrate that a key event in the artemisinin anti-proliferative effects in prostate cancer cells is the transcriptional down-regulation of CDK4 expression by disruption of Sp1 interactions with the CDK4 promoter.	artemisinin	64-75	cyclin dependent kinase 4	Homo sapiens	229-233
19255645-9	2009	Curcumin is reported to act synergistically with artemisinin which forms covalent adducts with the transmembrane proteins (SERCA enzyme) and inactivates them, thus inhibiting the activity of Plasmodium parasite.	artemisinin	49-60	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3	Homo sapiens	123-128
18784357-0	2008	Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells.	artemisinin	0-11	estrogen receptor 1	Homo sapiens	55-78
18784357-2	2008	Treatment of MCF7 cells with artemisinin, an antimalarial phytochemical from the sweet wormwood plant, effectively blocked estrogen-stimulated cell cycle progression induced by either 17beta-estradiol (E(2)), an agonist for both ERs, or by propyl pyrazole triol (PPT), a selective ERalpha agonist.	artemisinin	29-40	estrogen receptor 1	Homo sapiens	281-288
18784357-3	2008	Artemisinin strongly downregulated ERalpha protein and transcripts without altering expression or activity of ERbeta.	artemisinin	0-11	estrogen receptor 1	Homo sapiens	35-42
18784357-4	2008	Transfection of MCF7 cells with ERalpha promoter-linked luciferase reporter plasmids revealed that the artemisinin downregulation of ERalpha promoter activity accounted for the loss of ERalpha expression.	artemisinin	103-114	estrogen receptor 1	Homo sapiens	32-39
18784357-4	2008	Transfection of MCF7 cells with ERalpha promoter-linked luciferase reporter plasmids revealed that the artemisinin downregulation of ERalpha promoter activity accounted for the loss of ERalpha expression.	artemisinin	103-114	estrogen receptor 1	Homo sapiens	133-140
18784357-4	2008	Transfection of MCF7 cells with ERalpha promoter-linked luciferase reporter plasmids revealed that the artemisinin downregulation of ERalpha promoter activity accounted for the loss of ERalpha expression.	artemisinin	103-114	estrogen receptor 1	Homo sapiens	133-140
18784357-5	2008	Artemisinin treatment ablated the estrogenic induction of endogenous progesterone receptor (PR) transcripts by either E(2) or PPT and inhibited the estrogenic stimulation of a luciferase reporter plasmid driven by consensus estrogen response elements (EREs).	artemisinin	0-11	progesterone receptor	Homo sapiens	69-90
18784357-5	2008	Artemisinin treatment ablated the estrogenic induction of endogenous progesterone receptor (PR) transcripts by either E(2) or PPT and inhibited the estrogenic stimulation of a luciferase reporter plasmid driven by consensus estrogen response elements (EREs).	artemisinin	0-11	progesterone receptor	Homo sapiens	92-94
18784357-6	2008	Chromatin immunoprecipitation assays revealed that artemisinin significantly downregulated the level of endogeneous ERalpha bound to the PR promoter, whereas the level of bound endogeneous ERbeta was not altered.	artemisinin	51-62	estrogen receptor 1	Homo sapiens	116-123
18784357-6	2008	Chromatin immunoprecipitation assays revealed that artemisinin significantly downregulated the level of endogeneous ERalpha bound to the PR promoter, whereas the level of bound endogeneous ERbeta was not altered.	artemisinin	51-62	progesterone receptor	Homo sapiens	137-139
18784357-7	2008	Treatment of MCF7 cells with artemisinin and the pure antiestrogen fulvestrant resulted in a cooperative reduction of ERalpha protein levels and enhanced G(1) cell cycle arrest compared with the effects of either compound alone.	artemisinin	29-40	estrogen receptor 1	Homo sapiens	118-125
18784357-8	2008	Our results show that artemisinin switches proliferative human breast cancer cells from expressing a high ERalpha:ERbeta ratio to a condition in which ERbeta predominates, which parallels the physiological state linked to antiproliferative events in normal mammary epithelium.	artemisinin	22-33	estrogen receptor 1	Homo sapiens	106-113
18784357-8	2008	Our results show that artemisinin switches proliferative human breast cancer cells from expressing a high ERalpha:ERbeta ratio to a condition in which ERbeta predominates, which parallels the physiological state linked to antiproliferative events in normal mammary epithelium.	artemisinin	22-33	estrogen receptor 2	Homo sapiens	114-120
18784357-8	2008	Our results show that artemisinin switches proliferative human breast cancer cells from expressing a high ERalpha:ERbeta ratio to a condition in which ERbeta predominates, which parallels the physiological state linked to antiproliferative events in normal mammary epithelium.	artemisinin	22-33	estrogen receptor 2	Homo sapiens	151-157
20530490-2	2010	Mutation of an amino acid residue in mammalian SERCA1 (Glu(255)) to the equivalent one predicted in PfATP6 (Leu) was reported to induce sensitivity to artemisinin in the oocyte system.	artemisinin	151-162	ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1	Homo sapiens	47-53
20130467-3	2010	Intracellular iron uptake is regulated by the transferrin receptor (TfR), and the activity of artemisinin depends on the availability of iron.	artemisinin	94-105	transferrin receptor	Homo sapiens	68-71
20137162-4	2010	In this article, recent progress of study on transferrin receptor used in treating hematological malignant tumor are reviewed from aspects of transferrin receptor combined with drugs including artemisinin, doxorubicin, gambogic acid and so on, genes, antibodies, polyethylene glycol and nanoparticles.	artemisinin	193-204	transferrin receptor	Homo sapiens	45-65
19957999-0	2010	Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.	artemisinin	111-122	homeobox C10	Homo sapiens	70-74
19913412-0	2010	Bio-transformation of artemisinin using soil microbe: Direct C-acetoxylation of artemisinin at C-9 by Penicillium simplissimum.	artemisinin	22-33	complement C9	Homo sapiens	95-98
19913412-0	2010	Bio-transformation of artemisinin using soil microbe: Direct C-acetoxylation of artemisinin at C-9 by Penicillium simplissimum.	artemisinin	80-91	complement C9	Homo sapiens	95-98
19913412-1	2010	Potent antimalarial compound artemisinin, 1 was bio-transformed to C-9 acetoxy artemisinin, 2 using soil microbe Penicillium simplissimum along with C-9 hydroxy derivative 3.	artemisinin	29-40	complement C9	Homo sapiens	67-70
19913412-1	2010	Potent antimalarial compound artemisinin, 1 was bio-transformed to C-9 acetoxy artemisinin, 2 using soil microbe Penicillium simplissimum along with C-9 hydroxy derivative 3.	artemisinin	29-40	complement C9	Homo sapiens	149-152
19846912-0	2009	Artemisinin-transferrin conjugate retards growth of breast tumors in the rat.	artemisinin	0-11	transferrin	Rattus norvegicus	12-23
19846912-3	2009	Previously, we found that covalently tagging artemisinin to transferrin enhanced the selectivity and toxicity of artemisinin toward cancer cells in vitro.	artemisinin	45-56	transferrin	Rattus norvegicus	60-71
19846912-3	2009	Previously, we found that covalently tagging artemisinin to transferrin enhanced the selectivity and toxicity of artemisinin toward cancer cells in vitro.	artemisinin	113-124	transferrin	Rattus norvegicus	60-71
19846912-4	2009	In the present research, artemisinin-transferrin conjugate was tested in a rat breast cancer model.	artemisinin	25-36	transferrin	Rattus norvegicus	37-48
19846912-6	2009	Once tumors were formed, daily intravenous injections of artemisinin-transferrin conjugate were administered.	artemisinin	57-68	transferrin	Rattus norvegicus	69-80
19846912-9	2009	CONCLUSION: Artemisinin-transferrin conjugate could be developed into a potent therapeutic agent for cancer in humans.	artemisinin	12-23	transferrin	Rattus norvegicus	24-35
19702527-4	2009	CYP2B6 can metabolise approximately 8% of clinically used drugs (n > 60), including cyclophosphamide, ifosfamide, tamoxifen, ketamine, artemisinin, nevirapine, efavirenz, bupropion, sibutramine, and propofol.	artemisinin	138-149	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
19562679-0	2009	Artemisinin--a possible CYP2B6 probe substrate?	artemisinin	0-11	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	24-30
19562679-3	2009	Correlations between the metabolic rate constant for artemisinin and the other CYP2B6 substrates were examined.	artemisinin	53-64	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	79-85
19562679-8	2009	CONCLUSIONS: The rate of in vitro metabolism of artemisinin was correlated significantly to that of bupropion, propofol and efavirenz, suggesting artemisinin to be a potential alternative marker to assess CYP2B6 activity.	artemisinin	48-59	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	205-211
19562679-9	2009	Further studies characterizing the metabolic fate of artemisinin are needed in order to evaluate its utility as an in vitro and in vivo CYP2B6 probe substrate, since CYP2B6 might not be the only CYP isoform involved in the depletion of artemisinin.	artemisinin	53-64	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	136-142
19562679-9	2009	Further studies characterizing the metabolic fate of artemisinin are needed in order to evaluate its utility as an in vitro and in vivo CYP2B6 probe substrate, since CYP2B6 might not be the only CYP isoform involved in the depletion of artemisinin.	artemisinin	53-64	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	166-172
19562679-9	2009	Further studies characterizing the metabolic fate of artemisinin are needed in order to evaluate its utility as an in vitro and in vivo CYP2B6 probe substrate, since CYP2B6 might not be the only CYP isoform involved in the depletion of artemisinin.	artemisinin	53-64	peptidylprolyl isomerase G	Homo sapiens	136-139
19298255-0	2009	Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.	artemisinin	0-11	hypoxia inducible factor 1 subunit alpha	Homo sapiens	107-117
19298255-0	2009	Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.	artemisinin	0-11	ATP binding cassette subfamily B member 1	Homo sapiens	122-136
19298255-2	2009	As the sesquiterpene lactone thapsigargin, a known inhibitor of mammalian SERCA, enhances the expression of P-glycoprotein (Pgp) by increasing the intracellular Ca(++) ([Ca(++)](i)) level, we investigated whether artemisinin and its structural homologue parthenolide could inhibit SERCA in human colon carcinoma HT29 cells and induce a resistance to doxorubicin.	artemisinin	213-224	ATP binding cassette subfamily B member 1	Homo sapiens	108-122
19298255-2	2009	As the sesquiterpene lactone thapsigargin, a known inhibitor of mammalian SERCA, enhances the expression of P-glycoprotein (Pgp) by increasing the intracellular Ca(++) ([Ca(++)](i)) level, we investigated whether artemisinin and its structural homologue parthenolide could inhibit SERCA in human colon carcinoma HT29 cells and induce a resistance to doxorubicin.	artemisinin	213-224	ATP binding cassette subfamily B member 1	Homo sapiens	124-127
19298255-8	2009	In HT29 cells, artemisinin and parthenolide induced the phosphorylation of HIF-1alpha, which was inhibited by KN93.	artemisinin	15-26	hypoxia inducible factor 1 subunit alpha	Homo sapiens	75-85
19298255-9	2009	CONCLUSIONS AND IMPLICATIONS: Our results suggest that artemisinin and parthenolide may act as SERCA inhibitors and, like other SERCA inhibitors, induce resistance to doxorubicin in human colon cancer cells, via the CaMKII-dependent activation of HIF-1alpha and the induction of Pgp.	artemisinin	55-66	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	216-222
19298255-9	2009	CONCLUSIONS AND IMPLICATIONS: Our results suggest that artemisinin and parthenolide may act as SERCA inhibitors and, like other SERCA inhibitors, induce resistance to doxorubicin in human colon cancer cells, via the CaMKII-dependent activation of HIF-1alpha and the induction of Pgp.	artemisinin	55-66	hypoxia inducible factor 1 subunit alpha	Homo sapiens	247-257
19298255-9	2009	CONCLUSIONS AND IMPLICATIONS: Our results suggest that artemisinin and parthenolide may act as SERCA inhibitors and, like other SERCA inhibitors, induce resistance to doxorubicin in human colon cancer cells, via the CaMKII-dependent activation of HIF-1alpha and the induction of Pgp.	artemisinin	55-66	ATP binding cassette subfamily B member 1	Homo sapiens	279-282
18838215-2	2009	Artemisinin was covalently conjugated to a transferrin-receptor targeting peptide, HAIYPRH that binds to a cavity on the surface of transferrin receptor.	artemisinin	0-11	transferrin	Homo sapiens	43-54
18838215-2	2009	Artemisinin was covalently conjugated to a transferrin-receptor targeting peptide, HAIYPRH that binds to a cavity on the surface of transferrin receptor.	artemisinin	0-11	transferrin	Homo sapiens	132-143
18838215-3	2009	This enables artemisinin to be co-internalized with receptor-bound transferrin.	artemisinin	13-24	transferrin	Homo sapiens	67-78
18838215-4	2009	The iron released from transferrin can activate artemisinin to generate toxic radical species to kill cells.	artemisinin	48-59	transferrin	Homo sapiens	23-34
19408682-0	2009	[Antitumor mechanism of Qinghaosu derivatives--molecular docking studies of Qinghaosu derivatives with transferrin].	artemisinin	24-33	transferrin	Homo sapiens	103-114
19408682-0	2009	[Antitumor mechanism of Qinghaosu derivatives--molecular docking studies of Qinghaosu derivatives with transferrin].	artemisinin	76-85	transferrin	Homo sapiens	103-114
19408682-5	2009	Docking results unveil that Iron(II)-transferrin increased the cytotoxicity of Qinghaosu derivatives and provide a rational basis for further design and synthesis of novel Qinghaosu derivatives.	artemisinin	79-88	transferrin	Homo sapiens	37-48
19408682-5	2009	Docking results unveil that Iron(II)-transferrin increased the cytotoxicity of Qinghaosu derivatives and provide a rational basis for further design and synthesis of novel Qinghaosu derivatives.	artemisinin	172-181	transferrin	Homo sapiens	37-48
18793755-0	2008	Artemisinin can inhibit the calmodulin-mediated activation of phosphodiesterase in comparison with Cyclosporin A.	artemisinin	0-11	calmodulin 1	Homo sapiens	28-38
18793755-1	2008	Artemisinin and Cyclosporin A were examined for their ability to inhibit the calmodulin-mediated activation of phosphodiesterase, which is based on the hydrolysis of cAMP to AMP by phosphodiesterase in the presence or absence of inhibitors, followed by quantitative analysis using spectrophotometer method.	artemisinin	0-11	calmodulin 1	Homo sapiens	77-87
18793755-3	2008	Our results indicates that Artemisinin and Cyclosporin A induced some conformational changes on calmodulin and increased the fluorescence emission, but Artemisinin increased fluorescence emission of calmodulin in higher amounts compared with the Cyclosporin A.	artemisinin	27-38	calmodulin 1	Homo sapiens	96-106
18793755-3	2008	Our results indicates that Artemisinin and Cyclosporin A induced some conformational changes on calmodulin and increased the fluorescence emission, but Artemisinin increased fluorescence emission of calmodulin in higher amounts compared with the Cyclosporin A.	artemisinin	152-163	calmodulin 1	Homo sapiens	199-209
18793755-4	2008	Kinetic analysis of the Artemisinin-calmodulin and Cyclosporine A-calmodulin interaction showed that these agents competitively inhibited the activation of phosphodiesterase without affecting Vmax.	artemisinin	24-35	calmodulin 1	Homo sapiens	36-46
18793755-8	2008	However, the degree of decrease in DeltaG (H2O) value was as follows: Artemisinin>Cyclosporin A, which means Artemisinin induced more instability in the calmodulin structure.In conclusion, our findings showed a good correlation between the ability of both Artemisinin and Cyclosporin A to block the activation of phosphodiesterase and their ability to bind to the activator and that Artemisinin is a more potent inhibitor of phosphodiesterase compared with Cyclosporin A.	artemisinin	70-81	calmodulin 1	Homo sapiens	156-166
18793755-8	2008	However, the degree of decrease in DeltaG (H2O) value was as follows: Artemisinin>Cyclosporin A, which means Artemisinin induced more instability in the calmodulin structure.In conclusion, our findings showed a good correlation between the ability of both Artemisinin and Cyclosporin A to block the activation of phosphodiesterase and their ability to bind to the activator and that Artemisinin is a more potent inhibitor of phosphodiesterase compared with Cyclosporin A.	artemisinin	112-123	calmodulin 1	Homo sapiens	156-166
18793755-8	2008	However, the degree of decrease in DeltaG (H2O) value was as follows: Artemisinin>Cyclosporin A, which means Artemisinin induced more instability in the calmodulin structure.In conclusion, our findings showed a good correlation between the ability of both Artemisinin and Cyclosporin A to block the activation of phosphodiesterase and their ability to bind to the activator and that Artemisinin is a more potent inhibitor of phosphodiesterase compared with Cyclosporin A.	artemisinin	112-123	calmodulin 1	Homo sapiens	156-166
18793755-8	2008	However, the degree of decrease in DeltaG (H2O) value was as follows: Artemisinin>Cyclosporin A, which means Artemisinin induced more instability in the calmodulin structure.In conclusion, our findings showed a good correlation between the ability of both Artemisinin and Cyclosporin A to block the activation of phosphodiesterase and their ability to bind to the activator and that Artemisinin is a more potent inhibitor of phosphodiesterase compared with Cyclosporin A.	artemisinin	112-123	calmodulin 1	Homo sapiens	156-166
18353653-1	2008	From 9-substituted DHA, several new artemisinin-derived C-10 acetal ethers and esters were prepared with either a 9-fluoro or a 9-sulfonyl substituent.	artemisinin	36-47	homeobox C10	Homo sapiens	56-60
18456255-0	2008	Interferon-alpha enhances artemisinin-induced differentiation of HL-60 leukemia cells via a PKC alpha/ERK pathway.	artemisinin	26-37	protein kinase C alpha	Homo sapiens	92-101
18456255-0	2008	Interferon-alpha enhances artemisinin-induced differentiation of HL-60 leukemia cells via a PKC alpha/ERK pathway.	artemisinin	26-37	mitogen-activated protein kinase 1	Homo sapiens	102-105
18456255-6	2008	The increased cell differentiation by IFN-alpha and artemisinin was significantly suppressed by the inhibitors for protein kinase C (PKC), extracellular signal-regulated kinase (ERK) and jun N-terminal kinase (JNK), but not by the inhibitors for phosphatidylinositol 3-kinase (PI3-K) and p38 mitogen-activated protein kinase (MAPK).	artemisinin	52-63	protein kinase C alpha	Homo sapiens	133-136
18456255-6	2008	The increased cell differentiation by IFN-alpha and artemisinin was significantly suppressed by the inhibitors for protein kinase C (PKC), extracellular signal-regulated kinase (ERK) and jun N-terminal kinase (JNK), but not by the inhibitors for phosphatidylinositol 3-kinase (PI3-K) and p38 mitogen-activated protein kinase (MAPK).	artemisinin	52-63	mitogen-activated protein kinase 1	Homo sapiens	139-176
18456255-6	2008	The increased cell differentiation by IFN-alpha and artemisinin was significantly suppressed by the inhibitors for protein kinase C (PKC), extracellular signal-regulated kinase (ERK) and jun N-terminal kinase (JNK), but not by the inhibitors for phosphatidylinositol 3-kinase (PI3-K) and p38 mitogen-activated protein kinase (MAPK).	artemisinin	52-63	mitogen-activated protein kinase 1	Homo sapiens	178-181
18456255-6	2008	The increased cell differentiation by IFN-alpha and artemisinin was significantly suppressed by the inhibitors for protein kinase C (PKC), extracellular signal-regulated kinase (ERK) and jun N-terminal kinase (JNK), but not by the inhibitors for phosphatidylinositol 3-kinase (PI3-K) and p38 mitogen-activated protein kinase (MAPK).	artemisinin	52-63	mitogen-activated protein kinase 8	Homo sapiens	187-208
18456255-6	2008	The increased cell differentiation by IFN-alpha and artemisinin was significantly suppressed by the inhibitors for protein kinase C (PKC), extracellular signal-regulated kinase (ERK) and jun N-terminal kinase (JNK), but not by the inhibitors for phosphatidylinositol 3-kinase (PI3-K) and p38 mitogen-activated protein kinase (MAPK).	artemisinin	52-63	mitogen-activated protein kinase 8	Homo sapiens	210-213
18456255-6	2008	The increased cell differentiation by IFN-alpha and artemisinin was significantly suppressed by the inhibitors for protein kinase C (PKC), extracellular signal-regulated kinase (ERK) and jun N-terminal kinase (JNK), but not by the inhibitors for phosphatidylinositol 3-kinase (PI3-K) and p38 mitogen-activated protein kinase (MAPK).	artemisinin	52-63	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	246-275
18456255-6	2008	The increased cell differentiation by IFN-alpha and artemisinin was significantly suppressed by the inhibitors for protein kinase C (PKC), extracellular signal-regulated kinase (ERK) and jun N-terminal kinase (JNK), but not by the inhibitors for phosphatidylinositol 3-kinase (PI3-K) and p38 mitogen-activated protein kinase (MAPK).	artemisinin	52-63	mitogen-activated protein kinase 14	Homo sapiens	288-324
18456255-6	2008	The increased cell differentiation by IFN-alpha and artemisinin was significantly suppressed by the inhibitors for protein kinase C (PKC), extracellular signal-regulated kinase (ERK) and jun N-terminal kinase (JNK), but not by the inhibitors for phosphatidylinositol 3-kinase (PI3-K) and p38 mitogen-activated protein kinase (MAPK).	artemisinin	52-63	mitogen-activated protein kinase 1	Homo sapiens	326-330
18456255-8	2008	Taken together, these results indicate the enhancement of artemisinin-induced HL-60 cell differentiation by IFN-alpha through the activation of a PKC alpha/ERK signaling pathway, and suggest a possible use of IFN-alpha and artemisinin in the treatment of leukemic diseases.	artemisinin	58-69	interferon alpha 1	Homo sapiens	108-117
18456255-8	2008	Taken together, these results indicate the enhancement of artemisinin-induced HL-60 cell differentiation by IFN-alpha through the activation of a PKC alpha/ERK signaling pathway, and suggest a possible use of IFN-alpha and artemisinin in the treatment of leukemic diseases.	artemisinin	58-69	protein kinase C alpha	Homo sapiens	146-155
18456255-8	2008	Taken together, these results indicate the enhancement of artemisinin-induced HL-60 cell differentiation by IFN-alpha through the activation of a PKC alpha/ERK signaling pathway, and suggest a possible use of IFN-alpha and artemisinin in the treatment of leukemic diseases.	artemisinin	58-69	mitogen-activated protein kinase 1	Homo sapiens	156-159
18456255-8	2008	Taken together, these results indicate the enhancement of artemisinin-induced HL-60 cell differentiation by IFN-alpha through the activation of a PKC alpha/ERK signaling pathway, and suggest a possible use of IFN-alpha and artemisinin in the treatment of leukemic diseases.	artemisinin	58-69	interferon alpha 1	Homo sapiens	209-218
18350255-0	2008	A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.	artemisinin	75-86	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	32-38
18350255-0	2008	A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens.	artemisinin	75-86	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	43-50
18350255-6	2008	The production rate of CYP2C19 increased 51.2% by artemisinin, 14.8% by arteether and 24.9% by artemether.	artemisinin	50-61	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	23-30
18350255-7	2008	In conclusion, all studied artemisinin derivatives induced CYP2B6.	artemisinin	27-38	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	59-65
18350255-8	2008	CYP2C19 induction by arteether and artemether as well as CYP2B6 and CYP2C19 induction by artemisinin was confirmed.	artemisinin	89-100	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	68-75
18350255-1	2008	The study aim was to assess the inductive properties of artemisinin antimalarials using mephenytoin as a probe for CYP2B6 and CYP2C19 enzymatic activity.	artemisinin	56-67	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	115-121
18350255-1	2008	The study aim was to assess the inductive properties of artemisinin antimalarials using mephenytoin as a probe for CYP2B6 and CYP2C19 enzymatic activity.	artemisinin	56-67	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	126-133
18350255-5	2008	The production rate of CYP2B6 was increased 79.7% by artemisinin, 61.5% by arteether, 76.1% by artemether, 19.9% by dihydroartemisinin and 16.9% by artesunate.	artemisinin	53-64	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	23-29
18044948-8	2008	Along the artemisinin decomposition routes, especially B2 and B3, larger structural changes including formation of branched structures and CO2 release are related to increased exothermicity of the conversions, weakened attractive oxygen-oxygen interactions, and increased entropy of the formed species.	artemisinin	10-21	immunoglobulin kappa variable 5-2	Homo sapiens	55-64
18223457-6	2008	PCR product sequencing was applied to regulatory regions of MDR1, the CYP3A4 proximal promoter, and to exons 2 and 5 of PXR, a gene coding for a nuclear factor activated by artemisinin antimalarials and associated with the transcription induction of most of the studied genes.	artemisinin	173-184	nuclear receptor subfamily 1 group I member 2	Homo sapiens	120-123
18667841-0	2008	Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C.	artemisinin	0-11	vascular endothelial growth factor C	Mus musculus	63-99
18667841-6	2008	These data indicate that artemisinin may be useful for the prevention of lymph node metastasis by downregulating VEGF-C and reducing tumor lymphangiogenesis.	artemisinin	25-36	vascular endothelial growth factor C	Mus musculus	113-119
18667841-4	2008	Consistent with the decrease in lymph node metastasis, tumor lymphangiogenesis and expression of vascular endothelial growth factor C (VEGF-C) was significantly decreased in artemisinin-treated mice, as compared to control mice.	artemisinin	174-185	vascular endothelial growth factor C	Mus musculus	97-133
18667841-4	2008	Consistent with the decrease in lymph node metastasis, tumor lymphangiogenesis and expression of vascular endothelial growth factor C (VEGF-C) was significantly decreased in artemisinin-treated mice, as compared to control mice.	artemisinin	174-185	vascular endothelial growth factor C	Mus musculus	135-141
18667841-5	2008	Furthermore, IL-1beta-induced p38 mitogen-activated protein kinase (MAPK) activation and upregulation of VEGF-C mRNA and protein in LLC cells was also suppressed by artemisinin or by the p38 MAPK inhibitor SB-203580, suggesting that p38 MAPK could serve as a mediator of proinflammatory cytokine-induced VEGF-C expression.	artemisinin	165-176	interleukin 1 beta	Mus musculus	13-21
18667841-5	2008	Furthermore, IL-1beta-induced p38 mitogen-activated protein kinase (MAPK) activation and upregulation of VEGF-C mRNA and protein in LLC cells was also suppressed by artemisinin or by the p38 MAPK inhibitor SB-203580, suggesting that p38 MAPK could serve as a mediator of proinflammatory cytokine-induced VEGF-C expression.	artemisinin	165-176	mitogen-activated protein kinase 14	Mus musculus	30-33
18667841-5	2008	Furthermore, IL-1beta-induced p38 mitogen-activated protein kinase (MAPK) activation and upregulation of VEGF-C mRNA and protein in LLC cells was also suppressed by artemisinin or by the p38 MAPK inhibitor SB-203580, suggesting that p38 MAPK could serve as a mediator of proinflammatory cytokine-induced VEGF-C expression.	artemisinin	165-176	vascular endothelial growth factor C	Mus musculus	105-111
18667841-5	2008	Furthermore, IL-1beta-induced p38 mitogen-activated protein kinase (MAPK) activation and upregulation of VEGF-C mRNA and protein in LLC cells was also suppressed by artemisinin or by the p38 MAPK inhibitor SB-203580, suggesting that p38 MAPK could serve as a mediator of proinflammatory cytokine-induced VEGF-C expression.	artemisinin	165-176	mitogen-activated protein kinase 14	Mus musculus	233-241
18667841-5	2008	Furthermore, IL-1beta-induced p38 mitogen-activated protein kinase (MAPK) activation and upregulation of VEGF-C mRNA and protein in LLC cells was also suppressed by artemisinin or by the p38 MAPK inhibitor SB-203580, suggesting that p38 MAPK could serve as a mediator of proinflammatory cytokine-induced VEGF-C expression.	artemisinin	165-176	vascular endothelial growth factor C	Mus musculus	304-310
17521300-6	2007	The S-4"-hydroxymephenytoin/S-mephenytoin ratio (CYP2C19) was increased on day 5 by artemisinin [1.69 (1.47-1.94)] and arteether [1.33 (1.15-1.55)] compared with day -6.	artemisinin	84-95	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	49-56
17521300-0	2007	Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.	artemisinin	0-11	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	44-59
17521300-7	2007	The paraxanthine/caffeine ratio (CYP1A2) was decreased on day 1 after administration of artemisinin [0.27 (0.18-0.39)], arteether [0.70 (0.55-0.89)] and dihydroartemisinin [0.73 (0.59-0.90)] compared with day -6.	artemisinin	88-99	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	33-39
17521300-1	2007	The aim of this study was to investigate which principal human cytochrome P450 (CYP450) enzymes are affected by artemisinin and to what degree the artemisinin derivatives differ with respect to their respective induction and inhibition capacity.	artemisinin	112-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	63-78
17521300-1	2007	The aim of this study was to investigate which principal human cytochrome P450 (CYP450) enzymes are affected by artemisinin and to what degree the artemisinin derivatives differ with respect to their respective induction and inhibition capacity.	artemisinin	112-123	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	80-86
17521300-8	2007	The alpha-hydroxymetoprolol/metoprolol ratio (CYP2D6) was lower on day 1 compared with day -6 in the artemisinin [0.82 (0.70-0.96)] and dihydroartemisinin [0.83 (0.71-0.96)] groups, respectively.	artemisinin	101-112	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	46-52
17521300-5	2007	The 1-hydroxymidazolam/midazolam 4-h plasma concentration ratio (CYP3A) was increased on day 5 by artemisinin [2.66-fold (98.75% CI: 2.10-3.36)], artemether [1.54 (1.14-2.09)] and dihydroartemisinin [1.25 (1.06-1.47)] compared with day -6.	artemisinin	98-109	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	65-70
17521300-10	2007	These results show that intake of artemisinin antimalarials affect the activities of several principal human drug metabolizing CYP450 enzymes.	artemisinin	34-45	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	127-133
17115150-11	2007	It is important to determine if these differences, along with previously reported differences in cytochrome P450 2B6 allele frequencies, are associated with altered metabolism/effectiveness of artemisinin drugs.	artemisinin	193-204	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	97-116
17314215-2	2007	In this study, we explored the effect of artesunate, an artemisinin derivative, on tumour necrosis factor (TNF)-alpha-induced production of interleukins, IL-1beta, IL-6 and IL-8, in human rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS), and further investigated the signal mechanism by which this compound modulates those cytokines" production.	artemisinin	56-67	tumor necrosis factor	Homo sapiens	83-117
17279482-6	2007	Among them, tanshinone IIA and cryptotanshinone are found to be potent inhibitors to CYP1A2, while artemisinin is a marginal inhibitor to CYP1A2 and glycyrrhetic acid is a weak inhibitor to CYP2C9.	artemisinin	99-110	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	138-144
16412643-7	2006	Some reactivity of artemisinin with methemoglobin was indeed detected after addition of 50% v/v acetonitrile, most likely as a consequence of extensive protein unfolding.	artemisinin	19-30	hemoglobin subunit gamma 2	Homo sapiens	36-49
16919048-3	2006	The objective of this study was to characterize the inductive properties of artemisinin on drug-metabolizing cytochrome P450 (CYP450) enzymes.	artemisinin	76-87	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	109-124
16919048-3	2006	The objective of this study was to characterize the inductive properties of artemisinin on drug-metabolizing cytochrome P450 (CYP450) enzymes.	artemisinin	76-87	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	126-132
16919048-4	2006	The possibility of artemisinin to induce CYP450 was studied in artemisinin-treated (orally for four days) and vehicle-treated rats using reverse transcriptase polymerase chain reaction (RT-PCR).	artemisinin	19-30	cytochrome P450, family 21, subfamily a, polypeptide 1	Mus musculus	41-47
16919048-6	2006	Increased CYP2B1 mRNA levels in rats could be seen after artemisinin treatment as well as a weak but reproducible increase in the intensity of CYP1A2.	artemisinin	57-68	cytochrome P450, family 2, subfamily b, polypeptide 1	Rattus norvegicus	10-16
16919048-7	2006	Administration of artemisinin to mice up-regulated hepatic CYP2B10-dependent, and to a lesser extent, CYP2A5-dependent enzyme activities.	artemisinin	18-29	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	59-66
16919048-7	2006	Administration of artemisinin to mice up-regulated hepatic CYP2B10-dependent, and to a lesser extent, CYP2A5-dependent enzyme activities.	artemisinin	18-29	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	102-108
16919048-8	2006	In primary hepatocyte culture, artemisinin significantly increased the CYP2B10 mRNA levels whereas the CYP2A5 mRNA levels were increased to a lesser extent.	artemisinin	31-42	cytochrome P450, family 2, subfamily b, polypeptide 10	Mus musculus	71-78
16919048-10	2006	Artemisinin was an activator of constitutive androstane receptor (CAR) but not pregnane X receptor (PXR) in HEK293 cells.	artemisinin	0-11	nuclear receptor subfamily 1 group I member 3	Homo sapiens	32-64
16919048-10	2006	Artemisinin was an activator of constitutive androstane receptor (CAR) but not pregnane X receptor (PXR) in HEK293 cells.	artemisinin	0-11	nuclear receptor subfamily 1 group I member 3	Homo sapiens	66-69
16919048-12	2006	The weaker up-regulation of CYP2A5 might also be CAR-dependent or alternatively, a consequence of artemisinin toxicity.	artemisinin	98-109	cytochrome P450, family 2, subfamily a, polypeptide 5	Mus musculus	28-34
16919048-12	2006	The weaker up-regulation of CYP2A5 might also be CAR-dependent or alternatively, a consequence of artemisinin toxicity.	artemisinin	98-109	nuclear receptor subfamily 1, group I, member 3	Mus musculus	49-52
16730793-0	2006	Study of the interaction of artemisinin with bovine serum albumin.	artemisinin	28-39	albumin	Homo sapiens	52-65
16730793-1	2006	The study on the interaction of artemisinin with bovine serum albumin (BSA) has been undertaken at three temperatures, 289, 296 and 303 K and investigated the effect of common ions and UV C (253.7 nm) irradiation on the binding of artemisinin with BSA.	artemisinin	32-43	albumin	Homo sapiens	56-69
16919048-0	2006	In vivo and mechanistic evidence of nuclear receptor CAR induction by artemisinin.	artemisinin	70-81	nuclear receptor subfamily 1, group I, member 3	Mus musculus	53-56
16879742-2	2006	The change to artemisinin-based combination therapy (ACT) was initiated in 2004 using the co-blister of artesunate + sulfadoxine/pyrimethamine (AS+SP) and artemether + lumefantrine (ART+LUM), as first- and second-line, respectively.	artemisinin	14-25	lumican	Homo sapiens	186-189
16506047-1	2006	OBJECTIVE: Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of artemisinin drugs, a novel series of antimalarials.	artemisinin	73-84	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	11-30
16506047-1	2006	OBJECTIVE: Cytochrome P450 2B6 (CYP2B6) is involved in the metabolism of artemisinin drugs, a novel series of antimalarials.	artemisinin	73-84	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	32-38
15761118-0	2005	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.	artemisinin	13-24	ATP binding cassette subfamily B member 1	Homo sapiens	58-62
16512009-0	2006	[The OMS demands an immediate end to the commercialization of antimalarials only consisting of artemisinine].	artemisinin	95-107	chronic/recurrent otitis media	Homo sapiens	5-8
16491843-4	2006	In regard to many possible functions, the TCTP of Plasmodium falciparum (Pf) is known to bind with an antimalarial agent, artemisinin, which is activated by heme.	artemisinin	122-133	tumor protein, translationally-controlled 1	Homo sapiens	42-46
16185154-5	2005	By covalently tagging artemisinin to transferrin, artemisinin could be selectively picked up and concentrated by cancer cells.	artemisinin	22-33	transferrin	Homo sapiens	37-48
16185154-5	2005	By covalently tagging artemisinin to transferrin, artemisinin could be selectively picked up and concentrated by cancer cells.	artemisinin	50-61	transferrin	Homo sapiens	37-48
16185154-7	2005	Once an artemisinin-tagged transferrin molecule is endocytosed, iron is released and reacts with artemisinin moieties tagged to transferrin.	artemisinin	8-19	transferrin	Homo sapiens	27-38
16185154-7	2005	Once an artemisinin-tagged transferrin molecule is endocytosed, iron is released and reacts with artemisinin moieties tagged to transferrin.	artemisinin	8-19	transferrin	Homo sapiens	128-139
16185154-7	2005	Once an artemisinin-tagged transferrin molecule is endocytosed, iron is released and reacts with artemisinin moieties tagged to transferrin.	artemisinin	97-108	transferrin	Homo sapiens	27-38
16185154-7	2005	Once an artemisinin-tagged transferrin molecule is endocytosed, iron is released and reacts with artemisinin moieties tagged to transferrin.	artemisinin	97-108	transferrin	Homo sapiens	128-139
16185154-9	2005	The authors have found that artemisinin-tagged transferrin is highly selective and potent in killing cancer cells.	artemisinin	28-39	transferrin	Homo sapiens	47-58
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	97-108	NADH-ubiquinone reductase (H(+)-translocating) NDE1	Saccharomyces cerevisiae S288C	131-135
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	97-108	NADH-ubiquinone reductase (H(+)-translocating) NDI1	Saccharomyces cerevisiae S288C	139-143
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	97-108	NADH-ubiquinone reductase (H(+)-translocating) NDE1	Saccharomyces cerevisiae S288C	254-258
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	97-108	NADH-ubiquinone reductase (H(+)-translocating) NDI1	Saccharomyces cerevisiae S288C	262-266
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	215-226	NADH-ubiquinone reductase (H(+)-translocating) NDE1	Saccharomyces cerevisiae S288C	131-135
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	215-226	NADH-ubiquinone reductase (H(+)-translocating) NDI1	Saccharomyces cerevisiae S288C	139-143
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	215-226	NADH-ubiquinone reductase (H(+)-translocating) NDE1	Saccharomyces cerevisiae S288C	254-258
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	215-226	NADH-ubiquinone reductase (H(+)-translocating) NDI1	Saccharomyces cerevisiae S288C	262-266
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	215-226	NADH-ubiquinone reductase (H(+)-translocating) NDE1	Saccharomyces cerevisiae S288C	131-135
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	215-226	NADH-ubiquinone reductase (H(+)-translocating) NDI1	Saccharomyces cerevisiae S288C	139-143
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	215-226	NADH-ubiquinone reductase (H(+)-translocating) NDE1	Saccharomyces cerevisiae S288C	254-258
16170412-5	2005	Moreover, in a genetic study, we identify the electron transport chain as an important player in artemisinin"s action: Deletion of NDE1 or NDI1, which encode mitochondrial NADH dehydrogenases, confers resistance to artemisinin, whereas overexpression of NDE1 or NDI1 dramatically increases sensitivity to artemisinin.	artemisinin	215-226	NADH-ubiquinone reductase (H(+)-translocating) NDI1	Saccharomyces cerevisiae S288C	262-266
16261361-0	2005	Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.	artemisinin	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	55-74
16261361-0	2005	Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.	artemisinin	0-11	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	76-82
16261361-1	2005	OBJECTIVE: To investigate the likelihood of artemisinin and thiabendazole causing pharmacokinetic interactions involving cytochrome P450 (CYP1A2) in humans given their potent inhibitory effects on the isoform in vitro.	artemisinin	44-55	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	138-144
16261361-6	2005	RESULTS: Using the ratio of paraxanthine to caffeine after 4 h as an indicator of CYP1A2 activity, thiabendazole and artemisinin inhibited 92 and 66%, respectively, of the enzyme activity in vivo.	artemisinin	117-128	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	82-88
16261361-10	2005	CONCLUSIONS: Co-administration of thiabendazole or artemisinin with CYP1A2 substrates could result in clinically significant effects.	artemisinin	51-62	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	68-74
15761118-0	2005	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.	artemisinin	13-24	nuclear receptor subfamily 1 group I member 2	Homo sapiens	103-122
15761118-0	2005	Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.	artemisinin	13-24	nuclear receptor subfamily 1 group I member 3	Homo sapiens	127-159
15761118-5	2005	Because the xenosensors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) have been shown to mediate induction of drug-metabolizing enzymes and drug transporters, we investigated the hypothesis that artemisinin induces cytochrome P450 expression by activating PXR and/or CAR.	artemisinin	218-229	nuclear receptor subfamily 1 group I member 2	Homo sapiens	24-43
15761118-5	2005	Because the xenosensors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) have been shown to mediate induction of drug-metabolizing enzymes and drug transporters, we investigated the hypothesis that artemisinin induces cytochrome P450 expression by activating PXR and/or CAR.	artemisinin	218-229	nuclear receptor subfamily 1 group I member 2	Homo sapiens	45-48
15761118-5	2005	Because the xenosensors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) have been shown to mediate induction of drug-metabolizing enzymes and drug transporters, we investigated the hypothesis that artemisinin induces cytochrome P450 expression by activating PXR and/or CAR.	artemisinin	218-229	nuclear receptor subfamily 1 group I member 3	Homo sapiens	54-86
15761118-5	2005	Because the xenosensors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) have been shown to mediate induction of drug-metabolizing enzymes and drug transporters, we investigated the hypothesis that artemisinin induces cytochrome P450 expression by activating PXR and/or CAR.	artemisinin	218-229	nuclear receptor subfamily 1 group I member 3	Homo sapiens	88-91
15761118-5	2005	Because the xenosensors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) have been shown to mediate induction of drug-metabolizing enzymes and drug transporters, we investigated the hypothesis that artemisinin induces cytochrome P450 expression by activating PXR and/or CAR.	artemisinin	218-229	nuclear receptor subfamily 1 group I member 2	Homo sapiens	279-282
15761118-5	2005	Because the xenosensors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) have been shown to mediate induction of drug-metabolizing enzymes and drug transporters, we investigated the hypothesis that artemisinin induces cytochrome P450 expression by activating PXR and/or CAR.	artemisinin	218-229	nuclear receptor subfamily 1 group I member 3	Homo sapiens	290-293
15761118-6	2005	By combining in vitro transfection methods and quantitative analyses of gene expression in cell lines and primary human hepatocytes, we here show that artemisinin drugs activate human PXR as well as human and mouse CAR and induce the expression of CYP2B6, CYP3A4, and MDR1 in primary human hepatocytes and in the human intestinal cell line LS174T.	artemisinin	151-162	nuclear receptor subfamily 1 group I member 2	Homo sapiens	184-187
15761118-6	2005	By combining in vitro transfection methods and quantitative analyses of gene expression in cell lines and primary human hepatocytes, we here show that artemisinin drugs activate human PXR as well as human and mouse CAR and induce the expression of CYP2B6, CYP3A4, and MDR1 in primary human hepatocytes and in the human intestinal cell line LS174T.	artemisinin	151-162	nuclear receptor subfamily 1, group I, member 3	Mus musculus	215-218
15761118-6	2005	By combining in vitro transfection methods and quantitative analyses of gene expression in cell lines and primary human hepatocytes, we here show that artemisinin drugs activate human PXR as well as human and mouse CAR and induce the expression of CYP2B6, CYP3A4, and MDR1 in primary human hepatocytes and in the human intestinal cell line LS174T.	artemisinin	151-162	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	248-254
15761118-6	2005	By combining in vitro transfection methods and quantitative analyses of gene expression in cell lines and primary human hepatocytes, we here show that artemisinin drugs activate human PXR as well as human and mouse CAR and induce the expression of CYP2B6, CYP3A4, and MDR1 in primary human hepatocytes and in the human intestinal cell line LS174T.	artemisinin	151-162	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	256-262
15761118-6	2005	By combining in vitro transfection methods and quantitative analyses of gene expression in cell lines and primary human hepatocytes, we here show that artemisinin drugs activate human PXR as well as human and mouse CAR and induce the expression of CYP2B6, CYP3A4, and MDR1 in primary human hepatocytes and in the human intestinal cell line LS174T.	artemisinin	151-162	ATP-binding cassette, sub-family B (MDR/TAP), member 1B	Mus musculus	268-272
15761118-8	2005	In conclusion, activation of PXR and CAR and especially the resulting induction of CYP3A4 and MDR1 demonstrate that artemisinin has a higher risk of potential drug interactions than anticipated previously.	artemisinin	116-127	nuclear receptor subfamily 1 group I member 2	Homo sapiens	29-32
15761118-8	2005	In conclusion, activation of PXR and CAR and especially the resulting induction of CYP3A4 and MDR1 demonstrate that artemisinin has a higher risk of potential drug interactions than anticipated previously.	artemisinin	116-127	nuclear receptor subfamily 1 group I member 3	Homo sapiens	37-40
15761118-8	2005	In conclusion, activation of PXR and CAR and especially the resulting induction of CYP3A4 and MDR1 demonstrate that artemisinin has a higher risk of potential drug interactions than anticipated previously.	artemisinin	116-127	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	83-89
15761118-8	2005	In conclusion, activation of PXR and CAR and especially the resulting induction of CYP3A4 and MDR1 demonstrate that artemisinin has a higher risk of potential drug interactions than anticipated previously.	artemisinin	116-127	ATP binding cassette subfamily B member 1	Homo sapiens	94-98
15878303-8	2005	The Plasmodium translationally controlled tumor protein (TCTP) represents a known target protein of artemisinin and its derivatives in the malaria parasite.	artemisinin	100-111	tumor protein, translationally-controlled 1	Homo sapiens	57-61
16019941-1	2005	The aim was to obtain information on the one-electron reduction of the antimalarial natural drug artemisinin (ART).	artemisinin	97-108	artemin	Homo sapiens	110-113
15782383-0	2005	C10-modified artemisinin derivatives: efficient heme-alkylating agents.	artemisinin	13-24	homeobox C10	Homo sapiens	0-3
15642597-4	2005	In the present research, we covalently attached artemisinin to the iron-carrying plasma glycoprotein transferrin.	artemisinin	48-59	transferrin	Homo sapiens	101-112
15642597-6	2005	Thus, we hypothesize that by tagging artemisinin to transferrin, both iron and artemisinin would be transported into cancer cells in one package.	artemisinin	37-48	transferrin	Homo sapiens	52-63
15642597-6	2005	Thus, we hypothesize that by tagging artemisinin to transferrin, both iron and artemisinin would be transported into cancer cells in one package.	artemisinin	79-90	transferrin	Homo sapiens	52-63
15642597-7	2005	Once inside a cell, iron is released and can readily react with artemisinin close by tagged to the transferrin.	artemisinin	64-75	transferrin	Homo sapiens	99-110
15115411-1	2004	The synthesis of a series of C-10 trifluoromethyl ethers of artemisinin has been achieved from key bromide 8, itself carried out in two steps from artemisinin.	artemisinin	60-71	gene rich cluster, C10 gene	Mus musculus	29-33
15336316-3	2004	Iron(II)-glycine sulfate (Ferrosanol) and transferrin increased the cytotoxicity of free artesunate, artesunate microencapsulated in maltosyl-beta-cyclodextrin, and artemisinin toward CCRF-CEM leukemia and U373 astrocytoma cells 1.5- to 10.3-fold compared with that of artemisinins applied without iron.	artemisinin	165-176	transferrin	Homo sapiens	42-53
15115411-1	2004	The synthesis of a series of C-10 trifluoromethyl ethers of artemisinin has been achieved from key bromide 8, itself carried out in two steps from artemisinin.	artemisinin	147-158	gene rich cluster, C10 gene	Mus musculus	29-33
15115411-3	2004	The presence of the CF(3) group at C-10 of artemisinin clearly increased the chemical stability under simulated stomach acid conditions.	artemisinin	43-54	gene rich cluster, C10 gene	Mus musculus	35-39
12643911-1	2003	The alkylating properties of two artemisinin derivatives bearing a trifluoromethyl substituent at C10 were evaluated toward manganese(II) tetraphenylporphyrin, considered as a heme model.	artemisinin	33-44	homeobox C10	Homo sapiens	98-101
14698358-0	2003	Postsynaptic dopamine (D(2))-mediated behavioural effects of high acute doses of artemisinin in rodents.	artemisinin	81-92	dopamine receptor D2	Mus musculus	0-22
14660006-8	2003	Artemisinin enhanced PKC activity and protein level of PKC beta I isoform in only 1,25-(OH)(2)D(3)-treated HL-60 cells.	artemisinin	0-11	proline rich transmembrane protein 2	Homo sapiens	55-58
14660006-9	2003	Taken together, these results indicate that artemisinin strongly enhanced 1,25-(OH)(2)D(3)- and all-trans RA-induced cell differentiation in which PKC is differentially involved in arteminisin-mediated enhancement of leukemia cell differentiation.	artemisinin	44-55	proline rich transmembrane protein 2	Homo sapiens	147-150
13679021-4	2003	The natural antimalarial drug artemisinin is selectively toxic to iron-loaded cells (such as malarial parasites), and it has recently been suggested that, inasmuch as many cancers overexpress transferrin receptors, such cancers might be treatable with a regimen comprised of iron supplementation and high-dose artemisinin.	artemisinin	30-41	transferrin	Homo sapiens	192-203
13679021-4	2003	The natural antimalarial drug artemisinin is selectively toxic to iron-loaded cells (such as malarial parasites), and it has recently been suggested that, inasmuch as many cancers overexpress transferrin receptors, such cancers might be treatable with a regimen comprised of iron supplementation and high-dose artemisinin.	artemisinin	310-321	transferrin	Homo sapiens	192-203
12844133-0	2003	Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.	artemisinin	0-11	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	54-73
12844133-1	2003	AIM: Our goal was to investigate whether artemisinin autoinduction is caused by an increase in cytochrome P450 (CYP) 2B6 or CYP2C9 activities, we evaluated the effects of multiple-dose artemisinin administration on S-mephenytoin N-demethylation in healthy subjects.	artemisinin	41-52	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	95-120
12844133-1	2003	AIM: Our goal was to investigate whether artemisinin autoinduction is caused by an increase in cytochrome P450 (CYP) 2B6 or CYP2C9 activities, we evaluated the effects of multiple-dose artemisinin administration on S-mephenytoin N-demethylation in healthy subjects.	artemisinin	41-52	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	124-130
12844133-8	2003	The area under the concentration-time curve ratio of S-nirvanol/S-mephenytoin, an index of CYP2B6 activity, increased 1.9-fold (P <.05) in CYP2C19 poor metabolizers during artemisinin multiple-dose administration, whereas the urinary excretion ratio of hydroxytolbutamide plus carboxytolbutamide/tolbutamide remained constant during the study period.	artemisinin	175-186	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	142-149
12844133-9	2003	CONCLUSIONS: These results indicate that artemisinin induces the N-demethylation of S-mephenytoin probably by an increased capacity of CYP2B6.	artemisinin	41-52	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	135-141
12844133-10	2003	The autoinduction phenomenon of artemisinin may, therefore, be attributed, at least in part, to induction of CYP2B6, because this is the isozyme primarily involved in its metabolism.	artemisinin	32-43	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	109-115
14698358-7	2003	Bromocriptine, a D(2) receptor agonist, induced locomotor activity in mice pretreated with reserpine which was attenuated by artemisinin.	artemisinin	125-136	dopamine receptor D2	Mus musculus	17-30
14698358-8	2003	The results suggest that artemisinin possesses sedative property, which may be mediated via postsynaptic dopamine (D(2)) receptor in the CNS.	artemisinin	25-36	dopamine receptor D2	Mus musculus	92-129
14660006-0	2003	Differential involvement of protein kinase C in human promyelocytic leukemia cell differentiation enhanced by artemisinin.	artemisinin	110-121	proline rich transmembrane protein 2	Homo sapiens	28-44
14660006-7	2003	Particularly, protein kinase C (PKC) inhibitors inhibited HL-60 cell differentiation induced by artemisinin in combination with 1,25-(OH)(2)D(3) but not with all-trans RA.	artemisinin	96-107	proline rich transmembrane protein 2	Homo sapiens	14-30
14660006-7	2003	Particularly, protein kinase C (PKC) inhibitors inhibited HL-60 cell differentiation induced by artemisinin in combination with 1,25-(OH)(2)D(3) but not with all-trans RA.	artemisinin	96-107	proline rich transmembrane protein 2	Homo sapiens	32-35
14660006-8	2003	Artemisinin enhanced PKC activity and protein level of PKC beta I isoform in only 1,25-(OH)(2)D(3)-treated HL-60 cells.	artemisinin	0-11	proline rich transmembrane protein 2	Homo sapiens	21-24
14615418-6	2003	Artemisinin down-regulated hypoxia-inducible factor-1alpha and vascular endothelial growth factor (VEGF) expression, which control endothelial cell growth.	artemisinin	0-11	hypoxia inducible factor 1, alpha subunit	Mus musculus	27-58
14615418-6	2003	Artemisinin down-regulated hypoxia-inducible factor-1alpha and vascular endothelial growth factor (VEGF) expression, which control endothelial cell growth.	artemisinin	0-11	vascular endothelial growth factor A	Mus musculus	63-97
14615418-6	2003	Artemisinin down-regulated hypoxia-inducible factor-1alpha and vascular endothelial growth factor (VEGF) expression, which control endothelial cell growth.	artemisinin	0-11	vascular endothelial growth factor A	Mus musculus	99-103
14615418-7	2003	The antiangiogenic effects and the inhibition of hypoxia-inducible factor-1alpha and VEGF were reversed upon cotreatment with the free radical scavengers mannitol and vitamin E, indicating that artemisinin may act via reactive oxygen species generation.	artemisinin	194-205	hypoxia inducible factor 1, alpha subunit	Mus musculus	49-80
14615418-7	2003	The antiangiogenic effects and the inhibition of hypoxia-inducible factor-1alpha and VEGF were reversed upon cotreatment with the free radical scavengers mannitol and vitamin E, indicating that artemisinin may act via reactive oxygen species generation.	artemisinin	194-205	vascular endothelial growth factor A	Mus musculus	85-89
11855985-10	2002	On the basis of the products obtained from biomimetic Fe(II) degradation of the C-10 carba analogue (23), we propose that these analogues may have a mode of action subtly different from that of the parent drug artemisinin (series 1 (7-16)) and other C-10 ether derivatives such as artemether.	artemisinin	210-221	homeobox C10	Homo sapiens	80-84
12619052-3	2003	The metabolic fate of (14)C-artemisinin in microsomes from human B-lymphoblastoid cell lines transformed with CYP2A6, CYP2B6 and CYP3A4 was also investigated.	artemisinin	28-39	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	118-124
12619052-3	2003	The metabolic fate of (14)C-artemisinin in microsomes from human B-lymphoblastoid cell lines transformed with CYP2A6, CYP2B6 and CYP3A4 was also investigated.	artemisinin	28-39	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
11888669-0	2002	Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells.	artemisinin	41-52	transferrin	Homo sapiens	0-11
11697139-6	2001	Artemisinin was incubated with glutathione, NADPH and glutathione reductase and GSTs in a coupled assay system analogous to the standard assay scheme with cumene hydroperoxide as a substrate of GSTs.	artemisinin	0-11	glutathione-disulfide reductase	Homo sapiens	54-75
12536531-12	2001	Artemisinin has similar effectiveness to dexamethasone to inhibit the production of PLA2 in vitro.	artemisinin	0-11	phospholipase A2 group IB	Homo sapiens	84-88
11697139-6	2001	Artemisinin was incubated with glutathione, NADPH and glutathione reductase and GSTs in a coupled assay system analogous to the standard assay scheme with cumene hydroperoxide as a substrate of GSTs.	artemisinin	0-11	glutathione S-transferase kappa 1	Homo sapiens	80-84
11697139-9	2001	Using recombinant GSTs the activity of GSTs with artemisinin was at least two fold higher than the reaction with CDNB.	artemisinin	49-60	glutathione S-transferase kappa 1	Homo sapiens	18-22
11697139-9	2001	Using recombinant GSTs the activity of GSTs with artemisinin was at least two fold higher than the reaction with CDNB.	artemisinin	49-60	glutathione S-transferase kappa 1	Homo sapiens	39-43
11697139-6	2001	Artemisinin was incubated with glutathione, NADPH and glutathione reductase and GSTs in a coupled assay system analogous to the standard assay scheme with cumene hydroperoxide as a substrate of GSTs.	artemisinin	0-11	glutathione S-transferase kappa 1	Homo sapiens	194-198
11697139-10	2001	Considering these results, it is possible that GSTs may contribute to the metabolism of artemisinin in the presence of NADPH and GSSG-reductase.	artemisinin	88-99	glutathione S-transferase kappa 1	Homo sapiens	47-51
11697139-11	2001	We propose a model, based on the known reactions of GSTs and sesquiterpenes, in which (1) artemisinin reacts with GSH resulting in oxidised glutathione; (2) the oxidised glutathione is then converted to reduced glutathione via glutathione reductase; and (3) the latter reaction may then result in the depletion of NADPH via GSSG-reductase.	artemisinin	90-101	glutathione S-transferase kappa 1	Homo sapiens	52-56
11697139-7	2001	Artemisinin was shown to stimulate NADPH oxidation in cytosols from rat liver, kidney, intestines and in affinity purified preparations of GSTs from rat liver.	artemisinin	0-11	glutathione S-transferase kappa 1	Homo sapiens	139-143
11697139-11	2001	We propose a model, based on the known reactions of GSTs and sesquiterpenes, in which (1) artemisinin reacts with GSH resulting in oxidised glutathione; (2) the oxidised glutathione is then converted to reduced glutathione via glutathione reductase; and (3) the latter reaction may then result in the depletion of NADPH via GSSG-reductase.	artemisinin	90-101	glutathione-disulfide reductase	Homo sapiens	227-248
11697139-8	2001	Using human recombinant GSTs hetelorogously expressed in Escherichia coli, artemisinin was similarly shown to stimulate NADPH oxidation with the highest activity observed with GST M1-1.	artemisinin	75-86	glutathione S-transferase kappa 1	Homo sapiens	24-28
11697139-12	2001	The ability of artemisinin to react with GSH in the presence of GST may be responsible for the NADPH utilisation observed in vitro and suggests that cytosolic GSTs are likely to be contributing to metabolism of artemisinin and related drugs in vivo.	artemisinin	15-26	glutathione S-transferase kappa 1	Homo sapiens	159-163
11697139-12	2001	The ability of artemisinin to react with GSH in the presence of GST may be responsible for the NADPH utilisation observed in vitro and suggests that cytosolic GSTs are likely to be contributing to metabolism of artemisinin and related drugs in vivo.	artemisinin	211-222	glutathione S-transferase kappa 1	Homo sapiens	159-163
11575956-0	2001	Synthesis of new artemisinin analogues from artemisinic acid modified at C-3 and C-13 and their antimalarial activity.	artemisinin	17-28	complement C3	Homo sapiens	73-76
11575956-0	2001	Synthesis of new artemisinin analogues from artemisinic acid modified at C-3 and C-13 and their antimalarial activity.	artemisinin	17-28	homeobox C13	Homo sapiens	81-85
11124226-6	2001	Potent inhibitors of CYP1A2 were artemisinin, dihydroartemisinin, thiabendazole, primaquine, and niclosamide (K(i) = 0.43, 3.67, 1.54, 0.22, and 2.70 microM, respectively).	artemisinin	33-44	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	21-27
11432537-10	2001	CYP2B6 and CYP3A4 are involved in the metabolism of artemisinin and derivatives, but further studies may reveal involvement of more enzymes.	artemisinin	52-63	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	0-6
11432537-10	2001	CYP2B6 and CYP3A4 are involved in the metabolism of artemisinin and derivatives, but further studies may reveal involvement of more enzymes.	artemisinin	52-63	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	11-17
11432537-11	2001	Artemisinin may induce CYP2C19.	artemisinin	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	23-30
10543871-1	1999	Nine C-10 non-acetal derivatives of the natural trioxane artemisinin (1) were prepared as dimers using some novel chemistry.	artemisinin	57-68	homeobox C10	Homo sapiens	5-9
10626755-0	1999	Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19.	artemisinin	47-58	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	82-89
10583023-6	1999	Recombinant CYP3A4 was catalytically competent in metabolizing artemisinin, although the rate was 10% of that for recombinant CYP2B6.	artemisinin	63-74	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	12-18
10583023-10	1999	The rate of artemisinin metabolism in recombinant CYP2A6 was 15% of that for recombinant CYP2B6.	artemisinin	12-23	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	50-56
10583023-10	1999	The rate of artemisinin metabolism in recombinant CYP2A6 was 15% of that for recombinant CYP2B6.	artemisinin	12-23	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	89-95
10583023-11	1999	The inhibition of artemisinin metabolism in human liver microsomes by 8-methoxypsoralen (a CYP2A6 inhibitor) was 82% but CYP2A6 activity was not included in the regression tree.	artemisinin	18-29	cytochrome P450 family 2 subfamily A member 6	Homo sapiens	91-97
10583023-12	1999	CONCLUSIONS: Artemisinin metabolism in human liver microsomes is mediated primarily by CYP2B6 with probable secondary contribution of CYP3A4 in individuals with low CYP2B6 expression.	artemisinin	13-24	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	87-93
10583023-12	1999	CONCLUSIONS: Artemisinin metabolism in human liver microsomes is mediated primarily by CYP2B6 with probable secondary contribution of CYP3A4 in individuals with low CYP2B6 expression.	artemisinin	13-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	134-140
10583023-12	1999	CONCLUSIONS: Artemisinin metabolism in human liver microsomes is mediated primarily by CYP2B6 with probable secondary contribution of CYP3A4 in individuals with low CYP2B6 expression.	artemisinin	13-24	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	165-171
10583023-0	1999	Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin.	artemisinin	91-102	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	28-43
10583023-1	1999	AIMS: The study aimed to identify the specific human cytochrome P450 (CYP450) enzymes involved in the metabolism of artemisinin.	artemisinin	116-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	53-68
10583023-1	1999	AIMS: The study aimed to identify the specific human cytochrome P450 (CYP450) enzymes involved in the metabolism of artemisinin.	artemisinin	116-127	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	70-76
10583023-2	1999	METHODS: Microsomes from human B-lymphoblastoid cell lines transformed with individual CYP450 cDNAs were investigated for their capacity to metabolize artemisinin.	artemisinin	151-162	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	87-93
10583023-4	1999	The relative contribution of individual CYP450 isoenzymes to artemisinin metabolism in human liver microsomes was evaluated with a tree-based regression model of artemisinin disappearance rate and specific CYP450 activities.	artemisinin	61-72	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	40-46
10583023-5	1999	RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model.	artemisinin	38-49	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
10583023-5	1999	RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model.	artemisinin	38-49	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	122-128
10583023-5	1999	RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model.	artemisinin	38-49	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	122-128
10583023-5	1999	RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model.	artemisinin	95-106	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
10583023-5	1999	RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model.	artemisinin	95-106	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	122-128
10583023-5	1999	RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model.	artemisinin	95-106	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	122-128
10583023-5	1999	RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model.	artemisinin	95-106	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	28-34
10583023-5	1999	RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model.	artemisinin	95-106	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	122-128
10583023-5	1999	RESULTS: The involvement of CYP2B6 in artemisinin metabolism was demonstrated by metabolism of artemisinin by recombinant CYP2B6, inhibition of artemisinin disappearance in human liver microsomes by orphenadrine (76%) and primary inclusion of CYP2B6 in the tree-based regression model.	artemisinin	95-106	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	122-128
9929507-1	1999	The objective of this study was to investigate whether the decrease in artemisinin bioavailability after repeated oral dosing in humans can be a result of increased efflux of artemisinin by P-glycoprotein or decreased membrane transport at the intestinal barrier.	artemisinin	71-82	ATP binding cassette subfamily B member 1	Homo sapiens	190-204
10626755-1	1999	The purpose of the study was to determine the enantiomer pharmacokinetics of omeprazole and 5-hydroxy-omeprazole before and after administration of the antimalarial artemisinin to confirm artemisinin"s ability to induce CYP2C19.	artemisinin	188-199	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	220-227
10626755-11	1999	Artemisinin decreased the AUC of S-omeprazole to the same extent as that of R-omeprazole in extensive CYP2C19 metabolizers.	artemisinin	0-11	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	102-109
10626755-12	1999	suggesting that artemisinin induces a different enzyme in addition to CYP2C19.	artemisinin	16-27	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	70-77
10626755-13	1999	These results support and strengthen earlier findings that artemisinin induces CYP2C19 as well as at least one enzyme other than CYP3A4.	artemisinin	59-70	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	79-86
10626755-13	1999	These results support and strengthen earlier findings that artemisinin induces CYP2C19 as well as at least one enzyme other than CYP3A4.	artemisinin	59-70	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	129-135
9357485-1	1997	Bach Mai-Amsterdam Research Group on Artemisinin.	artemisinin	37-48	acyl-CoA thioesterase 7	Homo sapiens	0-4
9728896-1	1998	OBJECTIVE: This study investigated whether time-dependent artemisinin pharmacokinetics correlated to CYP3A4 or CYP2C19 activity in vivo.	artemisinin	58-69	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	101-107
9728896-1	1998	OBJECTIVE: This study investigated whether time-dependent artemisinin pharmacokinetics correlated to CYP3A4 or CYP2C19 activity in vivo.	artemisinin	58-69	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	111-118
9728896-13	1998	The increased elimination of omeprazole in both poor and extensive CYP2C19 metabolizers suggests artemisinin induces both CYP2C19 and another enzyme.	artemisinin	97-108	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	67-74
9728896-13	1998	The increased elimination of omeprazole in both poor and extensive CYP2C19 metabolizers suggests artemisinin induces both CYP2C19 and another enzyme.	artemisinin	97-108	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	122-129
9604124-8	1998	Artemisinin oral plasma clearance was about 400 L h-1 exhibiting a slight decrease with dose, although the effect was weak.	artemisinin	0-11	H1.5 linker histone, cluster member	Homo sapiens	50-53
11324528-2	1998	By using patch-clamp whole cell recording configuration, the effects of five artemisinin-derivatives on the voltage-gated INa and IK have been studied on differentiated NG108-15 cells with reference to procaine.	artemisinin	77-88	internexin neuronal intermediate filament protein, alpha	Mus musculus	122-132
11324528-3	1998	The results showed that all the five artemisinin-derivatives clearly inhibited the voltage-gated sodium current (INa) of the cells in a dose-dependent manner and the effect was partially reversibly.	artemisinin	37-48	internexin neuronal intermediate filament protein, alpha	Mus musculus	131-135
9373657-0	1997	Severe and complicated malaria treated with artemisinin, artesunate or artemether in Viet Nam.	artemisinin	44-55	SH3 and cysteine rich domain 3	Homo sapiens	90-93
9134741-1	1997	We determined the cytotoxicity of some artemisinin derivatives against EN2 tumor cells using the MTT assay.	artemisinin	39-50	engrailed homeobox 2	Homo sapiens	71-74
7709742-6	1994	The highest rcross2 of alignment D, indicated that the side chain of -C6-O2-O1-C10-O3-C7-O4-C12-O5- and atom C16 are important groups of artemisinin analogs for antimalarial activity.	artemisinin	137-148	chromosome 12 open reading frame 57	Homo sapiens	79-82
8080446-7	1994	However, artemisinin enhanced the inhibitory effect of iron (50 microM)-ascorbate (500 microM) on ATPase activity (46.3 +/- 3.9 vs 63 +/- 2.1% for basal; 57.2 +/- 2.5 vs 74.8 +/- 2.1% for CaM-activated).	artemisinin	9-20	dynein axonemal heavy chain 8	Homo sapiens	98-104
8080446-10	1994	Artemisinin enhanced hemin (10 microM)-induced inhibition of basal (36.0 +/- 6.0 vs 73.7 +/- 3.0%) and CaM-activated Ca2+ pump ATPase (31.6 +/- 2.8 vs 70.0 +/- 1.5%).	artemisinin	0-11	dynein axonemal heavy chain 8	Homo sapiens	127-133
34766463-8	2022	In addition, the synergistic effect of artemisinin and intracranial immunosuppression mediated by PD-L1 was more efficacious than either treatment alone.	artemisinin	39-50	CD274 molecule	Homo sapiens	98-103
33811898-0	2021	Artemisinin protects DPSC from hypoxia and TNF-alpha mediated osteogenesis impairments through CA9 and Wnt signaling pathway.	artemisinin	0-11	tumor necrosis factor	Homo sapiens	43-52
33811898-0	2021	Artemisinin protects DPSC from hypoxia and TNF-alpha mediated osteogenesis impairments through CA9 and Wnt signaling pathway.	artemisinin	0-11	carbonic anhydrase 9	Homo sapiens	95-98
33811898-8	2021	Moreover, the beneficial effect of artemisinin was dependent on upregulated expression of CA9 and CA9-mediated antioxidant responses, as CA9 knockdown abolished the protective role of artemisinin on DPSC osteogenesis.	artemisinin	35-46	carbonic anhydrase 9	Homo sapiens	90-93
33811898-8	2021	Moreover, the beneficial effect of artemisinin was dependent on upregulated expression of CA9 and CA9-mediated antioxidant responses, as CA9 knockdown abolished the protective role of artemisinin on DPSC osteogenesis.	artemisinin	35-46	carbonic anhydrase 9	Homo sapiens	98-101
33811898-8	2021	Moreover, the beneficial effect of artemisinin was dependent on upregulated expression of CA9 and CA9-mediated antioxidant responses, as CA9 knockdown abolished the protective role of artemisinin on DPSC osteogenesis.	artemisinin	35-46	carbonic anhydrase 9	Homo sapiens	98-101
33811898-8	2021	Moreover, the beneficial effect of artemisinin was dependent on upregulated expression of CA9 and CA9-mediated antioxidant responses, as CA9 knockdown abolished the protective role of artemisinin on DPSC osteogenesis.	artemisinin	184-195	carbonic anhydrase 9	Homo sapiens	90-93
33811898-8	2021	Moreover, the beneficial effect of artemisinin was dependent on upregulated expression of CA9 and CA9-mediated antioxidant responses, as CA9 knockdown abolished the protective role of artemisinin on DPSC osteogenesis.	artemisinin	184-195	carbonic anhydrase 9	Homo sapiens	98-101
33811898-8	2021	Moreover, the beneficial effect of artemisinin was dependent on upregulated expression of CA9 and CA9-mediated antioxidant responses, as CA9 knockdown abolished the protective role of artemisinin on DPSC osteogenesis.	artemisinin	184-195	carbonic anhydrase 9	Homo sapiens	98-101
34606334-0	2022	Mutation in Plasmodium falciparum BTB/POZ domain of K13 protein confers artemisinin resistance.	artemisinin	72-83	keratin 13	Homo sapiens	52-55
33588856-1	2021	BACKGROUND: The anti-malarial drug, amodiaquine, a commonly used, long-acting partner drug in artemisinin-based combination therapy, is metabolized to active desethyl-amodiaquine (DEAQ) by cytochrome P450 2C8 (CYP2C8).	artemisinin	94-105	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	189-208
33588856-1	2021	BACKGROUND: The anti-malarial drug, amodiaquine, a commonly used, long-acting partner drug in artemisinin-based combination therapy, is metabolized to active desethyl-amodiaquine (DEAQ) by cytochrome P450 2C8 (CYP2C8).	artemisinin	94-105	cytochrome P450 family 2 subfamily C member 8	Homo sapiens	210-216
34900697-0	2021	Artemisinin Mediates Its Tumor-Suppressive Activity in Hepatocellular Carcinoma Through Targeted Inhibition of FoxM1.	artemisinin	0-11	forkhead box M1	Homo sapiens	111-116
34931134-0	2021	Artemisinin Inhibits the Migration and Invasion in Uveal Melanoma via Inhibition of the PI3K/AKT/mTOR Signaling Pathway.	artemisinin	0-11	AKT serine/threonine kinase 1	Homo sapiens	93-96
34931134-0	2021	Artemisinin Inhibits the Migration and Invasion in Uveal Melanoma via Inhibition of the PI3K/AKT/mTOR Signaling Pathway.	artemisinin	0-11	mechanistic target of rapamycin kinase	Homo sapiens	97-101
34931134-5	2021	Assessment of the mechanisms underlying artemisinin anticancer action revealed that its use dramatically reduced the phosphorylation of PI3K, AKT, and mTOR in UM cells.	artemisinin	40-51	AKT serine/threonine kinase 1	Homo sapiens	142-145
34931134-5	2021	Assessment of the mechanisms underlying artemisinin anticancer action revealed that its use dramatically reduced the phosphorylation of PI3K, AKT, and mTOR in UM cells.	artemisinin	40-51	mechanistic target of rapamycin kinase	Homo sapiens	151-155
34774530-6	2021	Micromolar concentrations of several DIF derivatives strongly suppressed the growth of the four laboratory strains, including strains that exhibited resistance to chloroquine and artemisinin, as well as strains that were susceptible to these drugs.	artemisinin	179-190	tumor necrosis factor	Homo sapiens	37-40
34942304-6	2022	More importantly, the ART and PC co-loaded nanocomplexes showed the high efficacy against atherosclerosis of ApoE-/- mice model with both 8-week low dosage treatment or 1-week high dosage treatment.	artemisinin	22-25	apolipoprotein E	Mus musculus	109-113
34808366-6	2022	The overall results showed that artemisinin or its derivatives could significantly reduce fasting plasma glucose, 2-h plasma glucose (2hPG) in the intraperitoneal glucose tolerance test (IPGTT), 2hPG in the intraperitoneal insulin tolerance test (IPITT), glycated hemoglobin A1c, under the curve in the IPGTT/IPITT, total cholesterol, triglyceride, low-density lipoprotein cholesterol, free fatty acid, and urine volume.	artemisinin	32-43	B cell leukemia/lymphoma 2 related protein A1c	Mus musculus	275-278
34930267-5	2021	Further, the R561H mutation in the k13 gene, which confers artemisinin-resistance, was associated with delayed parasite clearance following treatment with artemether-lumefantrine in Rwanda in this study.	artemisinin	59-70	keratin 13	Homo sapiens	35-38
34931134-7	2021	In contrast, AKT or mTOR activator (Sc79 and MHY1485, respectively) attenuated the inhibitory effect of artemisinin on the migration and invasion abilities of UM cells, further validating that artemisinin"s anticancer effect is likely to be mediated via inhibition of the PI3K/AKT/mTOR pathway.	artemisinin	104-115	AKT serine/threonine kinase 1	Homo sapiens	13-16
34931134-7	2021	In contrast, AKT or mTOR activator (Sc79 and MHY1485, respectively) attenuated the inhibitory effect of artemisinin on the migration and invasion abilities of UM cells, further validating that artemisinin"s anticancer effect is likely to be mediated via inhibition of the PI3K/AKT/mTOR pathway.	artemisinin	104-115	mechanistic target of rapamycin kinase	Homo sapiens	20-24
34931134-7	2021	In contrast, AKT or mTOR activator (Sc79 and MHY1485, respectively) attenuated the inhibitory effect of artemisinin on the migration and invasion abilities of UM cells, further validating that artemisinin"s anticancer effect is likely to be mediated via inhibition of the PI3K/AKT/mTOR pathway.	artemisinin	104-115	AKT serine/threonine kinase 1	Homo sapiens	277-280
34931134-7	2021	In contrast, AKT or mTOR activator (Sc79 and MHY1485, respectively) attenuated the inhibitory effect of artemisinin on the migration and invasion abilities of UM cells, further validating that artemisinin"s anticancer effect is likely to be mediated via inhibition of the PI3K/AKT/mTOR pathway.	artemisinin	104-115	mechanistic target of rapamycin kinase	Homo sapiens	281-285
34931134-7	2021	In contrast, AKT or mTOR activator (Sc79 and MHY1485, respectively) attenuated the inhibitory effect of artemisinin on the migration and invasion abilities of UM cells, further validating that artemisinin"s anticancer effect is likely to be mediated via inhibition of the PI3K/AKT/mTOR pathway.	artemisinin	193-204	AKT serine/threonine kinase 1	Homo sapiens	13-16
34931134-7	2021	In contrast, AKT or mTOR activator (Sc79 and MHY1485, respectively) attenuated the inhibitory effect of artemisinin on the migration and invasion abilities of UM cells, further validating that artemisinin"s anticancer effect is likely to be mediated via inhibition of the PI3K/AKT/mTOR pathway.	artemisinin	193-204	mechanistic target of rapamycin kinase	Homo sapiens	281-285
34900697-3	2021	In our study, we have identified the antimalarial natural product, Artemisinin, to efficiently curb FoxM1 expression and activity in hepatic cancer cells, thereby exhibiting potential anticancer efficacy.	artemisinin	67-78	forkhead box M1	Homo sapiens	100-105
34900697-4	2021	Here, we demonstrated that Artemisinin considerably mitigates FoxM1 transcriptional activity by disrupting its interaction with the promoter region of its downstream targets, thereby suppressing the expression of numerous oncogenic drivers.	artemisinin	27-38	forkhead box M1	Homo sapiens	62-67
34900697-6	2021	Notably, FoxM1 overexpression rendered HCC cells poorly responsive to Artemisinin-mediated cytotoxicity while FoxM1 depletion in resistant liver cancer cells sensitized them to Artemisinin treatment, manifested in lower proliferative and growth index, drop in invasive potential and repressed expression of EMT markers with a concomitantly increased apoptosis.	artemisinin	70-81	forkhead box M1	Homo sapiens	9-14
34900697-6	2021	Notably, FoxM1 overexpression rendered HCC cells poorly responsive to Artemisinin-mediated cytotoxicity while FoxM1 depletion in resistant liver cancer cells sensitized them to Artemisinin treatment, manifested in lower proliferative and growth index, drop in invasive potential and repressed expression of EMT markers with a concomitantly increased apoptosis.	artemisinin	177-188	forkhead box M1	Homo sapiens	9-14
34900697-6	2021	Notably, FoxM1 overexpression rendered HCC cells poorly responsive to Artemisinin-mediated cytotoxicity while FoxM1 depletion in resistant liver cancer cells sensitized them to Artemisinin treatment, manifested in lower proliferative and growth index, drop in invasive potential and repressed expression of EMT markers with a concomitantly increased apoptosis.	artemisinin	177-188	forkhead box M1	Homo sapiens	110-115
34900697-7	2021	Moreover, Artemisinin, when used in combination with Thiostrepton, an established FoxM1 inhibitor, markedly reduced anchorage-independent growth and displayed more pronounced death in liver cancer cells.	artemisinin	10-21	forkhead box M1	Homo sapiens	82-87
34900697-9	2021	Altogether, our findings provide insight into the pivotal involvement of FoxM1 in the tumor suppressive activities of Artemisinin and shed light on the potential application of Artemisinin for improved therapeutic response, especially in resistant hepatic malignancies.	artemisinin	118-129	forkhead box M1	Homo sapiens	73-78
34764635-7	2021	Incubation with artemisinin decreased basal vascular tension, NAD(P)H oxidase activity and reactive oxygen species (ROS) levels, but it also increased endothelial nitric oxide (NO) synthase (eNOS) activity and NO levels in the mesenteric artery, coronary artery, and pulmonary artery of SHRs.	artemisinin	16-27	nitric oxide synthase 3	Rattus norvegicus	191-195
34832620-0	2021	Artemisinin Binds and Inhibits the Activity of Plasmodium falciparum Ddi1, a Retroviral Aspartyl Protease.	artemisinin	0-11	DNA damage inducible 1 homolog 1	Homo sapiens	69-73
34592395-4	2021	In this work, we report a stable, safe and potent alternative artemisinin-based injectable nanocomplex consisting of dimeric artesunate-choline conjugate (dACC) micelles coated with hyaluronic acid (HA).	artemisinin	62-73	Acetyl-CoA carboxylase	Drosophila melanogaster	155-159
34764635-8	2021	Artemisinin chronic administration to SHRs increased the protein expression of eNOS and decreased the protein expression of the NAD(P)H oxidase subunits NOX-2 and NOX-4 in the mesenteric artery.	artemisinin	0-11	nitric oxide synthase 3	Rattus norvegicus	79-83
34764635-8	2021	Artemisinin chronic administration to SHRs increased the protein expression of eNOS and decreased the protein expression of the NAD(P)H oxidase subunits NOX-2 and NOX-4 in the mesenteric artery.	artemisinin	0-11	cytochrome b-245 beta chain	Rattus norvegicus	153-158
34764635-8	2021	Artemisinin chronic administration to SHRs increased the protein expression of eNOS and decreased the protein expression of the NAD(P)H oxidase subunits NOX-2 and NOX-4 in the mesenteric artery.	artemisinin	0-11	NADPH oxidase 4	Rattus norvegicus	163-168
34764635-9	2021	Conclusion: These results indicate that treatment with artemisinin has beneficial effects on reducing the heart rate and basal vascular tension and improving endothelium-dependent vascular relaxation in hypertension, which might occur by increasing eNOS activation and NO release and inhibiting NAD(P)H oxidase derived ROS production.	artemisinin	55-66	nitric oxide synthase 3	Rattus norvegicus	249-253
34773836-1	2021	Decreased susceptibilities of the human malaria parasite Plasmodium falciparum towards the endoperoxide antimalarial artemisinin are linked to mutations of residue C580 of PfKelch13, a homologue of the redox sensor Keap1 and other vertebrate BTB-Kelch proteins.	artemisinin	117-128	kelch like ECH associated protein 1	Homo sapiens	215-220
34288018-7	2021	Numerous NF-kappaB-regulated downstream genes are downregulated by artemisinin and its derivatives, for example, cytokines, chemokines, and immune receptors, which regulate immune cell differentiation, apoptosis genes, proliferation-regulating genes, signal transducers, and genes involved in antioxidant stress response.	artemisinin	67-78	nuclear factor kappa B subunit 1	Homo sapiens	9-18
34270452-3	2021	Combining a published barcoding system of geographically restricted single-nucleotide polymorphisms (SNPs), mainly mitochondria of P. falciparum with SNPs in the K13 artemisinin resistance marker, could elucidate the parasite population structure and provide insight regarding the spread of drug resistance.	artemisinin	166-177	keratin 13	Homo sapiens	162-165
34577169-0	2021	Molecular Basis of Artemisinin Derivatives Inhibition of Myeloid Differentiation Protein 2 by Combined in Silico and Experimental Study.	artemisinin	19-30	lymphocyte antigen 96	Homo sapiens	57-90
34577169-3	2021	Recently, several reports mentioned that myeloid differentiation factor 2 (MD-2, also known as lymphocyte antigen 96) may be the endogenous target of artemisinin in the inhibition of lipopolysaccharide signaling.	artemisinin	150-161	lymphocyte antigen 96	Homo sapiens	95-116
34577169-7	2021	Molecular docking results showed that artemisinin, artesunate, and artemether had similar binding poses, and all complexes remained stable throughout the whole molecular dynamics simulations, whereas the binding of artemisinin and its derivatives to MD-2 decreased the TLR4(Toll-Like Receptor 4)/MD-2 stability.	artemisinin	38-49	toll like receptor 4	Homo sapiens	269-273
34577169-7	2021	Molecular docking results showed that artemisinin, artesunate, and artemether had similar binding poses, and all complexes remained stable throughout the whole molecular dynamics simulations, whereas the binding of artemisinin and its derivatives to MD-2 decreased the TLR4(Toll-Like Receptor 4)/MD-2 stability.	artemisinin	38-49	toll like receptor 4	Homo sapiens	274-294
34577169-7	2021	Molecular docking results showed that artemisinin, artesunate, and artemether had similar binding poses, and all complexes remained stable throughout the whole molecular dynamics simulations, whereas the binding of artemisinin and its derivatives to MD-2 decreased the TLR4(Toll-Like Receptor 4)/MD-2 stability.	artemisinin	215-226	toll like receptor 4	Homo sapiens	269-273
34577169-7	2021	Molecular docking results showed that artemisinin, artesunate, and artemether had similar binding poses, and all complexes remained stable throughout the whole molecular dynamics simulations, whereas the binding of artemisinin and its derivatives to MD-2 decreased the TLR4(Toll-Like Receptor 4)/MD-2 stability.	artemisinin	215-226	toll like receptor 4	Homo sapiens	274-294
34279219-0	2021	Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness.	artemisinin	62-73	keratin 13	Homo sapiens	22-25
34279219-1	2021	The emergence of mutant K13-mediated artemisinin (ART) resistance in Plasmodium falciparum malaria parasites has led to widespread treatment failure across Southeast Asia.	artemisinin	37-48	keratin 13	Homo sapiens	24-27
34279219-1	2021	The emergence of mutant K13-mediated artemisinin (ART) resistance in Plasmodium falciparum malaria parasites has led to widespread treatment failure across Southeast Asia.	artemisinin	50-53	keratin 13	Homo sapiens	24-27
34585460-9	2022	The 50% effective concentration (EC50 ) of artemisinin against SARS-CoV-2 Spike pseudovirus was found greater than 50 muM (EC45 ) in HEK293T cell line whereas the cell viability was 94% of the control (P < 0.01).	artemisinin	43-54	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	74-79
34585460-10	2022	The immunosuppressive effects of artemisinin on TNF-alpha production on both pseudovirus and lipopolysaccharide (LPS)-induced THP-1 cells were found significant in a dose dependent manner.	artemisinin	33-44	tumor necrosis factor	Homo sapiens	48-57
34567410-0	2021	Artemisinin Reverses Glucocorticoid-Induced Injury in Bone Marrow-Derived Mesenchymal Stem Cells through Regulation of ERK1/2-CREB Signaling Pathway.	artemisinin	0-11	mitogen-activated protein kinase 3	Homo sapiens	119-125
34567410-0	2021	Artemisinin Reverses Glucocorticoid-Induced Injury in Bone Marrow-Derived Mesenchymal Stem Cells through Regulation of ERK1/2-CREB Signaling Pathway.	artemisinin	0-11	cAMP responsive element binding protein 1	Homo sapiens	126-130
34567410-4	2021	At relatively low concentrations, artemisinin treatment improved BMSC survival by promoting a decline of reactive oxygen species (ROS) production that correlated with the decrease of caspase-3 activation, LDH release, mitochondrial membrane potential (Deltapsim) loss, and apoptosis induced by dexamethasone (DEXA).	artemisinin	34-45	caspase 3	Homo sapiens	183-192
34567410-7	2021	PD98059, the specific inhibitor of the ERK1/2 pathway, blocked ERK1/2 phosphorylation and artemisinin protection.	artemisinin	90-101	mitogen-activated protein kinase 3	Homo sapiens	39-45
34567410-8	2021	Similarly, siCREB attenuated the protective effect of artemisinin, strongly suggesting the involvement of the ERK1/2-CREB pathway in the protective action of artemisinin against DEXA-induced damage in BMSCs.	artemisinin	54-65	mitogen-activated protein kinase 3	Homo sapiens	110-116
34567410-8	2021	Similarly, siCREB attenuated the protective effect of artemisinin, strongly suggesting the involvement of the ERK1/2-CREB pathway in the protective action of artemisinin against DEXA-induced damage in BMSCs.	artemisinin	54-65	cAMP responsive element binding protein 1	Homo sapiens	117-121
34567410-8	2021	Similarly, siCREB attenuated the protective effect of artemisinin, strongly suggesting the involvement of the ERK1/2-CREB pathway in the protective action of artemisinin against DEXA-induced damage in BMSCs.	artemisinin	158-169	mitogen-activated protein kinase 3	Homo sapiens	110-116
34567410-8	2021	Similarly, siCREB attenuated the protective effect of artemisinin, strongly suggesting the involvement of the ERK1/2-CREB pathway in the protective action of artemisinin against DEXA-induced damage in BMSCs.	artemisinin	158-169	cAMP responsive element binding protein 1	Homo sapiens	117-121
34567410-9	2021	In addition, we found that the expression of antiapoptotic protein B-cell lymphoma 2 protein (BCL-2) was also upregulated by artemisinin.	artemisinin	125-136	BCL2 apoptosis regulator	Homo sapiens	94-99
34567410-10	2021	These studies demonstrate the therapeutic potential of artemisinin in the survival improvement of BMSCs exposed to glucocorticoid-induced apoptosis and suggest that artemisinin-mediated protection may occur via the activation of ERK1/2-CREB signaling pathway.	artemisinin	55-66	mitogen-activated protein kinase 3	Homo sapiens	229-235
34567410-10	2021	These studies demonstrate the therapeutic potential of artemisinin in the survival improvement of BMSCs exposed to glucocorticoid-induced apoptosis and suggest that artemisinin-mediated protection may occur via the activation of ERK1/2-CREB signaling pathway.	artemisinin	55-66	cAMP responsive element binding protein 1	Homo sapiens	236-240
34567410-10	2021	These studies demonstrate the therapeutic potential of artemisinin in the survival improvement of BMSCs exposed to glucocorticoid-induced apoptosis and suggest that artemisinin-mediated protection may occur via the activation of ERK1/2-CREB signaling pathway.	artemisinin	165-176	mitogen-activated protein kinase 3	Homo sapiens	229-235
34567410-10	2021	These studies demonstrate the therapeutic potential of artemisinin in the survival improvement of BMSCs exposed to glucocorticoid-induced apoptosis and suggest that artemisinin-mediated protection may occur via the activation of ERK1/2-CREB signaling pathway.	artemisinin	165-176	cAMP responsive element binding protein 1	Homo sapiens	236-240
34515013-0	2022	Inactivation of PDH can Reduce Anaplastic Thyroid Cancer Cells" Sensitivity to Artemisinin.	artemisinin	79-90	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	16-19
34515013-7	2022	RESULTS: Artemisinin treatment significantly decreased the expression levels of COX2 and COX7A2 and increased that of COX14, YEM1l1, ALAS1, and OAT after 48h.	artemisinin	9-20	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	80-84
34515013-7	2022	RESULTS: Artemisinin treatment significantly decreased the expression levels of COX2 and COX7A2 and increased that of COX14, YEM1l1, ALAS1, and OAT after 48h.	artemisinin	9-20	cytochrome c oxidase subunit 7A2	Homo sapiens	89-95
34515013-7	2022	RESULTS: Artemisinin treatment significantly decreased the expression levels of COX2 and COX7A2 and increased that of COX14, YEM1l1, ALAS1, and OAT after 48h.	artemisinin	9-20	cytochrome c oxidase assembly factor COX14	Homo sapiens	118-123
34515013-7	2022	RESULTS: Artemisinin treatment significantly decreased the expression levels of COX2 and COX7A2 and increased that of COX14, YEM1l1, ALAS1, and OAT after 48h.	artemisinin	9-20	5'-aminolevulinate synthase 1	Homo sapiens	133-138
34515013-9	2022	The CAL-62 cells showed transient and reversible resistance to artemisinin, which was correlated to time-dependent changes in HIF1 , PDK1, and PDHA levels.	artemisinin	63-74	hypoxia inducible factor 1 subunit alpha	Homo sapiens	126-130
34515013-9	2022	The CAL-62 cells showed transient and reversible resistance to artemisinin, which was correlated to time-dependent changes in HIF1 , PDK1, and PDHA levels.	artemisinin	63-74	pyruvate dehydrogenase kinase 1	Homo sapiens	133-137
34515013-9	2022	The CAL-62 cells showed transient and reversible resistance to artemisinin, which was correlated to time-dependent changes in HIF1 , PDK1, and PDHA levels.	artemisinin	63-74	pyruvate dehydrogenase E1 subunit alpha 1	Homo sapiens	143-147
34515013-11	2022	CAL-62 cells show transient resistance to artemisinin via PDH downregulation, indicating that PDH activation may enhance the cytotoxic effects of artemisinin on ATC cells.	artemisinin	42-53	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	58-61
34515013-11	2022	CAL-62 cells show transient resistance to artemisinin via PDH downregulation, indicating that PDH activation may enhance the cytotoxic effects of artemisinin on ATC cells.	artemisinin	42-53	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	94-97
34515013-11	2022	CAL-62 cells show transient resistance to artemisinin via PDH downregulation, indicating that PDH activation may enhance the cytotoxic effects of artemisinin on ATC cells.	artemisinin	146-157	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	58-61
34515013-11	2022	CAL-62 cells show transient resistance to artemisinin via PDH downregulation, indicating that PDH activation may enhance the cytotoxic effects of artemisinin on ATC cells.	artemisinin	146-157	pyruvate dehydrogenase phosphatase catalytic subunit 1	Homo sapiens	94-97
34358442-0	2022	Artemisinin inhibits NRas palmitoylation by targeting the protein acyltransferase ZDHHC6.	artemisinin	0-11	NRAS proto-oncogene, GTPase	Homo sapiens	21-25
34358442-0	2022	Artemisinin inhibits NRas palmitoylation by targeting the protein acyltransferase ZDHHC6.	artemisinin	0-11	zinc finger DHHC-type palmitoyltransferase 6	Homo sapiens	82-88
34358442-2	2022	Here, we identify artemisinin (ART), a clinically approved antimalarial endoperoxide natural product with promising anticancer activities, as an inhibitor of the ER-residing palmitoyl transferase ZDHHC6 in cancer cells using a chemoproteomic approach.	artemisinin	18-29	zinc finger DHHC-type palmitoyltransferase 6	Homo sapiens	196-202
34270452-13	2021	This study supports the use of mitochondrial SNPs to determine the origin of the parasite and suggests that the P. falciparum populations studied were susceptible to artemisinin during sampling because all K13 SNPs observed were outside the propeller domain for artemisinin resistance.	artemisinin	262-273	keratin 13	Homo sapiens	206-209
34306988-3	2021	Our in silico approach suggested that unique phytocompounds such as emodin, thymol and carvacrol, and artemisinin could physically bind SARS-CoV-2 spike glycoproteins (6VXX and 6VYB), SARS-CoV-2 B.1.351 South Africa variant of Spike glycoprotein (7NXA), and even with ACE2 and prevent the SARS-CoV-2 binding to the host ACE2, TMPRSS2 and neutrapilin-1 receptors.	artemisinin	102-113	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	147-152
34306988-3	2021	Our in silico approach suggested that unique phytocompounds such as emodin, thymol and carvacrol, and artemisinin could physically bind SARS-CoV-2 spike glycoproteins (6VXX and 6VYB), SARS-CoV-2 B.1.351 South Africa variant of Spike glycoprotein (7NXA), and even with ACE2 and prevent the SARS-CoV-2 binding to the host ACE2, TMPRSS2 and neutrapilin-1 receptors.	artemisinin	102-113	angiotensin converting enzyme 2	Homo sapiens	320-324
34306988-3	2021	Our in silico approach suggested that unique phytocompounds such as emodin, thymol and carvacrol, and artemisinin could physically bind SARS-CoV-2 spike glycoproteins (6VXX and 6VYB), SARS-CoV-2 B.1.351 South Africa variant of Spike glycoprotein (7NXA), and even with ACE2 and prevent the SARS-CoV-2 binding to the host ACE2, TMPRSS2 and neutrapilin-1 receptors.	artemisinin	102-113	transmembrane serine protease 2	Homo sapiens	326-333
34306988-4	2021	Since Chloroquine has been looked as potential therapy against COVID-19, we also compared the binding of chloroquine and artemisinin for its interaction with spike proteins (6VXX, 6VYB) and its variant 7NXA, respectively.	artemisinin	121-132	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	158-163
34306988-9	2021	Emodin showed best interactions with TMPRSS 2 and ACE2 with Etotal of -7.1 and -7.3 KJ mol-1 respectively, whereas artemisinin interacts with TMPRSS 2 and ACE2 with Etotal of -6.9 and -7.4 KJ mol-1 respectively.	artemisinin	115-126	transmembrane serine protease 2	Homo sapiens	142-150
34306988-9	2021	Emodin showed best interactions with TMPRSS 2 and ACE2 with Etotal of -7.1 and -7.3 KJ mol-1 respectively, whereas artemisinin interacts with TMPRSS 2 and ACE2 with Etotal of -6.9 and -7.4 KJ mol-1 respectively.	artemisinin	115-126	angiotensin converting enzyme 2	Homo sapiens	155-159
34216470-1	2022	In Southeast Asia, mutations in the Plasmodium falciparum k13 gene have led to delayed parasite clearance and treatment failures in malaria patients receiving artemisinin combination therapies.	artemisinin	159-170	keratin 13	Homo sapiens	58-61
34350834-7	2021	Connectivity Map and Comparative Toxicogenomics Database searches predicted dexamethasone may treat AF by reversing the expression of MIR100HG; artemisinin may reverse the expression of hub DEGs.	artemisinin	144-155	mir-100-let-7a-2-mir-125b-1 cluster host gene	Homo sapiens	134-142
34350834-7	2021	Connectivity Map and Comparative Toxicogenomics Database searches predicted dexamethasone may treat AF by reversing the expression of MIR100HG; artemisinin may reverse the expression of hub DEGs.	artemisinin	144-155	delta 4-desaturase, sphingolipid 1	Homo sapiens	190-194
34073895-0	2021	Artemisinin Protects Porcine Mammary Epithelial Cells against Lipopolysaccharide-Induced Inflammatory Injury by Regulating the NF-kappaB and MAPK Signaling Pathways.	artemisinin	0-11	nuclear factor kappa B subunit 1	Homo sapiens	127-136
34073895-4	2021	Pretreatment with 20 muM artemisinin weakened LPS-induced inflammatory damage in pMECs and decreased mRNA expression abundance and the content of inflammatory factors (IL-1beta, IL-6, and TNF-alpha) in pMECs (p < 0.05).	artemisinin	25-36	interleukin 1 alpha	Homo sapiens	168-176
34073895-4	2021	Pretreatment with 20 muM artemisinin weakened LPS-induced inflammatory damage in pMECs and decreased mRNA expression abundance and the content of inflammatory factors (IL-1beta, IL-6, and TNF-alpha) in pMECs (p < 0.05).	artemisinin	25-36	interleukin 6	Homo sapiens	178-182
34073895-4	2021	Pretreatment with 20 muM artemisinin weakened LPS-induced inflammatory damage in pMECs and decreased mRNA expression abundance and the content of inflammatory factors (IL-1beta, IL-6, and TNF-alpha) in pMECs (p < 0.05).	artemisinin	25-36	tumor necrosis factor	Homo sapiens	188-197
34073895-5	2021	Mechanistically, artemisinin inhibited LPS-induced activation of the mitogen-activated protein kinase (MAPK) and nuclear factor-kappaB (NF-kappaB) signaling pathways.	artemisinin	17-28	nuclear factor kappa B subunit 1	Homo sapiens	113-134
34073895-5	2021	Mechanistically, artemisinin inhibited LPS-induced activation of the mitogen-activated protein kinase (MAPK) and nuclear factor-kappaB (NF-kappaB) signaling pathways.	artemisinin	17-28	nuclear factor kappa B subunit 1	Homo sapiens	136-145
34514004-7	2021	Results: Molecular docking studies indicated that hybrids of artemisinin and thymoquinone showed a relevant interaction with the active fraction of the enzyme Mpro, when compared to the reference drugs.	artemisinin	61-72	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	159-163
34170261-10	2021	Simultaneous or separate administration of artemisinin and TSP-1-hEDSCs ameliorated this influence by considerably reducing Abeta plaque formation in the hippocampus, reducing glucose, MDA, ROS, and TNF-alpha levels, and increasing TAC levels.	artemisinin	43-54	tumor necrosis factor	Rattus norvegicus	199-208
34514004-11	2021	Conclusions: Hybrid products of artemisinin and thymoquinone have the potential to inhibit Mpro, with desirable pharmacokinetic and toxicity characteristics compared to commercially available drugs, being indicated for preclinical and subsequent clinical studies against SARS-CoV-2.	artemisinin	32-43	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	91-95
35490765-1	2022	The current work aimed to enhance the oral bioavailability of water-insoluble drug Artemisinin (ART) by the inclusion of ART with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) and then loaded with porous starch (PS).	artemisinin	83-94	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	166-173
35348414-10	2022	CONCLUSIONS: Intervention with artemisinin in maternal HFD resulted in reduced islet size, decreased number of beta-cells and improved islet microcirculation, insulin processing shear process, decreased insulinogen/insulin ratio, and restored islet function through increased expression of PC1/3.	artemisinin	31-42	proprotein convertase subtilisin/kexin type 1	Rattus norvegicus	290-295
35367585-1	2022	Dimeric artesunate phospholipid (ART-GPC), an amphiphilic derivative of artemisinin dimer reported in our previous work, can be applied to treat malaria effectively.	artemisinin	72-83	glycophorin C (Gerbich blood group)	Homo sapiens	37-40
35511795-2	2022	Genetic and epigenetic factors play a role in predisposing Plasmodium falciparum parasites to acquiring Pfkelch13 (K13) mutations associated with delayed artemisinin parasite clearance as reported in Southeast Asia.	artemisinin	154-165	keratin 13	Homo sapiens	115-118
35511795-3	2022	In this study, we report on the prevalence of mutations in the K13, pfmdr-2 (P. falciparum multidrug resistance protein 2), fd (ferredoxin), pfcrt (P. falciparum chloroquine resistance transporter), and arps10 (apicoplast ribosomal protein S10) genes in Plasmodium falciparum parasites prior to (2005) and after (2013) introduction of artemisinin combination therapies for malaria treatment in Uganda.	artemisinin	335-346	keratin 13	Homo sapiens	63-66
35349764-0	2022	Artemisinin upregulates neural cell adhesion molecule L1 to attenuate neurological deficits after intracerebral hemorrhage in mice.	artemisinin	0-11	L1 cell adhesion molecule	Mus musculus	24-56
35183684-3	2022	Here, we characterized the Plasmodium spp populations in wild Anopheles vectors by analyzing the genetic diversity of the P. falciparum kelch13 and mdr1 gene fragments implicated in artemisinin and partner drug resistance across Cameroon in three major malaria vectors.	artemisinin	182-193	ATP binding cassette subfamily B member 1	Homo sapiens	148-152
35497913-8	2022	Finally, we verified the IL-17 signaling pathway and key cytokines, and ELISA and immunohistochemical results showed that artemisinin could downregulate the expression of proinflammatory cytokines such as IL-1beta and IL-17 in the IL-17 signaling pathway and upregulate the expression of the anti-inflammatory cytokine PPAR-gamma.	artemisinin	122-133	interleukin 17A	Rattus norvegicus	25-30
35497913-8	2022	Finally, we verified the IL-17 signaling pathway and key cytokines, and ELISA and immunohistochemical results showed that artemisinin could downregulate the expression of proinflammatory cytokines such as IL-1beta and IL-17 in the IL-17 signaling pathway and upregulate the expression of the anti-inflammatory cytokine PPAR-gamma.	artemisinin	122-133	interleukin 1 alpha	Rattus norvegicus	205-213
35497913-8	2022	Finally, we verified the IL-17 signaling pathway and key cytokines, and ELISA and immunohistochemical results showed that artemisinin could downregulate the expression of proinflammatory cytokines such as IL-1beta and IL-17 in the IL-17 signaling pathway and upregulate the expression of the anti-inflammatory cytokine PPAR-gamma.	artemisinin	122-133	interleukin 17A	Rattus norvegicus	218-223
35497913-8	2022	Finally, we verified the IL-17 signaling pathway and key cytokines, and ELISA and immunohistochemical results showed that artemisinin could downregulate the expression of proinflammatory cytokines such as IL-1beta and IL-17 in the IL-17 signaling pathway and upregulate the expression of the anti-inflammatory cytokine PPAR-gamma.	artemisinin	122-133	interleukin 17A	Rattus norvegicus	231-236
35497913-8	2022	Finally, we verified the IL-17 signaling pathway and key cytokines, and ELISA and immunohistochemical results showed that artemisinin could downregulate the expression of proinflammatory cytokines such as IL-1beta and IL-17 in the IL-17 signaling pathway and upregulate the expression of the anti-inflammatory cytokine PPAR-gamma.	artemisinin	122-133	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	319-329
35370688-5	2022	The networks were constructed based on 50 artemisinin-disease intersection targets related to inflammation, cytokines, proliferation and apoptosis, showing the importance of GALNT2, BMP7 and TGFBR2 in the treatment of disease, which may be due to the occupation of the ricin B-type lectin domain of GALNT2 by artemisinin compounds or de novo designed candidates.	artemisinin	42-53	polypeptide N-acetylgalactosaminyltransferase 2	Homo sapiens	174-180
35422868-9	2022	It was concluded that artemisinin treatment can reduce oxidative stress damage and alleviate CIRI through the SIRT1/FOXO1 signaling pathway, thereby achieving neuroprotective effects.	artemisinin	22-33	sirtuin 1	Mus musculus	110-115
35422868-9	2022	It was concluded that artemisinin treatment can reduce oxidative stress damage and alleviate CIRI through the SIRT1/FOXO1 signaling pathway, thereby achieving neuroprotective effects.	artemisinin	22-33	forkhead box O1	Mus musculus	116-121
35370688-5	2022	The networks were constructed based on 50 artemisinin-disease intersection targets related to inflammation, cytokines, proliferation and apoptosis, showing the importance of GALNT2, BMP7 and TGFBR2 in the treatment of disease, which may be due to the occupation of the ricin B-type lectin domain of GALNT2 by artemisinin compounds or de novo designed candidates.	artemisinin	42-53	bone morphogenetic protein 7	Homo sapiens	182-186
35370688-5	2022	The networks were constructed based on 50 artemisinin-disease intersection targets related to inflammation, cytokines, proliferation and apoptosis, showing the importance of GALNT2, BMP7 and TGFBR2 in the treatment of disease, which may be due to the occupation of the ricin B-type lectin domain of GALNT2 by artemisinin compounds or de novo designed candidates.	artemisinin	42-53	transforming growth factor beta receptor 2	Homo sapiens	191-197
35370688-5	2022	The networks were constructed based on 50 artemisinin-disease intersection targets related to inflammation, cytokines, proliferation and apoptosis, showing the importance of GALNT2, BMP7 and TGFBR2 in the treatment of disease, which may be due to the occupation of the ricin B-type lectin domain of GALNT2 by artemisinin compounds or de novo designed candidates.	artemisinin	42-53	polypeptide N-acetylgalactosaminyltransferase 2	Homo sapiens	299-305
35370688-5	2022	The networks were constructed based on 50 artemisinin-disease intersection targets related to inflammation, cytokines, proliferation and apoptosis, showing the importance of GALNT2, BMP7 and TGFBR2 in the treatment of disease, which may be due to the occupation of the ricin B-type lectin domain of GALNT2 by artemisinin compounds or de novo designed candidates.	artemisinin	309-320	polypeptide N-acetylgalactosaminyltransferase 2	Homo sapiens	174-180
35370688-5	2022	The networks were constructed based on 50 artemisinin-disease intersection targets related to inflammation, cytokines, proliferation and apoptosis, showing the importance of GALNT2, BMP7 and TGFBR2 in the treatment of disease, which may be due to the occupation of the ricin B-type lectin domain of GALNT2 by artemisinin compounds or de novo designed candidates.	artemisinin	309-320	bone morphogenetic protein 7	Homo sapiens	182-186
35370688-5	2022	The networks were constructed based on 50 artemisinin-disease intersection targets related to inflammation, cytokines, proliferation and apoptosis, showing the importance of GALNT2, BMP7 and TGFBR2 in the treatment of disease, which may be due to the occupation of the ricin B-type lectin domain of GALNT2 by artemisinin compounds or de novo designed candidates.	artemisinin	309-320	transforming growth factor beta receptor 2	Homo sapiens	191-197
35370688-5	2022	The networks were constructed based on 50 artemisinin-disease intersection targets related to inflammation, cytokines, proliferation and apoptosis, showing the importance of GALNT2, BMP7 and TGFBR2 in the treatment of disease, which may be due to the occupation of the ricin B-type lectin domain of GALNT2 by artemisinin compounds or de novo designed candidates.	artemisinin	309-320	polypeptide N-acetylgalactosaminyltransferase 2	Homo sapiens	299-305
35293664-8	2022	The therapeutic dose of ART reduced the CAT activity and the GSH level, nonsignificantly.	artemisinin	24-27	catalase	Mus musculus	40-43
35293664-9	2022	The toxic dose of ART reduced the CAT activity and increased the POX activity.	artemisinin	18-21	catalase	Mus musculus	34-37
35215242-0	2022	Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants.	artemisinin	21-32	angiotensin converting enzyme 2	Homo sapiens	133-137
35345364-0	2022	Design and Development of Nanostructured Co Delivery of Artemisinin and Chrysin for Targeting hTERT Gene Expression in Breast Cancer Cell Line: Possible Clinical Application in Cancer Treatment.	artemisinin	56-67	telomerase reverse transcriptase	Homo sapiens	94-99
34978886-5	2022	In this study, we compared the asexual and sexual stage activities of cipargamin, ganaplacide and artesunate in artemisinin resistant P. falciparum isolates (N=7, K13 mutation; C580Y, G449A and R539T) from Thailand and Cambodia.	artemisinin	112-123	keratin 13	Homo sapiens	163-166
35045938-0	2022	Corrigendum to "Artemisinin protects DPSC from hypoxia and TNF-alpha mediated osteogenesis impairments through CA9 and Wnt signaling pathway" (Life Sci.	artemisinin	16-27	tumor necrosis factor	Homo sapiens	59-68
35045938-0	2022	Corrigendum to "Artemisinin protects DPSC from hypoxia and TNF-alpha mediated osteogenesis impairments through CA9 and Wnt signaling pathway" (Life Sci.	artemisinin	16-27	carbonic anhydrase 9	Homo sapiens	111-114
35151247-9	2022	To verify the mechanism of cell death induced by artemisinin in A-253 cells, we found an increased level of Bax, Bim, Bad, Bak and reduced level of antiapoptotic protein Bcl-2, Bcl-XL with concomitant release of mitochondrial resident protein cytochrome c into the cytoplasm.	artemisinin	49-60	BCL2 associated X, apoptosis regulator	Homo sapiens	108-111
35151247-9	2022	To verify the mechanism of cell death induced by artemisinin in A-253 cells, we found an increased level of Bax, Bim, Bad, Bak and reduced level of antiapoptotic protein Bcl-2, Bcl-XL with concomitant release of mitochondrial resident protein cytochrome c into the cytoplasm.	artemisinin	49-60	BCL2 like 11	Homo sapiens	113-116
35151247-9	2022	To verify the mechanism of cell death induced by artemisinin in A-253 cells, we found an increased level of Bax, Bim, Bad, Bak and reduced level of antiapoptotic protein Bcl-2, Bcl-XL with concomitant release of mitochondrial resident protein cytochrome c into the cytoplasm.	artemisinin	49-60	BCL2 antagonist/killer 1	Homo sapiens	123-126
35151247-9	2022	To verify the mechanism of cell death induced by artemisinin in A-253 cells, we found an increased level of Bax, Bim, Bad, Bak and reduced level of antiapoptotic protein Bcl-2, Bcl-XL with concomitant release of mitochondrial resident protein cytochrome c into the cytoplasm.	artemisinin	49-60	BCL2 apoptosis regulator	Homo sapiens	170-175
35151247-9	2022	To verify the mechanism of cell death induced by artemisinin in A-253 cells, we found an increased level of Bax, Bim, Bad, Bak and reduced level of antiapoptotic protein Bcl-2, Bcl-XL with concomitant release of mitochondrial resident protein cytochrome c into the cytoplasm.	artemisinin	49-60	BCL2 like 1	Homo sapiens	177-183
35151247-9	2022	To verify the mechanism of cell death induced by artemisinin in A-253 cells, we found an increased level of Bax, Bim, Bad, Bak and reduced level of antiapoptotic protein Bcl-2, Bcl-XL with concomitant release of mitochondrial resident protein cytochrome c into the cytoplasm.	artemisinin	49-60	cytochrome c, somatic	Homo sapiens	243-255
35151247-10	2022	Additionally, we found that artemisinin augments the production of reactive oxygen species which further leads to the activation of proapoptotic proteins PARP1, and caspase-3, in a concentration-dependent manner thereby triggering apoptosis.	artemisinin	28-39	poly(ADP-ribose) polymerase 1	Homo sapiens	154-159
35151247-10	2022	Additionally, we found that artemisinin augments the production of reactive oxygen species which further leads to the activation of proapoptotic proteins PARP1, and caspase-3, in a concentration-dependent manner thereby triggering apoptosis.	artemisinin	28-39	caspase 3	Homo sapiens	165-174
35204156-0	2022	Effect of Artemisinin on the Redox System of NADPH/FNR/Ferredoxin from Malaria Parasites.	artemisinin	10-21	2,4-dienoyl-CoA reductase 1	Homo sapiens	45-65
35215242-8	2022	Furthermore, artemisinin interactions with angiotensin converting enzyme 2 (ACE2) were dependent on the ACE2 allelic variants.	artemisinin	13-24	angiotensin converting enzyme 2	Homo sapiens	43-74
35215242-8	2022	Furthermore, artemisinin interactions with angiotensin converting enzyme 2 (ACE2) were dependent on the ACE2 allelic variants.	artemisinin	13-24	angiotensin converting enzyme 2	Homo sapiens	76-80
35215242-8	2022	Furthermore, artemisinin interactions with angiotensin converting enzyme 2 (ACE2) were dependent on the ACE2 allelic variants.	artemisinin	13-24	angiotensin converting enzyme 2	Homo sapiens	104-108
35215242-10	2022	A molecular dynamic simulation showed sufficient stability of the artemisinin-Mpro complex on the trajectory of 100 ns simulation frame.	artemisinin	66-77	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	78-82
35215242-11	2022	These binding interactions, together with drug-likeness and pharmacokinetic findings, confirmed that artemisinin might inhibit Mpro activity and explain the ethnopharmacological use of the herb and its possible antiviral activity against SARS-CoV-2 infection inducing COVID-19.	artemisinin	101-112	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	127-131
35002180-3	2022	Herein, we investigated the potential of artemisinin and its derivatives as possible inhibitors of SARS-CoV-2 Nsp1 through various computational approaches.	artemisinin	41-52	SH2 domain containing 3A	Homo sapiens	110-114
35047402-5	2021	Recently, we have shown that artemisinin derivatives enhance TRAIL-induced apoptosis in colon cancer cells.	artemisinin	29-40	TNF superfamily member 10	Homo sapiens	61-66
35002180-4	2022	Molecular docking results show that artemisinin (CID68827) binds to Nsp1 with a binding energy of -6.53 kcal/mol and an inhibition constant of 16.43 microM.	artemisinin	36-47	SH2 domain containing 3A	Homo sapiens	68-72
35002180-9	2022	Thus, the findings of our research highlight the importance of artemisinin and its derivatives in the development of drugs to inhibit SARS-CoV-2 Nsp1 protein.	artemisinin	63-74	SH2 domain containing 3A	Homo sapiens	145-149
34975311-3	2022	Specifically, both in vitro and in vivo experiments showed that HF or HF-ATS induces apoptosis via activation of caspase-9 and caspase-8 while only caspase-9 is involved in ATS-induced apoptosis.	artemisinin	173-176	caspase 9	Homo sapiens	148-157